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Intra-adipose cortisol is derived from the systemic circulation via the hypothalamic-pituitary-
adrenal axis (HPAA) and generated locally through conversion of inactive cortisone to 
cortisol by the intra-cellular enzyme 11 -hydroxysteroid dehydrogenase type 1 (11 HSD1). 
This thesis addresses the relative contributions of the HPAA and adipose tissue 11 HSD1 to 
the adipose tissue glucocorticoid pool and describes development and validation of a novel 
stable  isotope  tracer,  1,2  [2H]2-cortisone (d2-cortisone),  to measure 11 HSD1-
dehydrogenase activity in adipose tissue and skeletal muscle in vivo.  
 
In otherwise healthy females (n=6) undergoing hysterectomy for a benign indication, an 
intravenous infusion of d4-cortisol was administered and subcutaneous and omental adipose 
tissue biopsies were obtained along with concomitant peripheral venous blood, to measure 
the rate of exchange of cortisol between plasma and adipose tissue for comparison with rates 
of intra-cellular cortisol generation by 11 HSD1. Cortisol concentrations and enrichment 
with d4-cortisol were lower in adipose tissue than in plasma.  The rate of accumulation of 
d4-cortisol in adipose tissue depots was ~0.5nmol/kg/h despite the infusion contributing 
1.9 mol/h d4-cortisol into the circulation, and the proportion of the intra-adipose cortisol 
pool replaced each hour was ~10%. The contribution of 11 HSD1 to this turnover could not 
be quantified since very little substrate d3-cortisone accumulated in adipose during infusion.  
 
Method development for d2-cortisone included optimising LC-MS/MS conditions, 
confirming that d2-cortisone was a substrate for human 11 HSD1 and that no significant 
primary isotope effect existed. The pharmacokinetics of d2-cortisone were assessed in vivo 
in healthy male volunteers (n=3). The method was validated by measuring whole body 
cortisone production in healthy volunteers (n=3) before and after eating liquorice which 
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resulted in a ~50% fall in cortisone production. 11 HSD1-dehydrogenase activity was 
measured in adipose tissue and skeletal muscle in healthy volunteers (n=6) using d2-
cortisone and substantial 11 -dehydrogenase activity was present in both tissues (~1.5-fold 
higher 11 -dehydrogenase activity than 11 -reductase activity in adipose tissue and 
approximately equal 11 -reductase and 11 -dehydrogenase activity in skeletal muscle). 
11 HSD1-reductase activity was also assessed using a 9,11,12,12 [2H]4-cortisol infusion (d4-
cortisol). Skeletal muscle and adipose tissue displayed 11 -reductase activity. In adipose 
tissue this activity was of a similar magnitude to previous reports. Insulin increased whole 
body 11 -reductase activity, but did not switch 11 HSD1 direction in muscle or adipose 
tissue, indicating the predominant effect of insulin may be on hepatic 11 HSD1.  
 
Therefore, turnover of the intra-adipose tissue glucocorticoid pool is slow and it is unlikely 
that rapid acute fluctuations in circulating cortisol are reflected in adipose tissue, although 
this has not been confirmed under normal physiological conditions. Secondly, 11 HSD1 
may be bidirectional in human subcutaneous adipose tissue and skeletal muscle in vivo, and 
insulin does not regulate the balance of activities. However, in this study blood sampling 
occurred from blood vessels which express 11 HSD2, and thus some of the measured 
dehydrogenase activity in this study may reflect endothelial 11 HSD2 activity. Together 
these findings further our understanding of adipose tissue cortisol physiology in health, 
suggesting that 11 HSD1 may play a relatively important role in modulating activation of 
glucocorticoid receptors in adipose tissue, and that dysregulation or inhibition of 11 HSD1 
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Glucocorticoids, such as cortisol, have a number of physiological functions including 
homeostatic regulation of carbohydrate, amino acid, lipid metabolism, blood pressure 
regulation and modulation of the immune response. It is crucial that cortisol levels are 
elevated  in  times  of  acute  physical  stress  such  as  sepsis  or  physical  trauma,  but  if  cortisol  
elevations are sustained for prolonged periods in the absence of these stimuli, the 
homeostatic responses become maladaptive and the features of Cushing’s syndrome result, 
including central obesity and hyperglycaemia. As some of the Cushing’s syndrome 
phenotype is largely reversible upon removal of glucocorticoid excess, the potential of 
modulating glucocorticoid action was conceived as a therapeutic target in diabetes and 
obesity. However, antagonising glucocorticoids systemically presents the risk of inducing 
adrenal insufficiency at times of acute stress. Therefore strategies have been developed to 
modulate glucocorticoid action specifically in target tissues to circumvent this side effect. 
One particular drug target is the intracellular enzyme 11 -hydroxysteroid dehydrogenase 
type 1 which is expressed in many tissues including adipose.  To develop an effective 
treatment, glucocorticoid physiology in the target tissues need to be fully understood. 
Therefore, this thesis will focus on regulation of glucocorticoid metabolism in adipose tissue 




1.1.1Hormone structure, synthesis, transport and metabolism 
 
Glucocorticoids (predominantly cortisol in man and corticosterone in rodents) are 
synthesised de novo from the common precursor cholesterol in the adrenal gland. All steroid 
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hormones have a similar structure comprising a cyclopentane ring and three cyclohexane 
rings; the properties of each individual steroid are determined by the presence of different 
chemical groups at specific positions on the molecule (Figure 1.1). Glucocorticoids are 
mainly  synthesised  in  the  zona  fasiculata  of  the  adrenal  cortex,  catalysed  by  a  series  of  
cytochrome P450 (CYP) enzymes, which reside in the membranes of the endoplasmic 
reticulum and mitochondria. There is some glucocorticoid synthesis in the zona reticularis 
also. Glucocorticoids are not stored in the adrenal gland but are synthesised de novo and 













Figure 1.1 Basic steroid structure 
 
The basic steroid ring structure comprising a cyclopentane ring and three cyclohexane rings. 
Conventional labelling identifies the four carbon ring structures by letters, and the individual 
carbon atoms by numbers.  Chemical groups are designated according to the number of the 























Glucocorticoid synthesis and release is regulated by neuro-endocrine signals such as physical 
stress and pro-inflammatory cytokines released during inflammation. Both TNF  and IL-1  
stimulate glucocorticoid production by enhanching expression of both CRH and ACTH, 
which modulate the hypothalamic-pituitary-adrenal axis (Munck et al, 1984; Turnbull & 
Rivier, 1999). Glucocorticoids negatively feedback to the hypothalamic-pituitary-adrenal 












Figure 1.2 The hypothalamic-pituitary-adrenal axis 
 
Corticotrophin releasing hormone (CRH) is released from the hypothalamus (H) and 
stimulates the anterior pituitary (P) to release adrenocorticotrophic hormone (ACTH). 
ACTH stimulates the adrenal cortex (A) to produce cortisol, which in turn provides 
negative feedback control on CRH and ACTH to maintain physiological circulating 
glucocorticoid levels. 
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As a result of diurnal changes in ACTH pulse frequency and amplitude, glucocorticoid 
synthesis is subject to diurnal variation, with plasma levels highest just prior to waking and 
falling prior to sleep (Dallman et al, 1993). In addition to a diurnal rhythm, glucocorticoids 
are also secreted in an ultradian pattern which affects transcriptional regulation in vivo and in 
cells lines (Stavreva et al, 2009). This may serve to modulate the response to the 
glucocorticoid receptor activation (Stavreva et al, 2009). 
 
Plasma glucocorticoids are largely bound to corticosteroid-binding globulin (CBG) and 
albumin, with only 5-10% circulating in the free unbound state (Hammond et al, 1990). 
These binding proteins act as a buffer as only free steroids are able to cross cell membranes 
to bind to the intracellular glucocorticoid receptors, and affect gene transcription. At high 
glucocorticoid concentrations eg prior to waking in the morning, binding proteins may 
become saturated, which may amplify the normal diurnal variations in circulating levels of 
free glucocorticoids.  
 
Traditionally, glucocorticoid transport across the cell membrane was assumed to be a passive 
process following a concentration gradient. However, an increasing number of transporters 
of steroids have been identified, such as the organic anion transporter-3 (OAT3) in the 
adrenal (Asif et al, 2005), the multi-drug resistance (MDR) P-glycoprotein in the central 
nervous system (Karssen et al, 2001), and the glucocorticoid importer in the liver (Lackner 
et al, 1998). Moreover, these mechanisms can differentially allow transport of specific 
steroids into tissues, for example in the mouse central nervous system corticosterone can 
enter the tissues freely, whilst the MDR1 glycoprotein membrane pump reduces access of 
infused [3H]-cortisol (Karssen et al, 2001).  
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Inactivation of glucocorticoids involves conversion to inactive metabolites, which 
predominantly occurs in the liver. However, the kidney also displays some catabolic activity. 
Glucocorticoids are then renally excreted (Figure 1.3).  
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Figure 1.3 Metabolism of cortisol and cortisone 
 
Cortisol and inert cortisone are interconverted by the isozymes of 11 -hydroxysteroid 
dehydrogenase (11 HSD). The steroid A-ring is reduced across the 4-5 double bond by 
-reductases to form the dihydro-product. Glucocorticoids reduced at the 5 –position 
are substrates for 3 -hydroxysteroid dehydrogenases (3 HSD), which are further 
reduced by the 20 -hydroxysteroid dehydrogenases to form cortols and cortolones. 
Glucocorticoid metabolites are transformed into hydrophilic molecules (the process of 
conjugation) to ensure solubility in aqueous biological fluids prior to excretion. The two 
major pathways of conjugation include the formation of glucuronides through uridine 
diphosphoglucuronic acid (UDPGA) and a glucuronyl transferase and the formation of 
sulphates, catalysed by sulphokinases.  
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1.2 Glucocorticoid action 
 
Glucocorticoids act predominantly through binding to intracellular receptors. There are two 
receptor subtypes: mineralocorticoid (MR) and glucocorticoid (GR) receptors. GR are 
widespread whereas MR are found in aldosterone-sensitive tissues such as the distal 
convoluted tubule, loop of Henle, and collecting tubules of the kidney and the absorptive 
epithelia of duodenum, jejunum, ileum, colon (Hirasawa et al, 1997), the hippocampus and 
heart (Funder, 2005). Glucocorticods are able to bind to both GR and MR with equal 
affinity, however pre-receptor metabolism of glucocorticoids by the enzyme 11 -
hydroxysteroid dehydrogenase type 2 (please see section 1.6.1) prevents illicit occupation of 
MR in aldosterone-sensitive tissues. 
 
Once inside the cell, glucocorticoid binding leads to dissociation of GR from inhibitory heat 
shock proteins, GR phosphorylation and activation, dimerisation and translocation to the 
nucleus where the GR complex binds to specific palindromic DNA motifs called 
glucocorticoid response elements (GREs). GREs are located in  the promoter region of target 
genes (Yamamoto, 1985) and activation leads to transcription of responsive genes, a process 
called transactivation. Negative regulation of transcription, transrepression, can also occur 
through GR binding to negative GREs. Activated GR may also indirectly influence gene 
transcription through interactions with other transcription factors, such as the signal 
transducer and activator of transcription-5 (Stat5).  It has been demonstrated that Stat5 and 
GR form a molecular complex which cooperates in the induction of transcription of milk 






1.3 Physiological effects of glucocorticoids 
 
1.3.1 Effects on metabolism 
 
Glucocorticoids have many metabolic effects. Regarding insulin and glucose homeostasis, 
glucocorticoids impair insulin-dependent glucose uptake in the periphery eg skeletal muscle, 
enhance gluconeogenesis in the liver (Rooney et al, 1994), and inhibit insulin secretion from 
pancreatic -cells (Delaunay et  al, 1997). Glucocorticoids also alter lipid metabolism by 
stimulating adipocyte lipolysis, which releases free fatty acids into the circulation. In adipose 
tissue, glucocorticoids induce expression of hormone sensitive lipase (Slavin et al, 1994), 
which hydrolyses diacylglycerides in adipocytes (reviewed in (Macfarlane et al, 2008)).  
 
In Cushing’s syndrome glucocorticoid excess is associated with marked skeletal muscle 
atrophy and proximal myopathy. This reduction in skeletal muscle is as a result of reduced 
protein synthesis and increased protein catabolism. Specifically, synthesis is inhibited by 
reducing amino acid transport into muscle and abolishing the anabolic effects of insulin and 
IGF-1 (reviewed in (Schakman et al, 2008)). Proteolytic systems such as the ubiquitin-
protesome system, which degrade insulin signalling machinery, are also activated by 
glucocorticoids (Morgan et al, 2009; reviewed in (Schakman et al, 2008)). 
 
Glucocorticoid excess can also induce osteoporosis, by inhibiting intestinal calcium 
absorption, increasing renal calcium excretion and by inhibiting new bone formation 
(Canalis & Delany, 2002). Glucocorticoids have adverse effects on connective tissue through 
inhibition of fibroblast function (Pratt & Aronow, 1966). 
 
 31 
1.4 Glucocorticoid action and Metabolic Syndrome 
 
1.4.1 Glucocorticoid secretion 
 
The metabolic abnormalities found in central obesity, type 2 diabetes and the metabolic 
syndrome are similar to those seen in syndromes of prolonged exogenous or endogenous 
glucocorticoid excess (Cushing’s syndrome). Bjorntorp et al (Bjorntorp et al, 1999) 
proposed that subtle alterations in the hypothalamic-pituitary-adrenal axis (HPA) and 
cortisol homeostasis may provide the link between the cause and metabolic consequences of 
central obesity. The metabolic syndrome refers to a clustering of metabolic abnormalities 
that are associated with an increased risk of type 2 diabetes and cardiovascular disease 
(Balkau & Charles, 1999). The principal features are insulin resistance, central abdominal 
obesity, abnormalities of glucose and lipid metabolism, hypertension, and a pro-
inflammatory state.  
 
Cross-sectional and case-control studies have shown higher plasma, urinary or salivary 
cortisol levels in association with some components of the Metabolic Syndrome, including 
hypertension, insulin resistance, glucose intolerance, and in older men with type 2 diabetes 
(Filipovsky et al, 1996;Litchfield et al, 1998;Liu et al, 2005;Phillips et al, 1998;Reynolds et 
al, 2001;Reynolds et al, 2001b;Stolk et al, 1996;Walker et al, 1998;Walker et al, 2000). 
Moreover, long-term exogenous glucocorticoid excess is associated with increased risk of 
cardiovascular events (Souverain et al, 2004;Wei et al, 2004). However, in idiopathic 
obesity, although cortisol production rate is increased, this may be as a consequence of 
enhanced metabolic clearance of cortisol (Walker, 2006; Lottenberg SA et al, 1998) or 
impaired HPA-axis negative feedback (Mattsson et al, 2009) and circulating cortisol levels 
are not elevated (Ljung et al, 1996;Phillips et al, 1998;Walker et al, 2000).  
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1.5 Tissue responses to glucocorticoids 
 
Until recently, tissue glucocorticoid levels were thought to be exclusively determined by 
plasma levels of free glucocorticoids and tissue responses to glucocorticoids controlled by 
the density and availability of glucocorticoid receptors. It is now established that the 
biological effects of cortisol are controlled not only by circulating hormone levels via the 
HPA axis, but at the tissue level by pre-receptor enzymes that either limit or amplify access 
of ligands to glucocorticoid receptors. There is some evidence of GR dysfunction in 
Metabolic Syndrome (van Rossum et al, 2004; Walker, 2007), perhaps with a genetic basis 
in type 2 diabetes and hypertension (Franks et  al 2004; Nair et al 2004; Walker, 2006). 
However, from a therapeutic perspective, the pre-receptor enzymes have attracted more 
attention. The presence of an enzyme in some target tissues which amplifies local cortisol 
concentrations provides an opportunity for development of enzyme inhibitors selectively to 
reduce glucocorticoid action in specific sites. 
 
1.6 11 -Hydroxysteroid dehydrogenases 
 
Intra-cellular glucocorticoid levels are influenced in many tissues by the two isozymes of 
11 -hydroxysteroid dehydrogenase (11 HSD).  
 
1.6.1 11 - Hydroxysteroid dehydrogenase type 2  
 
11 HSD type 2 is found in aldosterone sensitive tissues such as the distal nephron, colon and 
placenta (Edwards  et al 1988; Stewart et al 1987) and functions to rapidly inactivate cortisol 
(corticosterone in rats and mice) and reserve MR activation specifically for aldosterone 
(Figure 1.4) (Funder et al, 1988; Edwards et al 1988). In the hippocampus however, MR is 
 33 
not protected by 11 HSD2 and is activated by both glucocorticoids and mineralocorticoids 
(Sheppard & Funder, 1987). 
 
The gene for 11 HSD2, located on chromosome 16 in humans and chromosome 8 in mice, 
has 77% sequence homology between the 2 species (White, 2001). 11 HSD2 is a 
microsomal membrane-bound enzyme which uses nicotinamide adenine dinucleotide (NAD) 
as  its  cofactor  and  has  a  Km  for  cortisol  in  the  nanomolar  range  (Brown  et al, 1993). 
Congenital deficiency of 11 HSD2 (Dave-Sharma et al, 1998), or transgenic deletion 
(Kotelevtsev et al, 1999) in mice, produces the syndrome of apparent mineralocorticoid 
excess with a phenotype of hypertension and sodium retention due to activation of MR by 
cortisol. Similar abnormalities result from consumption of large quantities of liquorice 
(Epstein et al, 1977), which contains inhibitors of 11 HSD2 (Stewart et al, 1987). More 
subtle 11 HSD2 deficiency may be important in essential hypertension (Ferrari et al, 
1996;Walker et al, 1993).  
 
Mice with adipose tissue specific over-expression of human 11 HSD2 (under the control of 
the murine aP2 promoter; aP2-h11 HSD2) (Kershaw et al, 2005) resist weight gain on high-
fat diet and have improved glucose tolerance and insulin sensitivity. aP2-h11 HSD2 Mice 
also have a favourable adipocytokine profile, suggesting that inactivation of glucocorticoids 
specifically in adipose tissue is an important determinant of a favourable metabolic 
phenotype.  
 
Although initial studies failed to demonstrate any significant 11 HSD2 in adipose tissue 
(Bujalaska et al, 2002), more recent studies have  shown 11 HSD2 expression in both rat 
adipocytes and adipose stromal vascular (ASV) cells (Milagro et al, 2007), in subcutaneous 
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adipocytes of obese women (albeit at much lower levels than 11 HSD1) (Engeli et al, 2004), 













Figure 1.4 Pre-receptor metabolism of active glucocorticoids by 11 HSD2 
Active glucocorticoids (cortisol, corticosterone) are inactivated by the type 2 isozyme of 
11 -hydroxysteroid dehydrogenase, thus preventing illicit occupation of the MR by 












1.6.2 11 - Hydroxysteroid dehydrogenase type 1  
 
11 HSD type 1 is a low affinity NADPH-dependent microsomal (endoplamic reticulum) 
enzyme that belongs to the short chain alcohol dehydrogenase / reductase family (SDRs). 
The gene for 11 HSD1 is located on chromosome 1 in both humans and mice, and is highly 
conserved between species, with ~80% sequence homology (Tomlinson et al, 2004). In early 
purification studies, 11 HSD1 activity showed bi-directionality in vitro (Lakshmi  &  
Monder, 1988). Further studies have demonstrated that the predominant reaction direction in 
intact cells in vitro and  in vivo is reductase (Seckl & Walker, 2001), converting cortisone to 
cortisol, driven by co-localisation within the lumen of the endoplasmic reticulum of the 
NADPH-generating enzyme hexose-6-phosphate dehydrogenase (H6PDH) as it catalyses the 
first step in the pentose phosphate pathway (Hewitt et al, 2005) (Figure 1.5). 
 
11 HSD1 is highly expressed in the liver (Lakshmi & Monder, 1988) and in adipose tissue 
(Bujalska et al, 1997) although it is also found in a number of other tissues, including brain 
(Sandeep et al, 2004), blood vessel wall (Small et al, 2005), macrophages (Gilmour et al, 
2006), eye (Rauz et al, 2003), bone (Eijken et al, 2005), lung (Hundertmark et al, 2002), and 
ovary (Thomas et al, 1998). 
 
Congenital 11 HSD1 deficiency or apparent cortisone reductase deficiency (ACRD) is 
characterised by failure to regenerate cortisol from inert cortisone, resulting in increased 
cortisol clearance, compensatory activation of the HPA axis, and androgen excess mediated 
through the ACTH drive.  Clinically, ACRD is characterised by hirsutism, oligomenorrhoea 
and sub-fertility. Inactivating mutations in the H6PDH gene which  prevent 11 HSD1- 



















Figure 1.5: Relationship between hexose-6-phosphate dehydrogenase (H6PDH) and 
11 HSD1 in vivo. 
 
11 HSD1 is co-localised with H6PDH within the lumen of the endoplasmic reticulum.  
H6PDH generates NADPH cofactor for the reductase reaction of 11 HSD1as it catalyses 
the first step in the pentose phosphate pathway. In this pathway, glucose-6-phosphate 
(G6P) enters the ER lumen via the glucose-6-phosphate transporter (G6PT) and is a 
substrate for glucose-6-phosphatase-  and undergoes hydrolysis to form glucose (G) and 
inorganic  phosphate  (Pi),  or  is  utalised  by  H6PDH.  H6PDH  converts  G6P  to  6-  
phosphogluconolactonate (6PG) and generates NADPH for 11 HSD1. Adapted from 
(Tomlinson et al, 2004) and (Walker et al 2007). 
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1.7 11 HSD1 in adipose tissue 
 
Human adipose tissue contains a glucocorticoid pool derived from both the systemic 
circulation and from local regeneration of cortisol by 11 HSD1. Concentrations of 
glucocorticoids in human subcutaneous adipose tissue biopsies have been estimated using 
radio-immunoassays (RIAs) and liquid chromatography tandem mass spectrometry (LC-
MS/MS)  with  contrasting  results  (Wake  et al, 2003; Lindsay et al, 2003; Ronquist-Nii & 
Edlund, 2005). Using highly specific and sensitive LC-MS/MS, adipose cortisol has been 
reported at concentrations of 12.4±0.6 and cortisone at 3.0±0.3 nmol/kg (Ronquist-Nii & 
Edlund, 2005), whereas cortisol concentrations ranging from 16.0- 157.0 nmol/kg have been 
reported using RIAs in subjects with a range of BMIs. Using in vivo microdialysis, 
subcutaneous adipose interstitial fluid cortisol concentrations have been reported as 
~7nmol/L (Tomlinson et al, 2007).    
 
Ex-vivo, 11 HSD1 is ‘set’ towards generation of cortisol in human omental adipocytes 
(Bujalska et al, 2002) and omental stromal vascular cells (SVCs) when stimulated with 
insulin and cortisol (Bujalska et al, 1997). The reductase reaction also predominates in 
murine SVCs from mesenteric and subcutaneous depots (De Sousa Peixoto et al, 2008). In 
both species visceral cells display greater reductase activity than subcutaneous cells (De 
Sousa Peixoto et al, 2008;Bujalska et al, 1997). In vivo,  significant release of cortisol from 
subcutaneous adipose tissue (Stimson et al, 2009) has also been described. 
 
Ex-vivo and in vivo studies have also demonstrated subcutaneous and omental SVC and 
subcutaneous whole adipose tissue dehydrogenase activity in primary cell culture 
experiments and in subcutaneous adipose microdialysis studies (Bujalska et al, 2002;Wake 
et al, 2006). In states of NADPH deficiency eg when 11 HSD1 is liberated from the 
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microsomal environment or when H6PDH is lost through transgenic manipulations in mice 
(Lavery et al, 2006), 11 HSD1-dehydrogenase activity predominates. As some studies have 
shown that adipose tissue 11 HSD2 expression is very low / negligible (Lee et al, 2008; 
Svendson et al, 2009) and 11 HSD1 expression is abundant (Bujalska et al, 2002), human 
adipose may have 11 HSD1-dehydrogenase activity in vivo.  
 
However, as acknowledged by the authors of the in vivo study (Wake et al, 2006),  the 
finding of 11 HSD1-dehydrogenase activity needs to be interpreted with some caution. 
Firstly, measured dehydrogenase activity may relate to the presence of vascular endothelial 
11 HSD2 in adipose tissue (Wake et al, 2006). Secondly, the technique of micro-dialysis 
can cause local tissue trauma upon insertion of the cannulae into the adipose tissue, which 
may act to increase dehydrogenase activity through causing disruption of the co-localised 
H6PDH and 11 HSD1 and thus diminishing co-factor availability. Therefore, the question of 
whether 11 HSD1-dehydrogenase activity occurs in human adipose tissue in vivo remains 
controversial.  
 
The issue of adipose tissue possessing some dehydrogenase activity in vivo remains  a  
priority that needs to be assessed for the development of new 11 HSD1 inhibitor drugs. 
These agents exert their effects by inhibiting 11 HSD1-reducatse and thus lowering 
intracellular glucocorticoids. If 11 HSD1 functions as a dehydrogenase, inactivating 
glucocorticoids, an 11 HSD1 inhibitor might actually increase, rather than decrease, 
intracellular cortisol concentrations, depending on the balance of activities. So, although at 
present there is no convincing evidence of in vivo dehydrogenase activity attributable to 




1.8 Regulation of 11 HSD1 in adipose 
 
11 HSD1 is highly transcriptionally regulated. Factors known to increase 11 HSD1 
expression include glucocorticoids, peroxisome proliferator-activated receptor-  agonists, 
and some proinflammatory cytokines (TNF , IL-1 ) (Tomlinson et al, 2004).  Growth 
hormone (acting via IGF-I) and liver X receptor agonists inhibit 11 HSD1 expression 
(Tomlinson et al, 2004). The effect of other factors such as sex steroids, insulin, and thyroid 
hormone (T3) vary between tissues and species studied (Tomlinson et al, 2004). 
 
In adipose tissue, the effects of diet, intralipid infusions, PPAR-  and -  agonists and insulin 
on 11 HSD1 transcription have been assessed, but again the studies show inconsistent 
regulation depending on the species studied. In both mice (Morton et al, 2004b) and rats 
(Drake et al, 2005) a high fat diet decreases 11 HSD1 activity. In humans intravenous 
intralipid acutely increases subcutaneous adipose 11 HSD1 activity (Wake et al, 2006), but 
longer term treatment with an oral high fat- low carbohydrate diet or medium fat- medium 
carbohydrate diet does not affect subcutaneous adipose 11 HSD1 mRNA or activity 
(Stimson et al, 2007). 
 
PPAR-  and -  agonists reduce 11 HSD1 activity in the liver (Hermanowsi-Vosatka et al, 
2000) and adipose tissue (Berger et al, 2001) of rodents, but in healthy male volunteers, 7 
days of fenofibrate (PPAR-  agonist) failed to have an effect on cortisol secretion. Short 
term rosiglitazone administration (PPAR –  agonist) did however marginally reduce adipose 
11 HSD1-activity (Wake et al 2007). Four-five weeks of rosiglitazone had no effect on 
adipose 11 HSD1, whereas longer term treatment in individuals with type 2 diabetes 
reduced 11 HSD1 expression in subcutaneous adipose tissue (Wake et al 2007) in keeping 
with the rodent studies. 
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In vitro insulin reduces 11 HSD1 in rodent hepatocytes (Jamieson et al, 1995), but does not 
alter 11 HSD1 expression in adipocytes (Bujalska et al, 1999). In vivo, acute 
hyperinsulinaemia in humans has ben shown to either increase (Wake et al, 2006) or 
temporarily decrease (Sandeep et al, 2005) subcutaneous adipose tissue 11 HSD1 activity in 
lean subjects. However, hyperinsulinaemia does increase whole body 11 HSD1 activity 
(Wake et al, 2006). Given that hyperinsulinaemia increases glucose flux into cells, we aimed 
to assess if increasing intracellular glucose availability would increase flux in the pentose 
phosphate pathway, hypothesising that increased glucose delivery to H6PDH may result in 
increased NADPH co-factor generation. This may in turn increase 11 HSD1-reductase 
activity, which is NADPH-dependent, or even switch directionality of 11 HSD1 in adipose 
tissue. This hypothesis has been examined in Chapter 5. 
  
1.9 11 HSD1 in obesity and type 2 diabetes 
 
Alterations in 11 HSD1 have been documented in both animal models and clinical studies of 
idiopathic obesity and type 2 diabetes. These changes are tissue-specific: 
 
In most, but not all (Morton et al, 2005), obese rodents 11 HSD1 expression and activity is 
reduced in the liver and increased in adipose tissue (Livingstone et al, 2000;Masuzaki et al, 
2001;Liu et al, 2003; Morton et al, 2004.). Similar differences have been described in obese 
humans, in whom there is reduced hepatic (Rask et al, 2001;Rask et al, 2002;Stewart et al, 
1999), and increased adipose (Desbriere et al, 2006;Engeli et al, 2004;Kannisto et al, 
2004;Lindsay et al, 2003;Paulmyer-Lacroix et al, 2002;Rask et al, 2001;Rask et al, 
2002;Sandeep et al, 2005;Wake et al, 2003;Westerbacka et al, 2003) 11 HSD1 activity 
(Table 1.1).  
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Many of these observations in obesity have been made in biopsied adipose tissue. However, 
using in vivo microdialysis, it has been demonstrated that cortisol generation within 
subcutaneous adipose tissue is increased in obesity (Sandeep et al, 2005). Using stable 
isotope tracer methods however, splanchnic cortisol generation was not increased in obesity 
(Basu et al, 2005), suggesting that any increase in cortisol production by visceral tissue is 
compensated for by a decrease in hepatic cortisol production (Walker & Andrew, 2006). 
Therefore, it is important to make tissue-specific measurements in order to dissect the role of 
11 HSD1. The magnitude of the effect of altered 11 HSD1 expression on intra-adipose 
cortisol concentrations in normal conditions also remains to be determined. 
 
Fewer studies of 11 HSD1 have been conducted in type 2 diabetes (Valsamakis et al, 2004). 
Although hepatic 11 HSD1 activity is mildly impaired, adipose tissue 11 HSD1 activity 
appears to be normal in lean patients with type 2 diabetes (Andrews et al, 2002). In obese 
type 2 diabetic patients, 11 HSD1 expression in skeletal muscle myotubes is increased, 
which may contribute to the pathogenesis of insulin resistance (Abdallah et al, 2005). 
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Table 1.1: Summary of studies examining tissue 11 HSD1 expression and activity in 
obese rodents and humans. 
 
Reference Adipose 11 HSD1 
expression or activity 
Hepatic 11 HSD1 
expression or activity 
(Morton et al, 2005)   
(Livingstone et al, 2000), 
(Rask et al, 2001),  
(Rask et al, 2002), 









(Masuzaki et al, 2001), 
(Desbriere et al, 2006), 
(Engeli et al, 2004),  
(Lindsay et al, 2003), 
(Sandeep et al, 2005), 
(Wake et al, 2003),  
(Kannisto et al, 2004), 




















1.10 Transgenic rodent models of altered 11 HSD1
 
Manipulations of 11 HSD1 in mice have confirmed the potential importance of this enzyme 
in obesity, type 2 diabetes and the Metabolic Syndrome. Mice over-expressing 11 HSD1 in 
white adipose tissue under the aP2 promoter have normal serum glucocorticoid levels, as in 
human obesity (Masuzaki et al, 2001). However, intra-adipose corticosterone concentrations 
are increased and these animals develop a Metabolic Syndrome phenotype, with increased 
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visceral fat mass, glucose intolerance, insulin resistance, and elevated portal corticosterone 
and free-fatty acid levels (Masuzaki et al, 2001). Since the fold-increase in 11 HSD1 
activity in adipose tissue is similar in these mice to the up-regulation observed in adipose 
tissue in human obesity, these findings suggest that increased intra-adipose 11 HSD1 may 
be responsible for the metabolic complications of obesity, which when present in humans are 
associated with increased cardiovascular risk.  
 
Conversely, mice with targeted disruption of the HSD11B1 gene locus (11 HSD1 -/- mice) 
resist hyperglycaemia provoked by high fat feeding and, on starvation, show attenuated 
activation of key hepatic enzymes involved in gluconeogenesis (Glucose-6-Phosphatase 
(G6Pase) and phosphoenolpyruvate carboxykinase (PEPCK) (Kotelevtsev et al, 1997). 
11 HSD1 -/- mice also have a favourable lipid and lipoprotein profile compared to controls 
(Morton et al, 2001) and a metabolically favourable adipose tissue distribution, on a 
C57BL6J genetic strain which is susceptible to obesity and diabetes (Morton et al, 2004). 
These findings suggest that inhibiting 11 HSD1 pharmacologically, and thereby lowering 
intracellular but not circulating glucocorticoid levels, may lead to improvements in 
metabolic profiles in humans. 
 
1.11 In vivo measurement of the 11 HSDs in humans 
 
Transgenic models help to predict phenotypes in humans, but given their lifelong and 
developmental deficiency of 11 HSDs and thus ‘abnormal’ tissue glucocorticoid physiology, 
these mice may not be a good model to directly translate into human physiology, as changes 
in  11 HSD1  expression  in  humans  are  usually  as  a  result  of  specific  stimuli  eg  obesity.  
Therefore, clinical studies are useful to assess 11 HSD1 activity in vivo where disruption of 
the enzyme from the intra-cellular environment does not occur or exposure to different 
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physiological stimuli from before birth, as is the case with transgenic mouse models, does 
not need to be accounted for.  
 
Assessment of the 11 HSDs in humans is difficult. Traditionally, measurement of urinary 
free cortisol:cortisone ratios have been used as an index of renal 11 HSD2 activity (Best & 
Walker, 1997;Palermo et al, 1996), or urinary cortisol:cortisone metabolite ratios have been 
used to reflect predominantly intra-hepatic steroid levels. However, these ratios only reflect 
net balance between the activities of multiple enzymes and do not quantify the rates of 
turnover between cortisol and cortisone. 
 
Stable isotope tracers allow investigators to assess metabolic pathways in vivo without 
disrupting normal physiology. One example of a stable isotope tracer is 9,11,12,12 [2H]4-
cortisol (d4-cortisol),  which permits measurement of cortisol generated specifically by 
11 HSD1-reductase activity in vivo (Andrew et al, 2002). d4-Cortisol has 4 deuteriums 
attached in the 9, 11, 12, 12 positions of the steroid skeleton. When infused systemically, d4-
cortisol is metabolised by 11 -dehydrogenase and loses a deuterium in the 11 - position to 
become 9, 12, 12 [2H]3-cortisone (d3-cortisone) (Figure 1.6). d3-Cortisone is further reduced 
by 11 -reductase to form 9, 12,12 [2H]3-cortisol (d3-cortisol). Thus it is possible to 
distinguish between the substrates for 11 -dehydrogenase and the product of 11 -reductase 
and endogenous glucocorticoids.  As d4-cortisol can only be metabolised to d3-cortisone but 
d3-cortisol cycles (d3-cortisol to d3-cortisone and vice versa), by measuring the dilution of 
the infused d4-cortisol by the generated d3-cortisol, the specific cortisol-generating activity 
of 11 HSD1 can be calculated (Andrew et al, 2002).  Table 1.2 describes all published 












Figure 1.6: Metabolism of the stable isotope tracer d4-cortisol by the isozymes of 
11 HSD.  
When infused systemically, d4-cortisol is metabolised by 11 -dehydrogenase and loses a 
deuterium in the 11 - position to become 9, 12, 12 [2H]3-cortisone (d3-cortisone). d3-
Cortisone is further reduced by 11 -reductase to form 9, 12,12 [2H]3-cortisol (d3-cortisol). 
CH2OH 
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Several investigators have evaluated adipose tissue 11 HSD1 cortisol regeneration rate using 
an infusion of d4-cortisol. Andrew et al used hepatic vein catheterisation to measure 
splanchnic cortisol production and then a single oral dose of cortisone to measure cortisol 
generation in the liver (Andrew et al, 2005). Extra-hepatic splanchnic cortisol production 
(including visceral adipose) was estimated to generate cortisol at a rate of 29.9nmol/min 
(Andrew et al, 2005). However, this production rate was based on modelling estimates rather 
than direct measurements. Two subsequent studies (Basu et al, 2009; Stimson et al, 2009) 
utilised arteriovenous sampling techniques across the liver and demonstrated that the liver 
actually accounts for all splanchnic cortisol production. Only one study to date has used a 
d4-cortisol infusion and arteriovenous sampling to measure cortisol production across 
subcutaneous adipose and this has revealed that subcutaneous adipose 11 HSD1 generates 
cortisol at a rate of 15.0pmol/min/100g adipose tissue (Stimson et al, 2009). 
 
Key questions regarding adipose tissue physiology in health such as glucocorticoid uptake in 
adipose tissue and the contribution of adipose 11 HSD1 to the adipose glucocorticoid pool 
have yet to be answered using this technique and these questions will be addressed in this 
thesis. Furthermore, 11 -dehydrogenase activity cannot be quantified accurately with the d4-
cortisol tracer as this relies on exptrapolation of d3-cortisone measurements derived from 
non-steady state kinetics as d3-cortisone is not infused into the plasma pool. Therefore a 
reliable tracer method to measure 11 -dehydrogenase activity in the whole body and tissues 
is currently not available. During my PhD studies, I have developed and validated a tracer-
method to measure 11 -dehydrogenase activity in vivo and have subsequently used it to 
answer the question as to whether any 11 HSD1-dehydrogenase activity exists in human 







Interventions T:T of 
infusion 
(d4F:F) 
Whole body RaF 
nmol/min 
Whole body Rad3F 
nmol/min 
(Andrew et al, 
2002) 
 
6 healthy  
BMI not reported 
4 hours Placebo or CBX 
1.74mg/h d4F 






6 lean  BMI 24.6 
6 obese  BMI 36.6 
 
5 hours Placebo or CBX in 
obese group. 
1.74mg/h d4F 
20:80 23.1 lean 
26.0 obese plac 
17.2 obese CBX 
13.9 lean 
14.1 obese plac 
9.2 obese CBX 
(Wake et al, 
2006)  
 
9 healthy  
BMI 25.5 
7 hours Non-fasting. Run in 
period - tracers only 
(basal), then 
intervention: saline, 
insulin or intra-lipid. 
1.74mg/h d4F 
 
20:80 23.9 basal -12.7 
saline 
33.1 basal -21.5 
insulin 
34.2 basal -16.7 lipid 
16.8 basal -16.7 saline 
16.8 basal -19.3 insulin 
16.7 basal -17.7 lipid 
(Wake et al, 
2007) 
9 healthy  
BMI 27.3 



















Interventions T:T of 
infusion 
(d4F:F) 
Whole body RaF 
nmol/min 




8 healthy  
BMI 22.7 


















6  BMI 30.8 
(subcut. adipose 
study) 












40:60 33.8 (subcut study) 
13.5 (splanchnic) 








Interventions T:T of 
infusion 
(d4F:F) 
Whole body RaF 
nmol/min 
Whole body Rad3F 
nmol/min 
(Basu et al, 
2004)  
11 subjects. Sex n/s 
BMI 31 





100 50 basal 
66.2 with insulin 
u/k 
(Basu et al, 
2005)  
10 lean BMI<24  
(4 ) 
10 obese BMI>28 
(4 ) 
11 obese diabetics 
(5M:6F) 








9.6  obese diabetic 
10.4  obese non-diabetic 
10.1  lean 
(Basu et al, 
2009) 
10 obese BMI 46 
(2 ) 
n/s Bariatric surgery 
0.19mg/h d4F 
 







Table 1.2 summarises the published studies using the d4-cortisol infusion technique. The first eight studies used an infusion of both cortisol and d4-
cortisol whereas the last three studies use d4-cortisol only. The studies examine whole body cortisol / d3-cortisol production, response to 
interventions, and some arteriovenous sampling studies assessing tissue cortisol / d3-cortisol production. d4F= d4-cortisol; d=deuterium; F=cortisol; 
T:T = tracer:tracee ratio; RaF = rate of appearance of cortisol; Rad3F = rate of appearance of d3-cortisol; BMI = body mass index  (kg/m2); CBX = 
carbenoxolone; n/s= not stated;  = male; prod=production 
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1.12 Cortisol antagonism as a therapeutic target 
 
It has been proposed that reducing GR activation by cortisol may be of therapeutic benefit in 
patients with features of the metabolic syndrome. In contrast with many current therapies 
available for the treatment of type 2 diabetes and obesity, cortisol antagonism might be 
expected to be associated with improvements in all of the major features of the metabolic 
syndrome. Amongst many actions, lowering glucocorticoid activity would be expected to 
reduce hepatic glucose output (Kotelevtsev et al, 1997), improve lipid profiles (Morton et al, 
2001), improve adipose insulin sensitivity and adipokine release (Masuzaki et al, 2001) and 
potentially improve insulin secretion from pancreatic -cells (Davani et al, 2000). 
 
However, cortisol plays vital roles in the stress response, with important effects on cellular 
growth and differentiation and immune modulation. A major challenge has been to devise a 
strategy for antagonising glucocorticoid effects on cardiometabolic parameters which does 
not risk inducing adrenal insufficiency at times of stress. Several approaches have been 
proposed. 
 
1.12.1 Antagonism of adrenal steroidogenesis 
 
Targeting steroid biosynthesis in the adrenal is one potential method of reducing 
glucocorticoid activity, and has been trialled in depression (Wolkowitz et al, 1999). 
Ketoconazole, aminoglutethimide and metyrapone, traditionally used for the treatment of 
Cushing’s syndrome, decrease plasma cortisol by inhibiting key enzymes in adrenal 
steroidogenesis. However, inhibiting enzymes at the level of the adrenal prevents the HPA 
axis adapting to stress and risks the development of a hypo-adrenal crisis during inter-current 
illness, and is not a safe long-term therapy.  
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1.12.2 Glucocorticoid receptor antagonism 
 
Others groups have focused on GR antagonists such as RU38486, a glucocorticoid and 
progesterone receptor antagonist, which opposes the actions of glucocorticoids in peripheral 
tissues. Administration of RU38486 to mice with diabetes (Gettys et al, 1997) led to 
improvements in plasma glucose levels. In Cushing’s syndrome, RU38486 delivered such 
marked improvements in glycaemic control that oral hypoglycaemic medications could be 
discontinued (Chu et al, 2001), demonstrating the beneficial metabolic effects of decreasing 
glucocorticoid activity.  
 
However, RU38486 prevents GR mediated negative feedback at central sites controlling the 
HPA axis. Consequently, the HPA axis stimulates adrenal steroidogenesis to overcome the 
peripheral block imposed by this drug. Activation of the HPA axis results in the increased 
production of adrenal androgens and mineralocorticoids, which in turn result in hirsutism 
and hypertension, respectively. It is also expected that at times of physiological stress, when 
elevations in glucocorticoid levels are necessary, systemic GR blockade may also be 
problematic since it impairs GR action indiscriminately in all tissues, including cells of the 
immune system. Therefore, pharmacological systemic GR antagonism potentially produces 
undesirable systemic effects and is not a suitable long-term therapy.  
 
To circumvent these systemic consequences, tissue-specific GR antagonists have been 
developed such as the Abbott liver-selective GR antagonist, which is a bile acid – RU38486 
conjugate (von Geldern et al, 2004). The bile acid ensures that concentrations of this drug 
are maximised in the liver by enterohepatic circulation. Oral dosing to ob/ob mice led to 
substantial improvement in plasma glucose levels and lipid parameters (von Geldern et al, 
2004). However, any dispersal of this compound into the systemic circulation may have 
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adverse effects. Indeed, this compound is no longer being developed by Abbott, perhaps this 
may reflect concerns about its potential abortifacient effects given that it is a progesterone -
receptor antagonist, although this is purely speculative. 
 
1.13 11 HSD1 Inhibition: pre-clinical and early clinical results 
 
More than 25 companies are now involved in 11 HSD1 inhibitor drug development 
programmes. In 2 years, over 70 international patent applications detailing 11 -HSD1 
inhibitors have been published (Fotsch et al, 2005;Webster & Pallin, 2007).  
 
1.13.1 Non-selective inhibitors: Carbenoxolone 
 
Carbenoxolone (CBX) is a hemisuccinate derivative of glycyrrhetinic acid and a non-
selective 11 HSD inhibitor (Figure 1.7).  The effects of CBX have been assessed in obese, 
insulin resistant Zucker rats and in LDL-receptor knockout mice (LDLR -/-), a model of 
hyperlipidaemia and obesity.  In Zucker rats, CBX had no effect on fasting glucose levels or 
11 HSD1 activity in the skeletal muscle or adipose tissue, but did inhibit 11 HSD1 activity 
in the liver (Livingstone & Walker, 2003).  When administered via a subcutaneous route to 
LDLR -/-  mice,  CBX was  detected  in  the  liver  and  adipose  tissue  one  hour  after  injection  
(Nuotio-Antar et al, 2007). These mice showed improvement in several metabolic 
parameters including lipid profiles, hepatic steatosis, and expression of genes involved in 
lipid metabolism and atherogenesis. However, improvements in fasting insulin levels were 
only seen in the most obese mice.  
 
When administered to healthy lean men, CBX improved insulin sensitivity (Walker et al, 
1995). In lean patients with type 2 diabetes, CBX administration enhanced hepatic insulin-
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sensitivity, and reduced glucose production and glycogenolysis (Andrews et al, 2003). 
However, in obese human subjects, like Zucker rats (Livingstone et al, 2003), CBX failed to 
have any effect on insulin sensitivity (Sandeep et al, 2005), suggesting that CBX loses its 
beneficial effect on insulin-glucose homeostasis in the obese. Possible mechanisms for this 
loss of efficacy may relate to down-regulation of 11 HSD1 in the liver in obesity and/or the 
drug being unable to penetrate adipose tissue, where 11 HSD1 is elevated in obesity. This is 
in keeping with the findings of the study in LDLR-/- mice, where the authors concluded that 
the subcutaneous route of administration may have allowed more of the drug to bypass 
hepatic first-pass metabolism and thus a higher concentration of drug was in the circulation 
to penetrate the different tissues (the levels of CBX 1 hour post-dose were higher in liver and 
adipose tissue than those described previously)(Nuotio-Antar et al, 2007).  
 
These studies with CBX provide important proof-of-principle evidence that 11 HSD1 
inhibition leads to improvements in several metabolic parameters. However, CBX 
administration had no effects on gluconeogenesis, peripheral glucose uptake or insulin-
mediated suppression of plasma free-fatty acids in individuals with type 2 diabetes (Andrews 
et al, 2003). Non-selective inhibitors, such as CBX, can also induce renal mineralocorticoid 
excess at higher doses. The resulting hypertension is undesirable in patients who already 
have type 2 diabetes, obesity and metabolic abnormalities. A therapeutic approach to 
circumvent CBX-induced hypertension would be to use a diuretic, such as Amiloride, in 
combination with CBX, as this would block the consequences of renal 11 HSD2 inhibition 
(Sandeep et al, 2004). However, given the potential adverse effects of blocking both 





















Figure 1.7 The structure of Carbenoxolone 
 
The non-selective 11 HSD inhibitor Carbenoxolone is orally bioavailable, able to penetrate 
liver and adipose (when administered subcutaneously) and improves insulin / glucose 










1.13.2 Selective 11 HSD1 inhibitors 
 
Merck Laboratories have a potent inhibitor of 11 HSD1 named Compound 544 (Figure 1.8). 
The compound has been studied in murine models of obesity (diet-induced obesity, DIO), 
type 2 diabetes (high-fat streptozotocin, HF-STZ) and atherosclerosis (ApoE deletion, 
C57BL/6). In DIO mice, inhibition of 11 HSD1 led to reduction in body weight and 
cumulative food intake (Hermanowski-Vosatka et al, 2005) with preferential loss of central 
fat mass. However, there was little effect on body weight in HF/STZ model (Hermanowski-
Vosatka et al, 2005). With regards to type 2 diabetes, in DIO mice Compound 544 lowered 
fasting glucose and insulin levels below that seen in lean controls (Hermanowski-Vosatka et 
al, 2005), and lowered fasting and post-prandial glucose excursions and improved insulin 
sensitivity in HF/STZ mice. In atherosclerosis, encouraging improvements were seen in lipid 
profiles. Triglycerides were lowered in all mouse models studied, and fatty acids and 
cholesterol improved in some. Inhibition of 11 HSD1 also slowed atherosclerotic plaque 
progression in ApoE -/- mice fed on a high-fat atherogenic diet (Hermanowski-Vosatka et al, 




Figure 1.8 Structure of Compound 544  
 
Compound 544 is orally bio-available, improves insulin / glucose homeostasis, lipid 
profiles, modulates appetite and prevents weight gain.  
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Thiazoles from Biovitrum are species-selective inhibitors of 11 HSD1.  In pre-clinical 
studies, a single oral bolus dose of BVT 2733 resulted in inhibition of hepatic 11 HSD1 
activity in hyperglycaemic KKAy mice (Alberts et al, 2002). Subcutaneous drug-delivery 
resulted in significant lowering of glucose and insulin levels and lowering of hepatic mRNA 
of G6Pase and PEPCK, reducing hepatic glucose production (Alberts et al, 2002).  
 
An Amgen – Biovitrum compound, BVT 3498 reached clinical development.  A phase one 
trial in healthy volunteers was undertaken in 2002 and a phase 2a double-blind, placebo-
controlled trial in individuals with type 2 diabetes in 2003. However, in 2004, Amgen 
announced that their series of Amgen-Biovitrum compounds had failed in phase 2 trials. 
 
Incyte is a further company that has progressed from pre-clinical to clinical trials with their 
orally administered 11 HSD1 inhibitors. A phase 1 double-blinded placebo-controlled 
clinical study of INCB13739 to evaluate pharmacokinetics and the ability of the drug to 
inhibit 11 HSD1 activity in adipose tissue and liver of subjects with a high BMI and insulin 
resistance has been completed. A phase 2a study using a 2-phase insulin clamp in 24 
volunteers was run in 2007 and demonstrated clinical improvements in glucose and lipid 
profiles in people with diabetes. A further phase 2b efficacy trial in 2008 demonstrated 
significant improvements in glucose control, insulin sensitivity and total cholesterol in 
patients with type 2 diabetes. 
 
1.13.3 Other compounds 
 
Other compounds in medical and everyday use have also proven to be useful inhibitors. The 
bile acid chenodeoxycholic acid (Diederich et al, 2000), coffee (Atanasov et al, 2006) and 
flavanone and its derivatives (found in orange and yellow fruit) can inhibit 11 HSD1 
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(Schweizer et al, 2003). As yet, there are no pre-clinical or clinical trials in the scientific 
literature describing these compounds as 11 HSD1 inhibitors. 
 
1.14 Effects of 11 HSD1 inhibition beyond Metabolic Syndrome 
 
In addition to its expression in liver and adipose tissue, 11 HSD1 is active in a number of 
other cells and tissues (Tomlinson et al, 2004). Accumulating evidence from 11 HSD1 -/- 
mice and from pharmacological inhibition of 11 HSD1 suggests that the enzyme is 
important in modulating effects of glucocorticoids not only on metabolism, but also on 
immunomodulatory, cognitive and other tissue functions. Small molecule selective 
11 HSD1 inhibitors are likely to affect these pathways. This may produce beneficial effects 
by reducing glucocorticoid action in skeletal muscle (Jang et al, 2007), the eye and brain. 
For example, carbenoxolone (CBX) improves cognition in elderly men, including those with 
type 2 diabetes (Sandeep et al, 2004), an effect which is mimicked by Merck’s 11 HSD1 
inhibitors in mice. CBX may also improve intra-ocular hypertension in people with 
glaucoma (Rauz et al, 2003). However, the effects of inhibitors on other tissues such as 
macrophages and vascular tissue, and indeed other sites in the brain, may or may not be 
beneficial.  
 
Since 11 HSD1 is expressed in macrophages (Thieringer et al, 2001), and glucocorticoids 
promote macrophage consumption of apoptotic neutrophils and hence promote resolution of 
inflammation, one potential side effect of 11 HSD1 inhibition is to exaggerate innate 
immune responses. 11 HSD1 -/- mice show delayed macrophage-phagocytic ability 
(Gilmour et al, 2006) and delayed resolution of inflammation in experimental arthritis 
(Chapman et al, 2006). Thus 11 HSD1 inhibitors may impair the inflammatory response and 
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in individuals susceptible to soft tissue infections, such as those with type 2 diabetes, this 
might lead to delayed wound healing. 
 
A further site of 11 HSD1 expression is the blood vessel wall. Supra-physiological doses of 
glucocorticoids are known to inhibit angiogenesis, as illustrated by the poor wound healing 
seen in Cushing’s syndrome.  11 HSD1 -/- mice show enhanced angiogenesis in wounds and 
in infarcted myocardium (Small et al, 2005). 11 HSD1 inhibitors might, therefore, promote 
angiogenesis. However, the mechanism for this effect and its relevance in different 
circumstances of angiogenesis is unknown. It could be potentially beneficial in wound 
healing and infarcted areas of tissue, but potentially disadvantageous in promoting cancer 
growth, and diabetic retinopathy. The latter is a particular concern because people with 
diabetes are most likely to gain from the beneficial metabolic effects of 11 HSD1 inhibitors. 
 
In the brain, 11 HSD1 is expressed in key areas including the hippocampus (Sandeep et al, 
2004) and most small molecule 11 HSD1 inhibitors penetrate this tissue. There have been 
concerns that inhibition of hippocampal 11 HSD1 will reduce local tissue glucocorticoid 
levels and reduce the negative feedback suppression of the HPA (Walker & Andrew, 2006). 
The expected effect of this is a compensatory increase in cortisol levels, and indeed mild 
elevations in basal corticosterone levels were found in 11 HSD1 -/- mice (Kotelevtsev et al, 
1997). However, despite the elevated corticosterone, these mice retain their protected 
metabolic profile and thus this may not be a clinically relevant problem for small molecule 
11 HSD1 inhibitors. Moreover, corticosterone concentrations were normal in 11 HSD1 -/- 
mice crossed onto a C57BL6 genetic background (Paterson et al, 2007).
 
11 HSD1 may be bidirectional in some metabolically important 11 HSD1-inhibitor target-
tissues eg adipose tissue (Wake et al, 2006). If 11 HSD1-inhibitors are not 11 HSD1-
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reductase selective, any 11 HSD1-dehydrogenase activity in these tissues may be inhibited 
which  may  actually  increase  tissue  glucocorticoid  levels.   It  is  not  clear  if  most  of  the  
published inhibitor-compounds are indeed reductase-selective. Therefore discrepancies in 
published clinical efficacy might be explained by non-selctive compounds inhibiting 




Transgenic mouse models have demonstrated that dysregulation of glucocorticoid production 
in tissues by 11 HSD1 leads to obesity and metabolic syndrome. In human idiopathic 
obesity, circulating cortisol levels are not elevated but glucocorticoid production by 
11 HSD1 in tissues is altered. Pre-clinical and clinical studies of 11 HSD1-inhibitors have 
shown promising metabolic results. However several key questions regarding adipose 
glucocorticoid regulation in health remain unanswered to ensure that these drugs provide 
metabolic benefits in humans without causing major side effects. These unanswered 
questions in human adipose tissue are the focus of the experiments in this thesis. 
 
1.16 Hypothesis  
 
The hypotheses examined in this PhD were as follows: 
 
1. Absolute levels of glucocorticoids in adipose tissue and the contribution of 11 HSD1 to 
the intra-adipose glucocorticoid pool can be accurately quantified using the stable isotope 
tracer d4-cortisol. 
 
2. 11 HSD1-dehydrogenase activity can be measured in vivo using stable isotope tracers. 
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3. Adipose tissue possess some potentially metabolically protective 11 HSD1-
dehydrogenase activity leading to cortisol inactvation in adipose tissue, which can be 




1. To develop a method to measure adipose tissue glucocorticoids using liquid 
chromatography tandem mass spectrometry (LC-MS/MS) (discussed in Chapter 3). 
 
2. To assess glucocorticoid uptake in adipose tissue using the stable isotope tracer 9,11,12,12 
[2H]4-cortisol (discussed in Chapter 3). 
 
3. To determine the relative contribution of the HPA axis and adipose tissue 11 HSD1 to the 
adipose glucocorticoid pool (discussed in Chapter 3). 
 
4. To develop a stable isotope tracer method with 1,2 [2H]2-cortisone to measure 11 -
dehydrogenase activity in vivo (discussed in Chapter 4). 
 
5. To measure 11 HSD1 directionality in adipose tissue and skeletal muscle in vivo using the 
stable isotope tracers 9,11,12,12 [2H]4-cortisol and 1,2 [2H]2-cortisone (discussed in Chapter 
5). 
 
6. To assess the effect of increased glucose flux into adipose tissue and skeletal muscle on 














Materials and Methods 
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2.1 Introduction to materials and methods 
 
All clinical measurements, sample collection, assays and analysis were carried out by the 
author after appropriate advice, except those detailed in the declaration page iv. Methods 
already in routine use within this research unit were modified and optimised for tracer 
studies in human tissues and plasma and human bioassays. De novo methods developed 
include measurement of tissue (adipose and liver) and salivary glucocorticoids using liquid 
chromatography tandem mass spectrometry (LC-MS/MS). Where room temperature is stated 




a) Centrifuges:  
 D2-cortisone studies (hepatic cytosol preparation), Chapter 2: Beckman Optima 
TLX Ultracentrifuge, (Beckman Coulter, High Wycombe, UK). 
 Method development, adipose glucocorticoid extraction, Chapter 3: Eppendorf 
centrifuge 5415C (Cambridge, UK).  
 Tissue tracer study, Chapter 3 (plasma and adipose): Eppendorf centrifuge 
5810R, (Cambridge, UK). 
 D2-cortisone studies (plasma, saliva), Chapter 4: Sigma 4K15 centrifuge, 
(SciQuip, Shrewsbury, UK). 
 Oxford arterio-venous sampling study (plasma), Chapter 5: Eppendorf 5702R 
centrifuge (Cambridge, UK).  
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b) Beta-scintillation counter: 
 Tri-carb 2100TR liquid scintillation analyser, (Packard Instruments, Chicago, 
IL). 
 
c) pH meter: 
 pH 210 microprocessor pH meter, (Hanna Instruments, Leighton Buzzard, UK). 
 
d) Homogeniser:  
 Pro200 homogeniser (Pro scientific Inc, Oxford, CT). 
 
e) Vortex:  
 MS2 Minishaker (IKA, Staufen, Germany). 
 
f) Sonicator:  
 Branson sonicator model 1210 (Branson, Danbury, CT). 
 
g) Whole blood oxygen saturation: 
 GEM OPL instrument (Instrumentation laboratory, Bedford, MA).  
 
h) Haematocrit: 
 Haematospin 1300 instrument (Hawksley, Lancing, Sussex, UK).  
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 2.3 Sources of materials 
 
All reagents were obtained from Sigma (Poole, UK) or VWR (Lutterworth, UK) unless 
otherwise specified. All solvents were glass distilled HPLC grade from Fisher Scientific 
(Loughborough, UK).  
 
2.3.1 Commonly used buffers  
 
a) Sodium phosphate buffer: 1 part sodium dihydrogenphosphate (NaH2PO4) (0.2M), 3 parts 
disodiumhydrogen phosphate (Na2HPO4) (0.6M), 5mM ethylenediaminetetraacetic acid 
(EDTA) dissolved in distilled water and adjusted to pH 7.0 using concentrated 
orthophosphoric acid. 
 
b) Sucrose / HEPES buffer: 250mM sucrose, 10mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), dissolved in distilled water, and adjusted to pH 7.5 
using sodium hydroxide (1M), and stored at 4 C. 
 
c) 40mM Sodium phosphate buffer: 40mM disodium hydrogen phosphate (Na2HPO4), 
dissolved in distilled water, and adjusted to pH 7.4 using concentrated orthophosphoric acid, 
and stored at 4 C. 
 
d) Sucrose / sodium phosphate buffer: 320nM sucrose, 1mM dithiothreitol (DTT) dissolved 
in sodium phosphate buffer (40mM, solution c), made fresh for each assay. 
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e) Potassium phosphate buffer: 50mM potassium dihydrogenphosphate (KH2PO4), 1mM 
EDTA dissolved in distilled water (adjusted to pH 7.4 using potassium hydroxide (1M), 
stored at 4 C). 
 
f) Sodium acetate buffer: 0.2M sodium acetate dissolved in distilled water (adjusted to pH 
4.6 using glacial acetic acid, and stored at 4 C). 
 
2.3.2 Drugs for clinical studies 
 
Stable isotopically labelled tracers 
 
All stable isotopically labelled tracers were obtained from Cambridge Isotope Laboratories 
(CIL, Andover, MA.). Chemical and isotopic purity were assessed by the manufacturer. 
 
a) 1,2-[2H]2-cortisone  powder (d2-cortisone): >96.3% purity and 98% isotopic enrichment 
as determined by single spot thin layer chromatography (TLC).  
 
b) 1,2-[2H]2-cortisol  powder (d2-cortisol): >99% purity and 98.9% isotopic enrichment as 
determined by 1H nuclear magnetic resonance.  
 
c) 9,11,12,12-[2H]4-cortisol powder (d4-cortisol): >98% purity and 98.6% isotopic 










a) Saline (NaCl): sodium chloride (0.9% w/v) (Baxter, Newbury, UK), containing 
77mmol/500ml (154mM) sodium and 77mmol/500ml (154mM) chloride. 
 
b) Dehydrated alcohol BP: Ethanol (100% v/v) (Martindale, Brentwood, UK). 
 
Insulin / glucose 
 
a) Dextrose: dextrose (20% w/v) (Baxter, Newbury, UK), containing 200g anhydrous 
dextrose / 1000ml (1.1M). 
 
b) Actrapid insulin: Actrapid (NovoNordisk, Crawley, UK), containing 1000units / ml.  
 
2.3.3 Drugs and reagents for in vitro assays 
 
a) Reduced Nicotinamide Adenine Dinucleotide Phosphate (NADPH): Required in a 
solution with the final concentration in the assay of 2mM. Therefore prepared initially in a 
solution with a concentration of 10mM and dissolved in potassium phosphate buffer (1ml). 
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b) D-Glucose-6-phosphate dipotassium salt hydrate: Required in a solution with the final 
concentration in the assay of 5mM. Therefore prepared initially in a solution with a 
concentration of 25mM and dissolved in potassium phosphate buffer (1ml). Solutions a) and 
b) were prepared fresh for each assay and stored at 4 C for no longer than 2 hours and 
protected from the light. 
 
c) 1,2n-[3H]2-Cortisone: 1,2n-[3H]2-cortisone was obtained from Amersham Radio chemicals 
(GE Healthcare UK Ltd, Little Chalfont, UK). Commercial stock solutions of 1, 2n-[3H]2-
cortisone were obtained in ethanol (with concentrations of 19.6 pmol/ml and specific activity 
of 0.037MBq/ l) and stored at -20 C. 
 
d) 1, 2, 6, 7-[3H]4-Corticosterone: 1, 2, 6, 7-[3H]4-corticosterone was also obtained from 
Amersham Radio chemicals. Commercial stock solutions of 1, 2, 6, 7-[3H]4-corticosterone 
were obtained in a toluene: ethanol (9:1) solution (with concentrations of 13.7 pmol/ml and 
specific activity of 0.037MBq/ l) and stored at -20 C. 
 
e) Unlabelled steroids: Corticosterone, cortisol, cortisone were obtained from Sigma (Poole, 
UK) and epi-cortisol, epi-tetrahydrocortisol, epi-corticosterone, epi-tetrahydrocorticosterone, 
,5 -tetrahydrocortisol, 3 ,5 -tetrahydrocortisone, 5 -dihydrocortisone, 20 - and 20 -
dihydrocortisone and - and -cortolone were obtained from Steraloids (Newport, RI). Each 
of these steroids were weighed and dissolved in methanol (final concentration 1mg/ml) and 
stored at -20 C.  
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2.3.4 Drugs and reagents for tissue culture 
 
a) Dulbecco’s Modified Eagle’s Medium (DMEM): Containing fetal calf serum (FCS) (10%) 
(stripped of steroids with charcoal), glucose 4.5g/L, glutamine (2mM) and penicillin (1% 
w/v)/ streptomycin (1% w/v), obtained from Lonza (Slough, UK). 
 
b) Trypsin: Trypsin (200mg/l) -EDTA, (Lonza, Slough, UK). 
 
c) Charcoal: Charcoal, dextran coated (Sigma, Poole, UK). 
 
Charcoal stripped serum 
 
To prepare serum stripped of steroids, fetal calf serum (500ml) and dextran coated charcoal 
(5g) were mixed (~16 hours) at 4ºC. The solution was filtered through a 250 m filter funnel, 
separated into aliquots and stored at -20ºC until use. 
 
2.3.5 Animal tissues 
 
Animals were obtained from Harlan Laboratories (Bicester, UK) and maintained under 
standard conditions, 12 hour dark / light cycle, constant temperature / humidity, with free 
access to normal chow in the Biomedical Research Facility, Little France. Maintenance 
conformed to good practice as dictated by the UK Home Office.  
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2.4 In vitro bioactivity assays 
 




Liver (100mg) was cut into small pieces on a bed of dry ice, weighed, transferred into a 
1.5ml tube and sucrose / HEPES buffer (1ml) added.  Liver pieces were stored on wet ice 
prior to mechanical homogenisation (3 x 10 second bursts placing on wet ice in between). 
When using human tissues, homogenisation was carried out in a Class 1 bio-safety cabinet. 
Aliquots (250 l) of rodent hepatic homogenate were diluted to a specific protein content 
with sucrose / HEPES homogenisation buffer and stored at -80 C. Human hepatic 
homogenates were stored undiluted at -80 C in 250 l aliquots. 
 
Cytosol preparation  
 
Human and rodent hepatic homogenates were subject to centrifugation (94 x g, 10min, 4ºC), 
the tissue pellet discarded and supernatant transferred into ultra-centrifuge tubes. The 
supernatant underwent further centrifugation (34 000 x g, 30min, and 124 000 x g, 60min, 4 




Determination of protein concentrations 
 
The protein concentrations of hepatic homogenates were determined using a colorimetric 
Bio-Rad DC protein assay kit (Bio-Rad, Hemel Hempstead, UK). Solutions of standards 
(0.1–1.4 mg/ml) were prepared in triplicate in distilled water from a stock protein solution 
(2mg/ml bovine serum albumin (BSA- fraction V) in water).  A solution of sodium dodecyl 
sulfate (SDS) (1%) in water was used as a blank in the assay. 5µl of either SDS (1%) or 
protein standards (in triplicate) were added to the 96-well plate.  Unknown protein solutions 
were also added in triplicate. Protein assay Reagent A (3ml) was mixed with Reagent S 
(60µl) to form working Reagent A. Working Reagent A (25µl) was added into each of the 
wells. Dye Reagent B was subsequently added (200µl). The plate was allowed to stand at 
room temperature (15 min) and absorbance of samples at 690nm was measured using a 
spectrophotometer. A standard curve was plotted with absorbance on the y axis vs 
concentration on the x axis and a line of best fit drawn. The concentration of protein in each 
sample was calculated from the equation of the regression line. Data were deemed 
acceptable if the regression was >0.99 and % coefficient of variation between triplicates was 
<10%. 
 
Assay development with rat hepatic cytosol 
 
The assay was adapted from one reported to quantify 5 -reductase activity in rat (Okuda & 
Okuda, 1984) and human liver (Iyer et al, 1990). Practice assays were performed with rat 
hepatic cytosol to determine the optimum amount of protein to use in the assay, the best 
buffer to use, incubation time, and optimise the chromatographic conditions.  
 
 72 
Metabolism of steroids by 5 -reductase in human hepatic cytosol  
 
Cytosols were incubated in duplicate (37ºC, 16h) in potassium phosphate buffer with 
substrate (10 M) and [3H]-substrate (10nM) in the presence of a co-factor generating system 
to assess the metabolism of the substrate by 5 -reductase and 3 HSD. The co-factor 
generating system was prepared by adding NADPH (2mM), glucose-6-phosphate (5mM) and 
glucose-6-phosphate dehydrogenase (0.5 unit/250 l) to the cytosol extract and reaction 
substrate. The reaction was terminated by mixing with ethyl acetate (10 vol) and steroids 
extracted as per section 2.6.1. Dried organic extracts were dissolved in mobile phase (200 l) 
and analysed by HPLC with radio-scintillation detection as per section 2.8.1. Experiments 
without co-factor or cytosol served as controls. Products formed from substrate were 
identified by comparison of their retention times with those of unlabelled standards.  
 
2.5 Cell culture 
 
2.5.1. Source of cells 
 
Human embryonic kidney cells (HEK293) stably transfected with human 11 HSD1 
(HEK293h11 HSD1) were obtained from Dr Scott Webster, Drug Discovery Manager, 
University of Edinburgh (Webster et al, 2007). 
 
2.5.2 HEK 293 cell culture 
 
HEK293h11 HSD1 cells were maintained in poly-D-lysine pre-treated flasks in standard 
tissue culture conditions (37oC, 95% O2: 5% CO2), in DMEM (15ml) containing glutamine 
(2mM) and penicillin (1% w/v)/ streptomycin (1% w/v) and fetal calf serum (FCS) (10% v/v).  
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Cells were passaged once they reached confluence (approximately twice weekly). Cells at 
their 3rd-4th passage were used for assays unless otherwise stated. 
 
To passage the cells, DMEM was aspirated off and the cells washed with phosphate-buffered 
saline (5ml). Trypsin / EDTA (3ml) was added and the cells incubated (37oC) for 2-3 
minutes. The cells were dislodged and observed under the microscope. Trypsin was 
neutralised with an equal volume of medium, and the cells then subject to centrifugation 
(1000 x g, 5 mins, room temp, 50ml screw-cap conical Falcon tube (BD Biosciences, 
Oxford,  UK))  to  remove  any  debris.   The  media  was  removed  and  the  cell  pellet  re-
suspended fresh media. The required volume of suspension was transferred into each flask 
and the flask topped-up to 15ml of media in total.  
 
To seed 60mm plates, cells were trypsinised as per passaging protocol, and the trypsin 
neutralised with an equal volume of medium. Medium containing cells (200 l) was removed 
and placed on a haemocytometer under a light microscope for counting. For each experiment 
2x105 cells were seeded in each well.   
 
2.5.3 Experimental conditions 
 
In vitro metabolism of steroids by 11 -reductase 
 
HEK293h11 HSD1 cells (2x105) were incubated (37oC, 5%CO2) in duplicate in DMEM 
(4ml) containing stripped fetal calf serum (10% v/v), glutamine (2mM), penicillin 
(1%w/v)/streptomycin (1%w/v) and substrate (2 M). Medium (250µl) was harvested (1-24h) 
and steroids extracted as per section 2.6.2. Steroids were dissolved in mobile phase (100 l), 
and analysed by liquid chromatography tandem mass spectrometry (LC-MS/MS) as per 
section 2.8.2. Controls were included without cells or addition of steroid. A standard curve 
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was prepared to quantify steroids extracted from medium, representing a concentration range 
of 0-400ng, with 500ng of internal standard (epi-cortisol). 
 
Assessment for a primary isotope effect on 11 -reductase  
 
The presence of a stable isotope label on a substrate may cause an alteration in reaction 
kinetics. To further test for a ‘primary isotope’ effect using a competition approach, 
HEK293/h11 HSD1 cells (2x105) were incubated (6-24h) in duplicate with [3H]-substrate 
(5nM) and increasing concentrations of deuterated or non-deuterated substrate (0nM - 
4955nM). Medium was extracted as per section 2.6.2 using conditioned Sep-Pak C18 
columns and steroids dissolved in mobile phase (1ml) in preparation for HPLC analysis as 
per section 2.8.1. Controls were included without cells or addition of steroid. 
 
2.6 Extraction of glucocorticoids from experimental matrices 
 
2.6.1 Bioactivity assay buffers 
 
Cytosol was mixed with ethyl acetate (10 vol), the organic layer removed and dried under 
oxygen-free nitrogen (OFN, 60ºC).  Organic extracts were dissolved in mobile phase (200µl) 
and analysed by HPLC as per section 2.8.1. 
 
2.6.2 Cell culture medium 
 
Samples of cell culture medium (250µl) were thawed at room temperature (30 min) prior to 
extraction and enriched with internal standard (500ng). Steroids were extracted using 
conditioned Sep-Pak C18 columns (300mg, Waters Millipore, Watford, UK).  To prepare 
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columns for use, methanol (5ml) was added to wash the column followed by water (5ml) to 
separate the C18 chains. The medium was applied, allowed to elute and then the column was 
washed once with water (5ml) and steroids eluted using methanol (2ml).  The eluate was 
dried, reconstituted in water (200µl) and steroids extracted in ethyl acetate (2ml). The 
organic layer was dried again and dissolved in mobile phase (100 l or 1ml) for analysis by 






Plasma was obtained during the clinical studies detailed in Chapters 3-5 after written 




To quantify deuterated tracers and endogenous glucocorticoids from plasma stock solutions 
of cortisone, cortisol, epi-cortisol, d2-cortisone, d2-cortisol and d4-cortisol in methanol were 
prepared. From these stock solutions, further solutions containing mixtures of the steroids 
were prepared for standard and enrichment curves for the analysis.  
 
The standard curve to quantify cortisol and cortisone represented a range of amounts from 0-
400ng with 500ng of internal standard (epi-cortisol). The enrichment curve represented a 
range from 0-20%. Standard curves to quantify d4-cortisol and d2-cortisone represented a 
range of amounts from 0-200ng.  Enrichment curves for d2-cortisone ranged from 0-20%. 
Table 2.1 shows an example of a standard and enrichment curve for d4-cortisol and cortisol.  
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Steroid solutions were placed in glass tubes, reduced to dryness under a stream of OFN 
(60ºC), dissolved in methanol (50 l) and distilled water (200 l) was added to mimic plasma 
and retain any hydrophilic molecules. Chloroform (2ml) was added, mixed and the water 
removed using a glass pipette and discarded. The remaining steroidal extract in chloroform 
was transferred into glass vials and reduced to dryness (60ºC, OFN). The extract was 
dissolved in a mobile phase (50 l) in preparation for analysis by LC-MS/MS (section 2.8.2). 
 
Plasma samples were thawed at room temperature (30 min) prior to extraction. In glass 
tubes, plasma (1.5-2.0ml) was enriched with epi-cortisol (500ng) and chloroform (15-20ml) 
added and mixed thoroughly. Excess plasma and lipid were removed using a glass pipette 
and discarded. The chloroform layer containing steroids was decanted into a clean glass tube, 
and reduced to dryness (OFN, 60ºC). Dried steroidal extracts were dissolved in mobile phase 
(50 l)  and placed in auto sampler  vials  in  preparation for  analysis  by LC-MS/MS (section 
2.8.2).  
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Table 2.1 Example of standard and enrichment curves used to quantify steroids in plasma and tissues 
 
In the standard curve a fixed quantity of internal standard (epi-cortisol) is added to increasing amounts of the analyte (eg cortisol and d4-cortisol). The 
enrichment curve reflects ratio of the tracer (eg d4-cortisol) to the tracee (eg cortisol).   
 
STANDARD CURVE ENRICHMENT CURVE 
Cortisol (ng) Epi-cortisol (ng) D4-cortisol (ng) Enrichment (%) Cortisol (ng) D4-cortisol (ng) 
0 500 0 0 500 0 
10 500 5 2.4 500 12.5 
20 500 10 4.8 500 25 
30 500 15 9.1 500 50 
50 500 25 13.0 500 75 
100 500 50 16.7 500 100 
200 500 100 20 500 125 
300 500 150    






Saliva was obtained during the clinical study detailed in Chapter 4 after written informed 




Frozen saliva samples (1ml) were thawed at room temperature, subject to centrifugation 
(3200 x g, 4 C, 3 min.) and enriched with 500ng epi-cortisol (internal standard). Salivary 
glucocorticoids were extracted into chloroform (10ml) as per plasma (section 2.6.3) and 






Urine was obtained during the clinical study detailed in Chapter 4 after written informed 




Steroids in urine (15ml) or water (containing known amounts of steroids) both containing 
internal standard (5 g epi-cortisol and 30 g epi-tetrahydrocortisol) were retained on 
conditioned Sep-Pak C18 columns (300mg) (section 2.6.2) and steroids subsequently eluted 
in methanol (2ml). Glucocorticoid conjugates were hydrolysed in sodium acetate buffer, 
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(2ml) using -glucuronidase (Helix pomatia, Type H-2, 85,000 units/mL; 100ul; 37°C for 48 
hours). Hydrolysates were passed through conditioned Sep-Pak C18 columns to retain 
steroids and a methanolic eluate reduced to dryness under OFN (60ºC). The residue was re-
constituted in water (200 l), re-extracted with ethyl acetate (2ml) and the organic layer dried 
(OFN, 60ºC). The steroids obtained were derivatised to form methoxime-trimethylsilyl (MO-
TMS) derivatives (section 2.7.2) (Best & Walker, 1997) and analysed using GC-MS (section 
2.8.4).  The standard curves to quantify cortisol and cortisone represented a range of amounts 
from 0-30 g. The standard curves to quantify - and -tetrahydrocortisol and 






A protocol to extract glucocorticoids from adipose tissue was developed and optimised 
(further details given in Chapter 3). The final method used was as follows: 
 
To release intracellular glucocorticoids, adipose samples (250mg) were mechanically 
homogenised in ethyl acetate (1ml), enriched with internal standard (epi-cortisol 250ng), and 
the homogenate dripped onto chilled ethanol: glacial acetic acid: water (95:3:2 v/v) (10ml) 
and stored at -80ºC overnight. Samples attained 4ºC, before being sonicated (8 x 15 sec 
bursts) and debris separated by centrifugation (3000x g, 30 min, 4ºC). The supernatant was 
reduced to dryness (OFN, 60ºC), methanol (10ml) added and stored at -80ºC overnight. To 
remove oils, tissue extracts attained room temperature and then hexane (10mls) was added 
and mixed. The hexane layer was discarded and the remaining methanol removed by 
evaporation. Water (400µl) and ethyl acetate (4ml) were added to the dried steroidal extract, 
the organic layer removed, dried and the residue re-suspended in 30% methanol (5ml). 
Adipose steroidal extracts (5ml) were applied to conditioned C18 Bond Elut columns 
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(Varian, Oxford, UK, 2g) (as described below), eluted in  methanol (5ml), dried (OFN, 60ºC) 
and dissolved in a mobile phase (50 l) in preparation for analysis by  LC-MS/MS (section 
2.8.2).  
 
To prepare a C18 Bond Elut cartridges (2g, Varian, Oxford, UK) the following method was 
used. Methanol (2 x 10ml) and water (2 x 10ml) were applied to the column under a small 
amount of vacuum (3-4 iu Hg). The adipose extracts were applied to the column and the 




To extract steroids from infusates a standard curve was prepared as per plasma extractions. 
Prior to starting the extraction, the expected amount of glucocorticoid in the infusate was 
calculated to ensure the values were within the range of the standard curve (5 l 60:40 
cortisol: d4-cortisol infusate = 120ng of cortisol mixture (72ng cortisol and 48ng d4-
cortisol)). For the samples, infusate (5 l) and water (195 l) were added to glass tubes and 
enriched with epi-cortisol (500ng). After mixing, chloroform (2ml) was added and the 
contents of the glass tubes mixed further. The layers were allowed to separate, and the water 
removed from the extract using a glass pipette. The remaining sample was transferred to a 
glass vial, reduced to dryness (OFN, 60oC) and dissolved in mobile phase (50 l) in 
preparation for LC-MS/MS (section 2.8.2).  
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2.7 Derivatisation of glucocorticoids for analysis by gas 
chromatography mass spectrometry 
 
2.7.1 Derivatisation agents 
 
a) Lipidex 5000 (Packard, Pangbourne, UK): Lipidex 5000 suspended in methanol, was 
filtered, the methanol discarded and the beads re-suspended in mobile phase (b) (200ml) 
below and stored in the dark at room temperature. 
b) Lipidex mobile phase: 98% cyclohexane (v/v), 1% hexamethyldisilazane (v/v), 1% 
pyridine (v/v). 
 
c) Methoxyamine in pyridine: methoxyamine hydrochloride in pyridine (2% w/v). 
 
d) Trimethylsilylimidazole (TMSI): undiluted. 
 
2.7.2 Preparation of Lipidex 5000 size occlusion columns 
 
To prepare a Lipidex 5000 column, a glass Pasteur pipette was plugged with a small amount 
of silanised glass wool. Lipidex 5000 (1ml) in mobile phase was added to the column and 
excess mobile phase allowed to elute. The trapped matrix was subjected to three washes with 
mobile phase (3 x 1ml).  
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2.7.3 Derivatisation conditions 
 
The following method was used to form methoxime-trimethylsilyl (MO-TMS) derivatives 
(Best & Walker, 1997): methoxyamine hydrochloride in pyridine (50µl 2% w/v) was added 
to the dried steroidal extract, mixed and heated in an oven (60ºC, 30 min). The extract was 
reduced to dryness; trimethylsilylimidazole (50µl) added, mixed and heated (100ºC, 2 hours). 
The sample was re-suspended in a mobile phase of cyclohexane: hexamethyldisilazane: 
pyridine (98:1:1) (1ml) before being passed through a Lipidex 5000 column. The glass 
Reacti-vial was washed with further mobile phase (2 x 0.5ml), which was also applied to the 
column. The eluate was collected, reduced to dryness (OFN, 60ºC) and re-suspended in 
decane (50µl).   
 
2.8 Chromatographic analysis 
 




Analysis of tritiated steroids was achieved using a Waters HPLC 600S pump (Elstree, UK), 
717 plus Autosampler and a -scintillation counter (Berthold LB509 detector (Harpenden, 
UK). When simultaneous analysis of non-tritiated steroids was required a Waters 2487 




To separate [3H]2-cortisone from [3H] 2-cortisol a Sunfire C18 column (5 m, 15cm, 4.6mm, 
35oC)  was used and a mobile phase of water: acetonitrile: methanol, 60:15:25 (1.0ml/min). 
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Approximate retention times for [3H] 2-cortisone and [3H] 2-cortisol were 19.0 and 21.8 mins 
respectively. To achieve optimal mixing and counting efficiency the scintillant flow rate 
(ProFlow G; Biotechnologies Ltd, Epsom, UK) was 2.0ml/ min.  
 
To detect [3H]2-cortisone and [3H]2-tetrahydrocortisone the above column, mobile phase and 
scintillant were used, except the column temperature was 45ºC and mobile phase flow rate 
1.5ml/min. Approximate retention times for [3H]2-cortisone and [3H]2- tetrahydrocortisone 
were 9.0 and 21.6 mins respectively. Products formed from [3H]2-cortisone were identified 
by comparison of their retention times with those of unlabelled standards detected by 





Following chromatography, the area under each peak was integrated using the Chromeleon 
software (version 6.8, Dionex, Leeds, UK) and the percentage conversion of [3H]-substrate 
to  [3H]-product quantified and converted into substrate and product concentrations. Peak 
areas were integrated when the response had a signal to noise ratio (SNR) >3. Data points 
were accepted if coefficients of variation between duplicates was <10%. 
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* THE 20.8 ** 
Figure 2.1 Representative radioactive (a) and UV (b & c) chromatograms of the products of metabolism of cortisone or [3H]2-




Human hepatic cytosol preparations were incubated with cortisone or d2-cortisone (10 M) each with [3H]2-cortisone (10nM). The 
upper chromatogram displays the tritiated substrate and products obtained during the reaction (top trace (a)). The lower traces (b and c) 
are those of unlabelled steroidal standards detected by absorbance ((b) 195nm; (c) 244nm) using UV/Visible detector. [3H]2E= tritiated 
cortisone, [3H]2THE = tritiated tetrahydro-cortisone, E= cortisone, THE= tetrahydrocortisone, min=minutes, mAU= milli-absorbance 
unit; * = -cortolone with a retention time of 15.0 mins; **= -cortolone with a retention time of 17.6 mins. 
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Steroids were analysed using a TSQ Quantum Discovery Mass Spectrometer and Surveyor 




Chromatographic separation of unlabelled and deuterated cortisol and cortisone was 
optimised using a Biphenyl Allure column (5 m, 10cm, 4.6mm, 38ºC (Restek, Saunderton, 
UK)). A mobile phase of methanol: ammonium acetate (5mM) (60:40 v/v, isocratic 
0.5ml/min) was used in combination with plasma, adipose tissue, infusates and cell medium 
extracts. Figure 2.2 shows a representative chromatogram of steroids extracted from human 
plasma. 
 
To measure cortisone and cortisol in salivary samples, the mobile phase used was methanol 
(+ 0.1% v/v formic  acid)  and  water  (+  0.1%  v/v formic  acid)  (45:55  ratio,  v/v) flowing 
through a Kinetex PFP column (2.6 m, 10cm, 3.0mm, 25ºC, 0.5ml/min; (Phenomenex, 
Torrance, CA). 
 
Ionisation was performed in positive electrospray mode, and mass transitions of protonated 
ions determined using tandem MS (spray voltage 3.25kV; source temperature 400ºC; 























18.04 min  
Epi-Cortisol  
15.14 min 
Figure 2.2 Mass chromatograms of ionised steroids extracted from human plasma 
 
Mass chromatograms displaying peaks eluting with retention times and mass transitions indicative of cortisone m/z 361 163, cortisol m/z 
363 121, epi-cortisol (internal standard, m/z 363 121), d3-cortisone m/z 364 164, d3-cortisol m/z 366 121, and d4-cortisol m/z 367 121 














Table 2.2 Mass spectrometric conditions used for LC-MS/MS analysis 
 
Steroid Mass transitions of 
protonated ion 
m/z 
Tube lens (V) 
Cortisone 361 163 168 
d2-Cortisone 363 165 118 
d3-Cortisone 364 164 168 
Cortisol 363 121 142 
d2-Cortisol 365 122 
363 329 
118 
d3-Cortisol 366 121 142 
d4-Cortisol 367 121 142 
Epi-cortisol 363 121 142 
 
d=deuterium; m/z = mass charge ratio; V=volts. 
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 Data analysis 
 
Compounds were quantified using the ratio of (area under the peak of interest) / (area under 
internal standard (epi-cortisol)) using Xcalibur Quan Browser software. The standard curve 
was derived from the amount of steroid (x-axis) plotted against the peak area ratio (y axis). A 
line of best fit was drawn in the form y=mx+c. Weighting was adjusted if necessary using 
the software (as specified in each chapter) to optimise reproducibility of quantitation of low 
concentrations. The ratios obtained for steroids in the analytical sample were calculated and 
the amount of steroid in the sample derived from a standard curve. An enrichment curve was 
plotted to determine the efficiency of ionisation of the deuterated steroids compared to that 
of endogenous steroids. For each point on the enrichment curve, the predicted enrichment (x-
axis) was plotted against the measured enrichment (y axis). A line of best fit was drawn as 




Linearity was assessed by creating a standard curve representing amounts over a wide range 
of physiological relevance as per section 2.6.3 and assessing the regression co-efficient (r2) 
values to ensure >0.99.  
 
As the  LCMS assay for d2-cortisone was newly developed during this PhD, accuracy (the 
closeness of the result to the true value) and precision (how close the results are to one 
another) of analysis of d2-cortisone were assessed at the lowest (2.5ng) and highest (200ng) 
concentrations of the standard curves, weighted for 1/ 2, and the relative mean error (RME, 
accuracy) and relative standard deviation (RSD, precision) calculated from n=6 replicates 
using the equations below (de Bievre et al, 1998). The limit of quantification (LOQ) was 
determined  to  be  the  level  where  RSD and  RME was<10%.  The  limit  of  detection  (LOD)  
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was defined as the lowest concentration of d2-cortisone detectable with a signal to noise 




RME= Amount of d2-cortisone measured (ng) - Amount of d2-cortisone added (ng) • 100 




RSD= (Standard deviation of mean / Mean amount of d2-cortisone detected (ng)) • 100 
 




The identities of the fragment ions used for quantitative analysis were confirmed for 
analytical standards by liquid chromatography Fourier Transform-mass spectrometry (FT-




Following elution from a Hypersil C18 column (Thermo Scientific, Hemel Hempstead, UK) 
(5 m, 5cm, 2.1mm, room temperature, mobile phase acetonitrile and water with formic acid 
(0.1% v/v) (90:10), at a flow rate of 250 l/min), compounds were subject to monitoring in 
full scan mode using collision-induced dissociation (CID) (45V). Masses of resultant ions 
were monitored in the range m/z 150-1000 amu (spray voltage 4.50kV; capillary temperature 
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250ºC). A secondary ion dependent scan was employed at 45% CID to assess fragmentation 




Xcalibur software was used to derive the chemical formulae of the compounds of interest 
using the exact masses derived during LC-FT-MS. 
 




a) Analysis of urinary and adipose steroids and products of 5 -reductase bioassays was 
achieved using a Polaris Q-Trace GC-MS (Thermo, Hemel Hempstead, UK). 
 
b) Analysis of d2-cortisone for impurities was achieved using a Finnigan Voyager GC-MS 




a) Urinary steroids and adipose steroids were separated using a RTX5MS column (30m, 
0.25mm id, 0.25µm (J&W Scientific, Folsom, CA)). Ionization was performed in electron 
impact mode (EI 70eV). For urinary steroids, the initial temperature was 50ºC (maintained 
for 1 minute and increased by 30ºC/minute to 200ºC, and then by 5ºC/minute to 300ºC and 
maintained for 5 minutes). Helium flow was 1ml/minute with source inlet and transfer line 
temperatures of 240ºC and 280ºC respectively. For steroids derived from adipose, the initial 
 91 
temperature was 150ºC (maintained for 1 minute and increased by 30ºC/minute to 200ºC, 
and then by 8ºC/minute to 300ºC and maintained for 6 minutes). Other conditions were as 
above. Table 2.3 shows ions monitored by selective ion monitoring. 
 
b) For d2-Cortisone a full scan (280-700amu) was executed following separation on a 
DB5MS column (30m, 0.25mm, 0. 5µm) (J&W Scientific, Folsom, CA). Ionization was 
performed in EI mode (70eV). The initial temperature was 50 C (maintained for 1 minute 
and increased by 30 C/ minute to 200 C, then by 8 C / minute to 250 C, and then by 6 C / 
minute to 300 C and maintained for 10 minutes). Helium flow was 1.5ml/minute with source 




Xcalibur software was used to quantify compounds of interest.  
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Table 2.3 Mass transitions monitored during GC-MS 
 




- Tetrahydrocortisol  652 





,5ß- and 5 -Tetrahydrocortisol  















d=deuterium; m/z = mass charge ratio. 
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2.9 Statistical and kinetic analysis 
 
Equations and calculations used in tracer analysis are detailed in each chapter. The software 
used for kinetic anaylsis was Kinetica (Thermo Scientific, Philadelphia, PA). Calculations 
were performed in Microsoft Excel and SPSS version 14 (Chicago, IL).  
 
All  values  are  expressed  as  mean  ±  standard  error  of  the  mean.  Data  were  analysed  using  
paired or single sample t-tests. Significance was taken at the conventional level p 0.05.  
 
In Chapter 4, all in vitro and in vivo data were n=3. As with all very small samples a normal 
distribution of the differences had to be assumed as neither graphical nor formal tests are 
useful to detect departures from normality, and non-parametric methods based on rank e.g. 
Wilcoxon Matched Pairs test are fundamentally incapable of detecting statistically 
significant differences at the 0.05 level with sample sizes of less than six (Bland, 1995). 
 
Graphpad software was used to calculate enyme kinetics (Km and Vmax) after input of 















Local versus systemic (HPA axis) cortisol 
generation- tissue tracer enrichment study 
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Despite the literature describing subcutaneous adipose 11 HSD1 being up-regulated in 
obesity / metabolic syndrome, absolute levels of glucocorticoids in adipose have not been 
accurately quantified nor the contribution of 11 HSD1 to the intra-adipose glucocorticoid 
pool. This chapter addresses aims 1-3 from Chapter 1 Introduction: to develop a method to 
measure adipose tissue glucocorticoids using LC-MS/MS; to assess glucocorticoid uptake in 
adipose tissue using the stable isotope tracer d4-cortisol; and to determine the relative 




Human adipose tissue contains a glucocorticoid pool derived from both the systemic 
circulation and from local regeneration of cortisol by the intracellular enzyme 11 HSD1 
(Sandeep et al, 2005;Stimson et al, 2009). Intra-adipose cortisol is physiologically important 
as it interacts with cytoplasmic glucocorticoid receptors to regulate gene transcription, eg of 
metabolic enzymes such as hormone sensitive lipase (Slavin et al, 1994), and influence the 
balance of pre-adipocyte proliferation and differentiation (Bujalska et al, 1999). Acute 
elevations in plasma cortisol in vivo in humans have been associated with increased lipolysis 
in adipose tissue (Djurhuus et al, 2002), although results are inconsistent (Samra et al, 1998) 
and vary according to the duration of glucocorticoid exposure (Gravholt et al, 2002). 
Longer-term glucocorticoid excess is associated with adipose lipid accumulation 
(Macfarlane et al, 2008). 
 
Concentrations of glucocorticoids in human subcutaneous adipose tissue biopsies have been 
estimated using several bio-analytical techniques with contrasting results (Feher & Bodrogi, 
1982;Lindsay et al, 2003;Ronquist-Nii & Edlund, 2005;Wake et al, 2003). Using highly 
specific and sensitive LC-MS/MS, adipose tissue cortisol has been reported as 12.4±0.6 and 
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cortisone 3.0±0.3 nmol/kg (Ronquist-Nii & Edlund, 2005). However, these methods do not 
measure the dynamics of uptake of cortisol by adipose tissue, which may explain 
discrepancies between effects after different durations of exposure. Traditionally, steroid 
transport  across  the  cell  membrane  was  assumed  to  be  a  passive  process  following  a  
concentration gradient. However, an increasing number of transporters of steroids have been 
identified (section 1.1.1). Moreover, measurement of concentration within adipose does not 
distinguish cortisol derived from the systemic circulation from that generated locally by 
11 HSD1 (Sandeep et al, 2005;Stimson et al, 2009), which may be important in determining 
glucocorticoid activity in human obesity (Rask et al, 2001;Wake et al, 2003) and is a target 
for pharmacological inhibition in diabetes (Hughes et al, 2008). 
 
Dynamic turnover in the intra-adipose cortisol pool can be investigated using a stable isotope 
tracer such as 9,11,12,12-[2H]4-cortisol (d4-cortisol) (section 1.11), which allows 
quantification of cortisol production in the plasma (Andrew et al, 2002) and across tissue 




To develop a protocol for efficient extraction of glucocorticoids from human adipose tissue 
biopsies, and study the incorporation and dilution of d4-cortisol tracer in adipose tissue 
during intravenous steady state infusion. This will allow calculation of the rate of cortisol 
uptake in adipose tissue and assessment of the amount of cortisol generated locally in 





3.3.1 Study Design 
 
The  study  was  approved  by  the  Local  Research  Ethics  Committee  and  all  subjects  gave  




To assess adipose cortisol dynamics, healthy female volunteers (n=6), who had not received 
glucocorticoid treatment by any route for 3 months, with normal haematological and renal 
indices, who were undergoing an elective abdominal hysterectomy for benign 
gynaecological indications attended the Clinical Research Facility between 08:30-10:30h 
after an overnight fast. Subjects were studied once in the Royal Infirmary of Edinburgh on 
the day of their elective operation. 
 
At the beginning of recruitment we aimed to assess individuals naive to any medication. We 
were unable to recruit the required number of subjects using this strategy as most were 
taking analgesia or taking part in other clinical research studies. By changing our recruitment 
strategy and accepting volunteers on some medications (known not to interfere with 





Height, weight (clothed), waist and hip circumference were measured using standard 
techniques. For height, volunteers stood without shoes against a fixed measuring ruler on a 
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wall and the measurement at the top of the head recorded in metres (to 2 decimal places). 
Weight was measured in kilogrammes on an electronic scale (Seca, Birmingham, UK) after 
ensuring the instrument was calibrated.  For waist: hip  ratio  (WHR),  waist  circumference  
was measured midway between the  lower  rib margin and the  iliac crest with  the  volunteer  
standing with their hands by  their sides, using a non-expandable measuring tape (Lufkin 
executive W606P).  Hip circumference was taken with the subject  in  the  same  position,  
by  wrapping  the  tape  measure  around  the  buttocks  and the maximum  circumference  
located. Body fat percentage was taken as the average of two consecutive readings, using an 
OMRON BF306 Body Fat Monitor (OMRON Healthcare (UK) Ltd, Henfield, UK) after an 
overnight fast.  The monitor was pre-set to the correct height, weight, age and gender with 
the results obtained on the morning of the study.  Volunteers stood with their feet apart and 
their arms at 90º to their trunk, with the palm of each hand placed firmly on both electrode 
handles.  Blood pressure was measured after sitting for at least 10 minutes using a 705IT 
automatic blood pressure monitor (OMRON Healthcare Europe BV, Hoofddorp, NL).   
 
Preparation of the stable isotope tracer (60% hydrocortisone and 40% d4-cortisol) 
  
To prepare the isotope for this study, unlabelled hydrocortisone (12mg) and d4-cortisol 
(8mg) were dissolved in pharmaceutical grade ethanol (2.5ml) and filtered in the radio 
pharmacy to achieve sterility. From this stock solution, 0.5ml was dissolved in sodium 
chloride 0.9% w/v (60ml) immediately prior to use to give a solution with a concentration of 
0.067mg/ml. 7.5ml of this solution was discarded, leaving 52.5ml (containing 3.5mg total 
steroid (cortisol + d4-cortisol)) for use as the bolus injection.  
 
For an intravenous infusion, 1.5ml (containing 12mg total steroid) of stock solution was 
diluted in sodium chloride 0.9% w/v (500ml) immediately prior to use to achieve a solution 
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with a final concentration 0.024mg/ml. This was infused at a rate of 72.5ml/hour to deliver 




One intravenous cannula was inserted into each antecubital fossa vein. Venous blood was 
collected for basal assessment of steroids and background isotopomers (Figure 3.1). An 
intravenous bolus of d4-cortisol was administered (3.5mg) over 5 minutes, followed by a 
continuous intravenous infusion (1.74mg/hour). Four venous blood samples were obtained at 
five minute intervals after 3 hours, when plasma steady state was achieved from the arm 
contra-lateral to the infusion (Andrew et al, 2002). Anaesthetists were asked to withhold 
medication that could interfere with endogenous glucocorticoid metabolism (e.g intravenous 
dexamethasone for post-operative anaesthesia-related vomiting) until after the study was 
complete. Study participants were then transferred to theatre with the d4-cortisol infusion 
running, where both subcutaneous and omental adipose tissue samples were obtained by the 
surgeon upon opening the abdomen. Three venous blood samples were taken at 5 minute 
intervals at the time of the subcutaneous adipose biopsy from the anterior abdominal wall to 
measure concurrent enrichment of plasma and adipose with d4-cortisol.  
 
Sample collection and processing 
 
Prior to obtaining any blood samples, 2ml of dead space / waste (a mixture of saline and 
blood in the cannula) was withdrawn from the sampling cannula to prevent contamination of 
the whole blood sample by saline. Whole blood samples were obtained in 5.5ml lithium 
heparin S-Monovette tubes (Starstedt, Beaumont Leys, UK). Blood samples were placed on 
wet ice prior to centrifugation (3000 x g 10min, 4°C) to obtain plasma and stored at -20º C. 
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Adipose samples were collected in conical bottom falcon tubes (50ml) without any 
preservative, snap frozen on dry ice and stored at -80ºC prior to analysis. A sample of d4-
















Figure 3.1: Study protocol.   
 
d4-Cortisol infusion was infused intravenously at 1.74mg / hour and commenced after 
obtaining venous blood for basal isotopomers. Arrows indicate blood sampling, (1) for basal 
isotopomers, (2) at steady state, t= +180-t=+195, (3) time of the first adipose biopsy at 5 
minute intervals.  
 
D4-cortisol infusion 1.74mg/h 
Adipose Biopsies 
Clinical Research Facility Gynaecology Ward Theatre 
1 2 3 
t= -10 mins t= +180 - +195 mins t= adipose biopsy 
(+210- +330 mins) 
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3.3.2 Extraction of adipose tissue glucocorticoids 
 
Sources of adipose tissue for assay development 
 
For assay development adipose tissue from a male Zucker rat, (593g body weight) was used. 
The animal had received a subcutaneous bolus injection of d4-cortisol (250 g in 0.9% saline: 
ethanol (95:5 v/v) (0.5ml)) an hour prior to sacrifice. Adipose depots were snap frozen on dry 
ice and stored at -80 C until analysis.  
 
Human adipose tissue was obtained surgically from this clinical study. A second source of 
human subcutaneous adipose tissue was from archived tissue samples obtained by needle 




The initial extraction method had been developed in-house and consisted of 4 main stages: a) 
splitting adipocytes to release intracellular glucocorticoids, b) cleaning the extract and 
removing oils, c) re-extracting glucocorticoids and d) derivatisation prior to analysis by GC-
MS. The quantity of steroid recovered was determined as a ratio to a known amount of added 
internal standard, and percentage recovery assessed on an un-extracted standard. At each 
step, alternative processing methods were compared and the protocol yielding the maximal 
recovery and best signal to noise ratio taken forward. All methods were performed in 
duplicate or triplicate at least one time. 
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a) Splitting adipocytes 
 
To split adipocytes and release intracellular glucocorticoid, adipose tissue (250mg) was cut 
into small pieces on a bed of dry ice and weighed in a glass dish. The tissue was transferred 
into a glass tube and sodium phosphate buffer (section 2.3.1a) added (1ml). Tissues were 
stored on dry ice before being subjected to 3x 10 seconds bursts of mechanical 
homogenisation (in a class 1 bio-safety cabinet when human tissues used). Samples were 
placed on dry ice for 30 seconds in-between bursts of homogenisation. Internal standards 
(1µg, epi-corticosterone and epi-tetrahydrocorticosterone for rodent tissues, epi-cortisol for 
human tissue) were added and the homogenate dripped onto glacial acetic acid: ethanol: 
water (3:95:2ml v/v, 10ml, chilled on dry ice) using a glass pipette. The homogenate 
remained in acetic acid-ethanol mix overnight (-80oC). Samples were placed on wet ice (30 
mins), before being subjected to sonication (8 x 15 sec bursts, placing on wet ice for 1 min 
between bursts) and centrifugation (5900 x g, 30 min, room temp) to separate the cell 
membranes from lighter cellular organelles. The supernatant was transferred to a clean tube, 
reduced to dryness (OFN, 60oC) and further methanol added (10ml), before storing the 
samples overnight (-80oC). 
 
To optimise the homogenisation step, sodium phosphate buffer stored at room temperature 
(section 2.3.1a) (1ml), fresh sodium phosphate buffer solution (section 2.3.1a) (1ml), HPLC-
grade water (1ml), and ethyl acetate (1ml) were tested as the homogenisation fluid. To 
minimise adsorption of endogenous glucocorticoids to centrifuge containers both plastic and 






b) Cleaning the extract and removing oils 
 
The samples attained room temperature and hexane (10mls) added and mixed. The hexane 
layer was discarded and the remaining methanol transferred into a clean glass tube and 
reduced to dryness (OFN, 60oC). This step was not altered. 
 
c) Re-extracting glucocorticoids 
 
Water (400µl) and ethyl acetate (4ml) were added to the extract and mixed. The organic 
layer was removed and reduced to dryness in glass vials. The re-extraction step was not 
altered, but prior to derivatisation for GC-MS an extra cleaning step was added to remove 
oils. 
 
To optimise removing oils, Lipidex 5000 mobile phase (1ml) (section 2.7.1), methanol (5ml) 
and 30% methanol (5ml) were assessed as solvents for dissolving the dried adipose extract 
prior to applying the extracts to 3 different types of column. The columns assessed were a 
Lipidex 5000 column (section 2.7.2), a Sep-Pak C18 column (section 2.6.2), and a C18 Bond 
Elut column (section 2.6.6). The solvents assessed for eluting the steroid from the column 
were water (2ml), 50% methanol (2ml), 100% methanol (2-5ml), acetonitrile (2ml), ethyl 
acetate (2-5ml) and hexane (2ml). 
 
d) Derivatisation prior to analysis by GC-MS 
 
The final step was derivatisation prior to GCMS. LC-MS/MS analysis was also assessed 





The final method used to extract adipose glucocorticoids is detailed in section 2.6.6. Please 
see Figure 3.2 for a summary of stages of the extraction process. Paired human subcutaneous 
and omental adipose samples were analysed in duplicate. 
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Homogenise adipose tissue 
in ethyl acetate. Add internal 
standard. 
Drip homogenate onto 
chilled glacial acetic acid: 
ethanol and store at -80ºC 
overnight 
Sonicate homogenate, 
centrifuge. Reduce to 
dryness. Dissolve in  
methanol. 
Add hexane, mix and 
remove hexane. Reduce 
remaining methanol to 
dryness. 
Re-suspend in 30% 
methanol. Apply to a 
prepared Bond Elut C18 
column and elute in 100% 
methanol. 
Reconstitute with water and 




Extraction with ethyl 
acetate 
Cleaning extract and 
removing oils 
Reduce sample to dryness, 
add mobile phase in 




3.3.3 Extraction of plasma glucocorticoids 
 
Endogenous and deuterated glucocorticoids were extracted from plasma using the method 
detailed in section 2.6.3.  
 
3.3.4 Analytical techniques 
 
Plasma and adipose tissue steroidal extracts were analysed using LC-MS/MS as per section 
2.8.2. 
 
3.3.5 Data analysis 
 
The peak area of d4-cortisol was corrected for interference from the m+4 isotopomer of 
cortisol and the m+1 isotopomer of d3-cortisol. The peak area of d3-cortisol was corrected 
for the m+3 isotopomer of cortisol and d3-cortisol signal in d4-cortisol. Equations 1  &  2  
were solved as simultaneous equations. Concentrations of cortisol and cortisone were 
determined from a standard curve. Calibration and enrichment curves were prepared for both 




Plasma d3-cortisol and d4-cortisol concentrations values were calculated by multiplying the 
concentrations of cortisol by their respective tracer:tracee ratios (Equation 3).  Rate  of  
appearance of cortisol and d3-cortisol in the plasma were calculated as per Equations 4 & 5 
(Stimson et al, 2009). Pre-operative data were calculated from the mean results in 4 samples 
obtained from each participant between 180-195 minutes of d4-cortisol infusion and intra-
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operative data from the mean results of 3 samples obtained after a variable period of infusion 
(234-331 min).  
 
Equation 1: 
  Peak area d3-cortisol = true area d3-cortisol + 6.8% of peak area d4-cortisol  
  
Equation 2: 
 Peak area d4-cortisol = true d4-cortisol + 15% of peak area d3-cortisol 
 
Equation 3: 
Concentration at steady state (Css) d3-cortisol or d4-cortisol (nM)  
    = [cortisol]nM • Tracer:Tracee (TTR) 
 
Equation 4: 
 Ra-cortisol (nmol/min)= 
(Rate of d4-cortisol infused / TTR(d4-cortisol: cortisol)) - Rate of cortisol infused 
 
Equation 5: 




For adipose tissue extracts, the limit of quantitation for the LC-MS/MS was assigned with a 
signal: noise ratio >3 and peaks underwent smoothing (x5). Amounts of cortisol and 
cortisone were determined from a standard curve. Adipose tissue d3-cortisol, d3-cortisone 
and d4-cortisol amounts (nmol/kg of adipose) were calculated using the calculated amount of 
the non-deuterated glucocorticoids multiplied by the respective tracer:tracee ratios. All 
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adipose tissue amounts in mass/kg were converted to concentrations in mass/l by multiplying 
by the relative density of fat of 0.9g/ml (Ross et al, 1991). 
 
The rate of accumulation of d4-cortisol in adipose tissue was calculated using Equation 6, 
expressed as nmol/kg/h, assuming that no d4-cortisol was present in the adipose tissue before 
infusion, and that the rate of accumulation of tracer in adipose tissue was approximately 





The proportion of the intra-adipose cortisol pool that was replaced during d4-cortisol 









Calculations were performed in Microsoft Excel and SPSS version 14 (Chicago, IL).  Values 
are expressed as mean ± SEM. Data were analysed using Student’s t-tests. Significance was 
taken at p=<0.05. 
 
Rate of net d4-cortisol uptake into adipose (nmol/kg/h) = [d4-cortisol] adipose / time to biopsy 
 
Proportion of adipose cortisol pool  
replaced by d4-cortisol   
(%/h)  =       (d4-cortisol/(d4-cortisol +cortisol)) adipose    / time to biopsy  • 100 




3.4.1 Adipose tissue method development 
 
The initial extraction method consisted of 4 main stages: a) splitting adipocytes to release 
intracellular glucocorticoids, b) cleaning the extract and removing oils, c) re-extracting 
glucocorticoids and d) derivatisation prior to analysis by GC-MS.  
 
Using this initial method recovery of internal standard was poor and inconsistent with rodent 
adipose tissue. The method was repeated without adipose extract ie with reagents only to 
assess recovery of added internal standard. Upon analysis, the GC-MS traces had a high 
signal to noise ratio and a low steroid recovery (<1-1.3%). To optimise the method and 
assess where the internal standard was being lost, the method was assessed in a stepwise 
fashion and divided into the 4 key steps described above. These stages were assessed 
individually by commencing the process at the sequential point with reagents only and 
internal standard (ie without adipose initially) and analysed by GC-MS. 
 
Starting with the last stages of the extraction method, the derivatisation, re-extraction with 
ethyl acetate, and removal of oils stages were all successful but gave variable recovery of 
internal standard (10-71%).   
 
It was noted that the sodium salts of the buffer solution used for homogenisation precipitated 
when added to the chilled ethanol: acetic acid mixture. To assess if the precipitated buffer 
solution or indeed debris in an older solution (stored at room temperature) was the cause of 
the poor GC-MS traces, the splitting cells step was further divided into 2 stages and assessed. 
Addition of the buffer led to lower internal standard recovery (15-20%) and interference on 
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the GC-MS trace with a high signal to noise ratio, compared to the stage without buffer 
(ethanol: acetic acid mixture alone).  
 
The splitting cells step was repeated with either fresh buffer solution or water (no adipose). 
Greater steroid recovery was achieved at this step with fresh buffer compared to water 
(>100% vs 16- 36%). The whole method (without adipose) was repeated with the freshly 
made sodium phosphate buffer. A small amount of internal standard was recovered (5-37%).   
 
As we had demonstrated that during each of the steps with reagents only, a variable amount 
of internal standard could be recovered; the whole method was repeated with adipose tissue 
and broken into 4 steps as above. Despite using fresh buffer solutions, recovery of added 
internal standard remained poor (recovery 1-17%).  
 
Optimising the homogenisation fluid 
 
As the homogenisation buffer had initially been problematic, ethyl acetate was assessed as a 
substitute (Ronquist-Nii & Edlund, 2005). When comparing fresh buffer to ethyl acetate for 
the homogenisation step, (the methods were assessed in parallel without adipose), recovery 
of added internal standards were comparable (76-100% for ethyl acetate vs 78-89% with 
buffer). However, the GC-MS traces were more reproducible with the ethyl acetate, with a 
lower signal to noise ratio. Therefore, ethyl acetate was chosen as the homogenisation fluid. 
 
Using ethyl acetate, the whole method was repeated with adipose. The centrifugation step 
was modified to allow the use glass tubes in the centrifuge (3000 x g, 30 min, 4ºC). This 
modification was to prevent endogenous or added glucocorticoids sticking to plastics in the 
centrifugation tubes thus lowering recovery, as other steroids such as oestrogen and 
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progesterone readily stick to plastics. Recovery of internal standard was poor and varied 
(0.5-14%), but there was little background noise on the GC-MS trace.  
 
Adding extra steps to purify the extracts 
 
Upon viewing the derivatised steroidal extract, they appeared oily and yellow in colour. 
Water is known to interfere with some derivatising agents and so it is possible that water and 
oils in the extract may have interfered with the derivatisation process. This may have 
accounted for the large variability of results in all of the previous experiments. A further 
purifying step was added prior to derivatisation and several purification columns assessed for 
this process (lipidex columns, Sep-Pak C18 columns, and Varian Bond Elut C18 columns).   
 
The lipidex column was not successful in improving the yield of derivatised steroids and the 
extract remained yellow in colour.  Prior to applying the adipose extracts to Sep Pak C18 
columns the solvent for re-suspending the adipose extract and for eluting the glucocorticoids 
was optimised. This was achieved by spiking adipose extracts with tritiated glucocorticoids 
and assessing the recovery of tritiated steroid in the eluate from the column using a beta-
counter. Initially 100% methanol (5ml) was assessed as the solution to re-suspend the 
adipose extract (1µl 3H-corticosterone added).  Only 12% of the added tritiated steroid was 
recovered.  On reviewing the results of the experiment, it was evident that 3H-corticosterone 
did not stick to the column. When the adipose extract was applied, 43% of radioactivity was 
lost. Further loss occurred when water was passed through the column. Therefore, to 
improve separation of 3H-corticosterone from adipose tissue, improve steroidal sequestration 
on the column and subsequent elution from the column, adipose extracts were reconstituted 
in a less polar solvent. Using 30% methanol (methanol: water 30:70 v/v), only 7.8% of 
radioactivity was lost when applying the extract to the column and a further 1.2% after 
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applying a wash (100% water). Therefore this was chosen as the solvent for re-suspending 
adipose extracts prior to using the column. 
 
The extracts were eluted with one of the following solvents: water (2ml), 50% methanol 
(2ml), 100% methanol (2ml), acetonitrile (2ml), ethyl acetate (2ml) and hexane (2ml) to 
assess the solvent giving optimum recovery of radioactivity. Ethyl acetate was the best 
(>100% recovery of tritiated steroids) with 100% methanol and acetonitrile being next best 
(62% and 70% respectively). However, ethyl acetate appeared to melt the plastics on the 
columns. When the solvents from these experiments were applied to adipose extracts with 
non-tritiated internal standards and analysed by GC-MS, recovery of internal standards 
remained poor (0.3-20%) and the adipose extracts remained light yellow in colour. 
 
C18 Bond Elut cartridges (2g, Varian, Oxford, UK) were prepared and adipose extracts (in 
5ml 30% methanol) applied and the steroids eluted in ethyl acetate. After passing the adipose 
extract sample through the column the eluate was colourless, but recovery of steroids 
remained variable (1.5-40%). As the ethyl acetate used to elute steroids from the column 
appeared to melt the plastic column, this was substituted for methanol: ethyl acetate (50:50 
v:v). With this modification the GC-MS traces improved but internal standard recovery 
remained low. The elution solvent was modified from methanol: ethyl acetate (50:50 v:v) to 
100% methanol as we were concerned that plasticisers from the melted column and resultant 







Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) 
 
After using the Varian column, the adipose steroidal extracts were colourless and oil-free. 
The analysis method was changed to LC-MS/MS, as the variability in the GC-MS results 
may have been due to inadequate derivatisation. Using LC-MS/MS, recovery of spiked 
internal standards (epi-cortisol, cortisol, cortisone and d4-cortisol) from rodent adipose was 
excellent (85->100%). The method was broken into stages and internal standard added in a 
stepwise fashion to assess if there was any point where recovery of steroids was sub-optimal. 
Each of the stages produced good added steroid recovery except the initial homogenisation 
step (homogenisation 46% recovery, splitting adipocytes with ethanol: acetic acid 67% 
recovery,  sonnication 67% recovery, removing oils with hexane 69% recovery, putting 
through columns 100% recovery).   
 
Optimising the method with human tissue 
 
With the method giving 85->100% recovery of added internal standard with rodent adipose 
tissue, the method was assessed with human adipose tissue. Cortisone concentrations in 
subcutaneous adipose were 11-19.5nmol/kg and 12-44nmol/kg in omental adipose. Cortisol 
concentrations were 16-36nmol/kg in subcutaneous and 29-47nmol/kg in omental tissue. D4-
cortisol was 7-10nmol/kg in both depots and d3-cortisol levels 50-60% of the d4-cortisol 
values. 
 
The technique was repeated using a larger amount of human adipose tissue to assess if this 
improved endogenous glucocorticoid recovery.  Endogenous steroid recovery was inferior 
with 400mg of adipose compared with 250mg, (cortisol 6.2 vs 16.9 nmoles/kg, cortisone 3.5 
vs 13.3 nmoles/kg, d4-cortisol 3.4 vs 10.2 nmoles/kg respectively).  A ‘null’ adipose sample 
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(archived tissue) for assessment of background isotopomers was analysed and did not reveal 
any d4-cortisol isotopomers.  The optimised method achieved an extraction efficiency of 
70.1±2.1% for internal standard using 250mg. The RSD of triplicates was 13.4% for omental 
and 22.8% for subcutaneous adipose tissue.  Please refer to Figure 3.3 for final experimental 
method. 
 
3.4.2 Clinical results: samples obtained 
 
The intravenous infusion was well tolerated with no serious adverse events. Unforeseen 
problems which precluded obtaining 100% of plasma samples included malfunction of 
sampling cannulae during volunteer transfer. Despite this, the majority of plasma (46/48, 
95.8%, n=6) samples, and all adipose tissue (12/12, 100%, n=6) samples were obtained from 
each study participant. 
 
3.4.3 Participant characteristics 
 
Participants were aged 48.3±3.8y, with BMI 30.9±2.9kg/m2, and fat mass 30.7±3.5kg (Table 
3.1). All were undergoing total abdominal hysterectomy under general anaesthesia for 
benign gynaecological indications (5 for uterine fibroids, 1 for endometrial polyp). Two 
were taking progestogens (norethisterone) and one was taking oral oestradiol (Elleste Solo) 
with intra-uterine progestogen (levonorgestrel). Other medications included anti-
hypertensives (an ACE-inhibitor, a thiazide diuretic, and a beta-blocker) (n=3), ferrous 
sulphate (n=2), mefenamic acid (n=1), and levo-thyroxine (n=1). 
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Table 3.1 Participant characteristics. 
 






























All data are mean ± SEM for n=6.  BMI= body mass index; kg/m2= kilograms per metre squared; WHR= waist-hip ratio; SBP= systolic blood pressure; 
DBP= diastolic blood pressure; mmHg = millimetres of mercury.  
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3.4.4 Plasma glucocorticoids 
 
Deuterated and endogenous cortisol isotopomers in plasma (Figure 3.3A) were in steady 
state by 3 hours of infusion (not shown) and were unchanged during surgery. Cortisone but 
not d3-cortisone concentrations decreased during surgery (Figure 3.3C). 
 
Dilution of d4-cortisol by unlabelled cortisol (from 40% in the infusate to ~16% in plasma, 
Table 3.2) was used to calculate rate of appearance of cortisol, which did not differ during 
surgery (pre-operative 128.3±12.2 nmol/min versus intra-operative 138.4±18.5 nmol/min, 
p=0.55). Dilution of d4-cortisol by d3-cortisol was used to calculate rate of appearance of 
d3-cortisol, which did not differ during surgery (pre-operative 30.5±2.2 nmol/min versus 
intra-operative 30.4±3.0 nmol/min, p=0.92). Study infusates were extracted to confirm the 
infusion was prepared correctly, and the mean amount infused was 1.67±0.28mg/h 
(4.6 mol/h); this comprised mean amounts of cortisol and d4-cortiol of 0.80±0.13mg/h 
(2.2 mol/h) and 0.87±0.15mg/h (2.4 mol/h), respectively. 
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 Table 3.2: Plasma and adipose tissue tracer:tracee ratios and enrichments  
 






d4-Cortisol enrichment (%) 
(d4-cortisol/(cortisol +d4-
cortisol))•100 
15.6±0.8 15.5±1.0 7.2±0.6* 7.4±0.7* 
d3-Cortisone enrichment (%) 
(d3-cortisone/ (cortisone 
+d3-cortisone)) •100 
24.5±0.8 25.4±1.0 3.8±1.2** 5.1±0.9** 
[d4-cortisol]: [d3-cortisol] 
ratio 
1.1±0.1 1.1±0.1 1.0±0.1 1.0±0.1 
Cortisol: d4-cortisol:d3-
cortisol ratio 
5.7:1:1 6.0:1:1 13.3:1.1:1 12.3:1:1 
 
All data are mean ± SEM for n=6.  d=deuterium; ** p<0.0001, * p<0.001 versus intra-
operative plasma values by paired Student’s t-tests.  
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 3.4.5 Adipose tissue glucocorticoids 
 
Endogenous and deuterated glucocorticoids were detected in both subcutaneous and omental 
adipose tissue (Figures 3.3B and 3.3D) after 3.5-5.5 hours of d4-cortisol infusion. Absolute 
steroid concentrations were ~10-fold in both adipose tissue depots than in plasma (intra-
operative plasma cortisol 289.3±49.2nmol/L vs subcutaneous adipose tissue cortisol 
27.4±2.3nmoles/L, p=0.003, intra-operative plasma cortisone 47.2±4.7nmol/L vs 
subcutaneous adipose tissue cortisone 8.6±1.0nmoles/L, p=0.0005). Cortisone and d3-
cortisone concentrations were higher in the omental compared to the subcutaneous depot 
(Figure 3.3).  
 
The proportions of cortisol:d4-cortisol:d3-cortisol in adipose tissue differed from those in 
plasma (Table 3.2). Dilution of d4-cortisol with cortisol was substantially greater in both 
adipose tissue depots than in plasma, but dilution of d4-cortisol with d3-cortisol was not 
different. Enrichment of the cortisone pool with d3-cortisone was similarly much lower in 
adipose tissue than in plasma. 
 
The estimated net rate of accumulation of d4-cortisol (please see Equation 6) was 0.5±0.1 
nmol/kg/h for subcutaneous and 0.4±0.1 nmol/kg/h for omental depots (p=0.73) despite the 
40% d4-cortisol infusion contributing 2.4 mol/h d4-cortisol into the circulation (see 
composition of extracted infusates above). The proportion of the adipose tissue cortisol pool 
replaced each hour was estimated as 10.7±1.0% for subcutaneous and 10.4±0.7% for 
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Figure 3.3: Concentrations of deuterated and endogenous cortisol and cortisone in plasma pre- and intra-
operatively and in adipose depots intra-operatively. 
A) Plasma cortisol and its isotopomers (nmol/L). B) Adipose tissue cortisol and its isotopomers (nmol/L adipose tissue). C) 
Plasma cortisone and d3-cortisone (nmol/L). D) Adipose tissue cortisone and d3-cortisone (nmol/L adipose tissue). All data are 
mean ± SEM for n=6. Pre-operative plasma values were mean of 4 samples over 15 minutes, intra-operative samples were 
mean of 3 samples over 10 minutes. Adipose tissue values were mean of duplicates. *p<0.05 versus the same steroid 
isotopomer within each panel compared by Student’s t-tests. All steroids were significantly lower in adipose tissue versus intra-





These data show that concentrations of deuterated cortisol and its metabolites in human 
adipose tissue during prolonged steady state intravenous infusion are substantially lower than 
the values of total cortisol (bound to CBG and free) measured in plasma. Concentrations of 
unlabelled cortisol and cortisone pools in adipose tissue are more than twice as high as 
previously reported with LC-MS/MS assays in subjects not receiving a tracer  infusion 
(Ronquist-Nii & Edlund, 2005). There were no differences in rates of tracer accumulation or 
endogenous steroid levels in omental versus subcutaneous adipose depots. Thus it can be 
concluded that in humans in vivo uptake of glucocorticoids into adipose tissue and turnover 
of the intra-adipose glucocorticoid pool is slow. However, the contribution of 11 HSD1 
cannot readily be assessed in this duration of study, nor the exact location of the cortisol pool 
in adipose tissue (eg the aqueous cytoplasm or lipid droplet). 
 
In order to assess adipose steroid turnover, a robust method for extraction of tissue steroids 
was developed. Most previous studies of concentrations of steroids in adipose tissue have 
relied on immunoassays (Feher & Bodrogi, 1982;Lindsay et al, 2003;Wake et al, 2003) and 
have paid insufficient attention to matrix effects in crude tissue extracts. Others have used 
highly sensitive and specific LC-MS/MS (Ronquist-Nii & Edlund, 2005), reporting lower 
steroid concentrations than described here, although the characteristics of the participants 
and the biopsy method are unclear, making comparison with this study difficult. Using the 
knowledge gained from developing the adipose tissue glucocorticoid extraction method and 
the difficulties encountered, it is likely that the procedures described in the literature to 
extract steroids from adipose tissue are unreliable, with poor yields as considerable effort 
was required to optimise recovery of steroids and hence quantification.  
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This is the first time the 40% d4-cortisol tracer infusion has been used during surgery and in 
women. There was disproportionately high endogenous whole body cortisol production (~4-
fold increase) but similar systemic d3-cortisol production rates as previously reported during 
40% tracer infusion (30 vs 28nmol/min) (Stimson et al, 2009), consistent with increased 
adrenal secretion in association with surgery. During abdominal or hip surgery, endogenous 
plasma cortisol rises rapidly after the skin incision and remains elevated for >72 hours (Naito 
et al, 1992). Interestingly, this high endogenous cortisol production occurred in anticipation 
of surgery as well as during the procedure. In the previous study using a 40% d4-cortisol 
infusion the subjects were male and had received dexamethasone the evening prior to the 
study to suppress endogenous cortisol production (Stimson et al, 2009) which may partly 
explain some of the differences. However, gender may also play a role, in keeping with the 
rodent literature where baseline corticosterone levels are higher and the hypothalamic-
pituitary-adrenal axis highly responsive to ACTH stimulation or stressors in females 
compared to males (Kitay, 1961). However in humans, gender differences in adrenocortical 
response to stress are more contentious, with no sexual dimorphism following either 
pharmacological or physical stimulation being reported, but actually a greater response in 
men occurs in anticipation of and during psychosocial stress (Kirschbaum et al, 1992).  
 
In spite of the confounding measures of cortisol production, rate of appearance of whole 
body d3-cortisol provides an index of 11 HSD1 reductase activity independently of adrenal 
production. Again this may be influenced by gender. It has been reported that hepatic and 
whole body 11 HSD1 activity does not display sexual dimorphism in healthy adults (Finken 
et al, 1999), in keeping with similar whole body  d3-cortisol production rates reported here 
in women and previously in men (Stimson et al, 2009).  However others have shown 
enhanced net 11 HSD1 activity in men (Andrew et al, 1998;Fraser et al, 1999). Urinary 
glucocorticoid metabolite ratios, an index of whole body 11 HSD1 activity, are also 
increased in post-menopausal compared to pre-menopausal females (Andersson et al, 2009), 
 122 
but this augmentation reflects an increase in hepatic 11 HSD1 rather then subcutaneous 
adipose tissue 11 HSD1 activity. Thus, the peri-menopausal age and hormonal status of the 
participants is unlikely to have affected tracer-derived measurements of systemic 11 HSD1 
activity and systemic rate of appearance of d3-cortisol is thought to mainly reflect splanchnic 
production (Basu et al, 2004;Stimson et al, 2009).  
 
Other factors may also have impacted on the rates of appearance of cortisol, d3-cortisol and 
kinetic measurements. For example, the study participants had a wide range of BMIs; 
subcutaneous adipose tissue 11 HSD1 activity is ~3-fold higher (per gram adipose tissue) in 
obesity (BMI 31.7kg/m2) compared to normal weight (BMI 22.9kg/m2) subjects (Rask et al, 
2001). However, the numbers in this study were too small to adjust for this statistically.  
 
Another factor that may have influenced the adipose tissue results is the effects of surgery. In 
skeletal muscle, the physiological stress of abdominal surgery can increase in 11 HSD1-
reductase activity 5-days post-operatively without changes in transcript levels (Jang et al, 
2009). However, to my knowledge there are no studies examining 11 HSD1 activity both 
pre-, post- and intra-operatively in adipose tissue. Although anaesthetists were asked to 
withhold medications known to interfere with glucocorticoid metabolism until the study was 
complete, all participants received an intravenous infusion of propofol for maintenance of 
anaesthesia. At plasma concentrations considered necessary for anaesthesia, propofol is 
unlikely to affect steroidogenesis compared to other agents such as etomidate (Kenyon et al, 
1985). However, one participant also received pre-operative benzodiazepine, which at high 
concentrations can inhibit adrenocortical steroidogenesis in vitro (Thomson et al, 1995), but 
is not known to modulate activity of 11 HSD1. 
 
During a primed continuous infusion of d4-cortisol, steady state is achieved in plasma almost 
immediately for d4-cortisol itself, within 120 min for d3-cortisone and within 180 min for 
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d3-cortisol (Andrew et al, 2002;Andrew et al, 2005). Uptake of steroid into adipose tissue is 
likely to vary in proportion to the plasma concentration. The net rate of accumulation of d4-
cortisol in adipose tissue can therefore be estimated from a single biopsy sample on the 
assumptions that plasma d4-cortisol concentrations were stable throughout infusion, that d4-
cortisol was absent from the adipose tissue before infusion (which was confirmed on 
archived human subcutaneous adipose samples; data not shown), and that steady state was 
not achieved in adipose tissue in advance of the biopsy. To confirm the lack of steady state 
and estimate rates of change, it would have been useful to have multiple biopsies obtained at 
different time points in each patient, but this was not feasible. However, the 
disproportionately low concentrations of all deuterated steroids in adipose tissue, compared 
with those in plasma, suggest that steady state has not been reached in adipose tissue. Unlike 
d4-cortisol, however, net accumulation rates cannot be estimated so accurately for d3-
cortisone and d3-cortisol since plasma concentrations for these steroids will have varied 
during the early period of infusion as they are generated from d4-cortisol in tissues.  
 
The net rate of accumulation of d4-cortisol into adipose during infusion was estimated at 
~0.5 nmol/kg/h (Equation 6). This figure reflects the balance between uptake into adipose 
tissue and any removal, for example by inactivation by enzymes or by export into plasma. 
The only relevant clearance enzymes expressed in human adipose tissue are 5 -reductase 
type 1 (Wake et al, 2007b), type 2 (Mackenzie et al, 2008) and 11 HSD1, which under some 
circumstances may catalyse 11 -dehydrogenase activity, converting cortisol to cortisone 
(Wake et al, 2006;White et al, 2007). However, a previous study in healthy men undergoing 
d4-cortisol tracer infusion did not detect removal of d4-cortisol across the subcutaneous or 
visceral adipose tissue using arteriovenous sampling (Stimson et al, 2009), which suggests 
that the slow rate of accumulation of d4-cortisol in adipose tissue is mainly determined by 
transport between plasma and intra-adipose steroid pools rather than by rapid enzymatic 
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inactivation. This contrasts very markedly, for example, with the liver where removal of d4-
cortisol from previously published arteriovenous sampling data (Stimson et al, 2009) can be 
calculated as >250nmol/h. It is possible that the slow accumulation reflects relatively low 
blood flow in adipose tissue (~3ml/ 100g adipose tissue / min (Frayn et al, 2003) vs ~400ml/ 
min in liver (Stimson et al, 2009)), and/or tissue-specific and steroid-specific differences in 
active transport of glucocorticoids in and out of tissues (Asif et al, 2005;Karssen et al, 
2001;Lackner et al, 1998). Although to my knowledge there are no previous in vivo studies 
assessing cortisol transport and turnover in adipose tissue, one ex-vivo study reported adipose 
tissue uptake of [3H]2-cortisol was ~5 times slower than that of sex steroids (only 12.7% 
uptake at 3 hours vs 60.8% and 59.6% for progesterone and testosterone respectively) (Bleau 
et al, 1974).  
 
A key question is whether it can be inferred from slow accumulation of tracer d4-cortisol in 
adipose tissue that turnover of the endogenous cortisol pool is also slow. Two important 
issues  to  address  this  question  are  whether  there  is  a  difference  in  d4-cortisol  and  
endogenous cortisol entering the adipose cells, and secondly if 11 HSD1 activity can be 
detected in adipose, and how much this contributes to the adipose pool. 
 
Firstly, there is no evidence that d4-cortisol and cortisol have different pharmacokinetics or 
rates of metabolism due to a ‘primary isotope effect’ by the 11 HSDs (Andrew et al, 2002), 
although this has not been tested with respect to clearance by 5 -reduction. The affinity of 
d4-cortisol for transporters has also not been tested. Transporters of steroids into cells have 
been identified in the adrenal (Asif et al, 2005), the central nervous system (Karssen et al, 
2001), and the liver (Lackner et al, 1998), but to my knowledge there have not been any 
reports of glucocorticoid transporters in adipose tissue. A further consideration is whether 
transport and binding of d4-cortisol to CBG in the plasma is similar to that of the 
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endogenous steroid. This has also not been formally tested, but is possible as commercial 
kits are now available to measure CBG. The absolute concentrations of cortisol in adipose 
tissue were ~10% those in plasma, consistent with the ~90% binding of cortisol to plasma 
proteins, making it unavailable for transport into adipose. Concentrations of cortisone were 
~20% those of plasma, which is somewhat lower than expected given the low plasma protein 
binding of cortisone. This might reflect conversion of cortisone to cortisol by 11 HSD1, and 
the lower cortisone values in subcutaneous adipose tissue may reflect higher enzyme activity 
in this depot, as suggested in previous studies (Stimson et al, 2009).  
 
The principal aim of the study was to assess the rate of formation of d3-cortisol in adipose 
tissue as an index of 11 HSD1-reductase activity. Theoretically, an established way to 
achieve this is to calculate the fractional synthetic rate (FSR). To do this, adipose biopsies 
taken at two different time points are obtained and the change in tracer: tracee ratio (d4-
cortisol /d3-cortisol) and rate of appearance of d3-cortisol measured. However, this was not 
feasible in this study as the adipose biopsies were taken at the beginning of surgery and 
further biopsies would have interfered with the normal operation. Furthermore, if another 
biopsy were taken at the end of the operation, this would have prevented anaesthetists 
administering certain intra-operative drugs such as glucocorticoids for post-anaesthetic 
nausea and vomiting. Therefore, this approach was not undertaken. 
 
Release of cortisol into plasma from subcutaneous adipose tissue has been demonstrated 
once before using arteriovenous sampling (Stimson et al, 2009). Dilution of d4-cortisol by 
unlabelled cortisol in adipose tissue can be attributed exclusively to 11 HSD1. The previous 
study used a similar tracer infusion protocol and carried out arteriovenous sampling in 
healthy men yielding cortisol production at 9 nmol/kg/h (Stimson et al, 2009). Production 
was not demonstrated across visceral tissues. There are several explanations why additional 
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dilution of d4-cortisol by d3-cortisol was not detected in adipose tissue compared to plasma 
in our present study. Firstly, the adipose tissue d4-cortisol pool was not in steady state, and 
the previous study demonstrating adipose tissue cortisol relase did not measure absolute 
tissue cortisol levels in biopsy samples, simply plasma levels across an arteriovenous 
gradient (Stimson et al, 2009). Secondly, very low concentrations of d3-cortisone were 
present  in  adipose tissue,  consistent  with slow uptake of  cortisone as  well  as  cortisol  from 
the plasma, and perhaps providing inadequate substrate for 11 HSD1 activity. Moreover, 
given that d3-cortisol levels rise rather slowly during d4-cortisol infusion, reaching steady 
state after up to 3 hours (Andrew et al, 2002), one might anticipate that accumulation of d3-
cortisol in adipose tissue would lag behind accumulation of d4-cortisol and thus the dilution 
of d4-cortisol with d3-cortisol would be more marked in plasma than adipose at early time 
points. The fact that d3-cortisol:d4-cortisol ratios were similar in adipose tissue as in plasma 
may therefore be an indication of 11 HSD1 activity in adipose tissue, but this cannot be 
concluded. Indeed, a previous arteriovenous sampling study in men has demonstrated d3-
cortisol production in subcutaneous adipose tissue of ~5.2 nmol/kg/h (Stimson et al, 2009). 
This figure may be an underestimate, given that the d4-cortisol infusion lasted only 210 
minutes in the previous study and the current data suggest that d3-cortisone substrate 
concentrations in adipose tissue would still have been low at the time of sampling. 
 
These results suggest that thinking on the short-term metabolic effects of glucocorticoids on 
adipose tissue needs to be revised. Cortisol accesses intracellular cytosolic glucocorticoid 
receptors to elicit its effects on fatty acid metabolism and cellular differentiation in adipose 
tissue. Furthermore, in vitro data suggest that ultradian hormone stimulation induces the 
pulsatile synthesis of RNA from GR-regulated genes (Stavreva et al, 2009). It is widely 
assumed that cortisol gains rapid access to adipose tissue given its lipophilicity, and induces 
lipolysis in the short term and obesity in the longer term. Certainly, ultradian fluctuations in 
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plasma glucocorticoids are reflected in hippocampal extracellular fluid in rodents (Droste et 
al, 2008). However, the current data indicating slow turnover between plasma and tissue 
pools of cortisol are consistent with the intra-adipose cortisol pool integrating the longer-
term variations in circulating glucocorticoid concentrations. However, unless there are 
multiple pools of glucocorticoid within the adipose, with a cytosolic ‘free’ pool that turns 
over more quickly than a triglyceride-bound pool, then it appears unlikely that intra-adipose 
cortisol concentrations vary widely during acute changes in plasma cortisol. This suggestion 
is supported by the suggestion that ~90% of an adipocyte is composed of lipid, whilst only 
~10% is composed of an aqueous phase (personal communication from Dr C Keynon). 
Therefore, we speculate that the majority of the glucocorticoid pool in adipose tissue is 
unlikely to be affected by acute changes in plasma glucocorticoids. Thus, diurnal variation in 
intra-adipose cortisol concentrations is likely to be small, but this delayed rate needs to be 
confirmed under normal physiological circumstances, for example where adipose blood 
flow, meal pattern and insulin levels normally occur, rather than during the acute physical 
stress of surgery. Moreover, the rates of regeneration of cortisol by intra-adipose 11 HSD1 
measured in previous studies are high compared with the rate of accumulation of plasma-
derived cortisol within adipose tissue, emphasising the importance of 11 HSD1 in human 
adipose tissue glucocorticoid signalling. Differences in glucocorticoid responses between 
visceral and subcutaneous adipose tissue are not explained by differences in uptake of 
cortisol. It will be important to establish the rates of exchange between plasma and other 












Quantifying cortisone production / 11 -




This chapter addresses aim 4 from Chapter 1 Introduction, to develop a stable isotope tracer 
method with 1,2-[2H]2-cortisone to measure cortisone production, reflecting 11 -




Cortisone is an inert steroid that is produced endogenously exclusively upon 11 -
dehydrogenation of cortisol. The 11 -dehydrogenation reaction, converting cortisol to 
cortisone in man,  is catalysed by 11 HSD2, eg in the distal nephron (Stewart & Krozowski, 
1999). As described in  section 1.6.1, 11 HSD2 functions to rapidly inactivate cortisol and 
reserve MR specifically for aldosterone.  
 
Conversely, 11 HSD type 1, a low affinity NADP-dependent microsomal enzyme, is 
expressed in many tissues and functions predominantly as a reductase, regenerating cortisol 
from cortisone (Seckl & Walker, 2001). Selective inhibitors of 11 HSD1 are in development 
for treating type 2 diabetes by lowering tissue cortisol levels (Hughes et al, 2008). However, 
recent data suggest that, in the absence of NADPH cofactor generation by hexose-6-
phosphate dehydrogenase, 11 HSD1 can catalyse predominant dehydrogenase inactivation 
of cortisol (Lavery et al, 2006). Furthermore, 11 HSD1-dehydrogenase activity has been 
reported in ASV primary cell culture experiments and in in vivo subcutaneous adipose tissue 
microdialysis studies (Bujalska et al, 2002;Wake et al, 2006), but has not been quantified in 
vivo.  Measurement of cortisone production by 11 -dehydrogenase in vivo will be key to 
determining whether these observations are important in physiological regulation of tissue 




Current methods for measuring 11 -dehydrogenase activity and/or cortisone production in 
vivo are inadequate. Most investigators have relied upon measuring urinary free 
cortisol:cortisone ratios as an index of renal 11 HSD2 activity (Best & Walker, 
1997;Palermo et al, 1996), or urinary cortisol:cortisone metabolite ratios which reflect 
predominantly intra-hepatic steroid levels. However, these ratios only reflect net balance 
between the activities of multiple enzymes and do not quantify the rates of turnover between 
cortisol and cortisone. Other investigators have administered labelled substrates for 11 -
dehydrogenase, including 11 -[3H]-cortisol (Hellman et al, 1971), 9,11,12,12-[2H]4-cortisol 
(Andrew et al, 2002), 11 -[2H]-cortisol (Kasuya et al, 2005), and 1,2-[2H]2-cortisol 
(Vierhapper et al, 2007) but the rate of removal of some of these compounds are not 
exclusively dependent on 11 -dehydrogenase, and rates of accumulation of 11 -
dehydrogenase product (labelled cortisone, or liberated [3H]) cannot be quantified accurately 
in steady state in the absence of simultaneous measurement of clearance of the product. No 
investigators have yet undertaken the gold standard approach in which endogenous cortisone 
production is inferred from dilution of ‘tracer’ labelled cortisone, infused in steady state. For 
ethical reasons surrounding ionizing radiation, and because of the specificity of simultaneous 
analysis of tracer and tracee by mass spectrometry in the presence of their metabolites, stable 
isotope tracers are preferred to radioisotopes for this purpose. 
 
The stable isotope tracer 1,2-[2H]2-cortisone (d2-cortisone) was chosen  as the compound to 
develop a method to study 11 -dehydrogenase in vivo. d2-Cortisone consists of a cortisone 
molecule with 2 deuteriums attached to the 1,2 positions of the steroid A-ring. When infused 
systemically we hypothesised that d2-cortisone would be reduced by 11 -reductase to form 
d2-cortisol, with both deuteriums remaining on the product (Figure 4.1). This was proposed 
as the deuteriums on d2-cortisone are not placed on carbon 6 or 11  of the steroid molecule, 
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the main sites where hydrogen atoms are lost during hydroxylation (by CYP3A4) or 










Figure 4.1: Proposed metabolism of d2-cortisone by 11 HSD type 1.  
 
This tracer could then be infused in vivo to assess cortisone production systemically (net 
production by 11 HSD1 and 11 HSD2) or used to measure arteriovenous differences in 
cortisone production across tissue beds. Changes in cortisone production may then be 
quantified in specific pathways or under pharmaceutical manipulation. 





















4.2 Hypothesis and Aim 
 
The hypothesis was that 11 HSD1 catalyses dehydrogenation of cortisol in vivo generating 
cortisone. The aim was to develop and validate a novel stable isotope tracer, d2-cortisone, to 





4.3.1 Assay Development  
 
Optimising measurement of d2-cortisone using LC-MS/MS 
 
d2-Cortisone and d2-cortisol (1mg/ml) were dissolved in mobile phase and infused into the 
source of the LC-MS/MS (for further details of the instrument see section 2.8.2). The 
protonated molecular ions were subjected to a range of tube lens voltages and temperatures 
to ascertain optimum ionisation conditions. LC-FT-MS was undertaken to identify the exact 




Specificity of detection of d2-cortisone in the presence of endogenous steroids was assessed, 
to ensure the substance detected was d2-cortisone and not other related naturally occurring 
mass isotopomers of cortisone, for example molecules with carbon 13 (natural abundance of 
13C 1.11%) and deuteriums (natural abundance of 2H 0.015%). The following interferences 
were quantified: cortisone (mass+2, m/z 363), which may interfere with d2-cortisone 
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analysis, and cortisol (mass+2 m/z 365) which may interfere with d2-cortisol analysis. 
However, the exact composition of the isotopomer detected e.g either 13C or 2H could not be 
determined. The purity ie absence of unlabelled steroid of both d2-cortisol and d2-cortisone 
was also assessed. 
 
To further characterise purity of d2-cortisone, d2-cortisone (10 g) was derivatised to form 
methoxime-trimethylsilyl derivatives (section 2.7.3) and analysed using a full scan protocol 




Linearity of quantitation 
 
Increasing amounts of cortisone and d2-cortisone were injected onto the column to calibrate 
quantitation. Epi-cortisol was used as an internal standard, by addition of 500ng to each 
sample. The calibration curve was plotted by calculating the peak area ratio of analyte versus 
that of internal standard (epi-cortisol, y axis) against the amount of added analyte (x axis) 




Equivalence of ionisation of tracer and tracee (ie d2-cortisone and cortisone) was assessed 
using an enrichment curve.  The enrichment is the sum of the tracer divided by the tracee 
plus tracee (enrichment = tracer / tracer + tracee). To assess the linearity of this relationship 
with instrumental response an enrichment curve with fixed proportions of tracer to tracee 





Accuracy and precision of analysis of d2-cortisone was assessed at the lowest (2.5ng) and 
highest (200ng) concentrations of the standard curves, and weighting adjusted to maximise 
the RME (accuracy) and RSD (precision) (de Bievre et al, 1998). The limit of detection 
(LOD) and limit of quantification (LOQ) were also determined (section 2.8.2).  
 
4.3.2 In vitro studies 
 
In vitro assessment of whether d2-cortisone is a substrate for 11 HSD1-reductase 
 
To establish that the experimental tracer, d2-cortisone, was a substrate for reduction by 
human 11 HSD1 and to compare the reaction kinetic parameters between the two substrates, 
d2-cortisone or cortisone (2 M) were incubated with HEK293h11 HSD1 cells (2x105) 
(Webster et al, 2007) (n=3) under conditions described in section 2.5.3. Steroids were 
extracted as described in section 2.6.2 and the presence of d2-cortisol and cortisol 
respectively assessed by LC-MS/MS (section 2.8.2). 
 
Assessment of a primary isotope effect of deuterium on the velocity of metabolism of 
substrate by 11 HSD1-reductase 
 
The stable isotope tracer contains 2 deuterium atoms in place of 2 hydrogen atoms in 
endogenous cortisone, which may influence the strength of interactions with the enzyme 
active site. To assess if this affected the kinetics of 11 HSD1, the velocities of product 
formation (d2-cortisol vs cortisol) were compared from the above experiment (n=3).  
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To test for a primary isotope effect using a competition approach; [3H]2-cortisone (5nM) was 
incubated with increasing concentrations of cortisone or d2-cortisone (0nM - 4955nM) with 
HEK293h11 HSD1cells (2x105) (n=3), under conditions described in section 2.5.3. Steroids 
were extracted as per section 2.6.2, and the velocity of formation of [3H]2-cortisol quantified 
following analysis by HPLC with radio-detection (section 2.8.1)   
 
Assessment of a primary isotope effect on the velocity of metabolism of substrate by 5 -
reductase /3 -hydroxysteroid dehydrogenase 
 
As 5 -reduced glucocorticoids are metabolised quickly by 3 HSDs in vitro (Iyer et al, 
1990), we were unable to assess metabolism of d2-cortisone by these two enzymes 
individually. Therefore human hepatic cytosol was used to assess the combined action of 
these two enzymes resulting in formation of 3 ,5 -tetrahydrocortisone or its d2-labelled 
isotopomer.  
 
For  assay  development,  liver  tissue  from a  lean  Zucker  rat,  aged  12  weeks  was  used.  The  
liver was removed from the animal intact, snap frozen on dry ice and stored at -80 C until 
required. Archived human liver tissue was kindly donated by Dr Roger Brown, from an 
anonymised stored tissue sample obtained 1994/95. Initial informed consent obtained in 
1994/5 allowed use of the tissue for research in general.  Advice confirming that the tissue 
was suitable for use under the ethical permission given and the Human Tissue (Scotland) Act 
2006 was obtained from Dr Rachel Smith, Training & Communications Co-ordinator, 
Medical Research Council (MRC) Regulatory Support Centre, Edinburgh. 
 
To test for a primary isotope effect, cytosol (778 g/ml protein) (n=3) were incubated with 
cortisone or d2-cortisone substrate (10 M) and [3H]2-cortisone (10nM) under conditions 
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described in section 2.4.1. Steroids were extracted as per section 2.6.1 and the velocity of the 
product quantified following analysis by HPLC with radio-scintillation detection (section 
2.8.1). Cold steroidal standards were subsequently co-infused with the tritiated reaction 
product to identify the steroids formed. The reaction was also repeated with cold substrate 
only and the products derivatised (section 2.7.3) and analysed by GC-MS (section 2.8.4) to 
confirm the identity of the product. 
 
4.3.3 In vivo clinical studies investigating d2-cortisone metabolism 
 
All in vivo studies were approved by the Local Research Ethics Committee and all subjects 
gave written informed consent.  
 




To assess pharmacokinetic characteristics of d2-cortisone, healthy lean male volunteers 
(n=3) on no regular medication, who had not received glucocorticoid treatment by any route 
for 3 months, with normal biochemical indices (haemoglobin, renal, thyroid, liver function 
tests and glucose), attended the Clinical research Facility at 08:30h after an overnight fast.  
 
Preparation of the stable isotope tracer d2-cortisone 
 
d2-Cortisone (500 g) was dissolved in 1.0ml pharmaceutical grade ethanol and filtered in 
the radio pharmacy to form a sterile stock solution. For a single bolus dose, 0.3ml of stock 
solution (containing 150 g of d2-cortisone) was added to sodium chloride 0.9% w/v (49.7ml) 
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to make a total volume of 50ml (3 g/ml). 3.0ml of the diluted solution was discarded to 




Blood pressure was measured after sitting for at least 10 minutes using a 705IT automatic 
blood pressure monitor (OMRON Healthcare Europe BV, Hoofddorp, NL) prior to the start 
of the study. 
   
Clinical administration protocol 
 
One cannula was placed using an aseptic technique into each antecubital fossa vein. Venous 
blood was collected for basal assessment of steroids and background isotopomers. An 
intravenous bolus of d2-cortisone was administered (141µg in 0.9%w/v saline, 50ml) over 5 
minutes into the contra-lateral arm. Venous blood was obtained at frequent intervals from 0 
to 90 minutes from the contra-lateral arm to the bolus injection. 
 
Sample collection and processing 
 
Prior to obtaining any blood samples, 2ml of dead space (a mixture of saline and blood in the 
cannula) was withdrawn from the sampling cannula to prevent contamination of the whole 
blood sample by saline. Samples for plasma enrichment with d2-cortisone were obtained in 
5.5ml lithium heparin S-Monovette tubes. Blood samples were placed on wet ice prior to 







Endogenous and deuterated glucocorticoids were extracted from plasma as described in 
section 2.6.3 and analysed by LC-MS/MS (section 2.8.2). 
 




To measure net endogenous cortisone production rate at steady state, male volunteers, (n=3) 
attended the Clinical Research Facility at 08:30h after an overnight fast. 
 
Preparation of the stable isotope tracer d2-cortisone 
 
d2-Cortisone (500 g) was dissolved in 1.0ml ethanol and filtered in the radio pharmacy to 
form a stock solution. From the stock, 0.2ml (containing 100 g d2-cortisone) was added to 
sodium chloride 0.9% v/w (49.8ml) to make a total volume of 50ml (3 g/ml). 12.0ml of the 
diluted solution was discarded to leave 38.0ml (containing 76 g d2-cortisone) to be 
administered as a loading dose. For the infusion, 0.8ml (containing 400 g of d2-cortisone) of 




Blood pressure was measured after sitting for at least 10 minutes using a 705IT automatic 
blood pressure monitor (OMRON Healthcare Europe BV, Hoofddorp, NL) prior to the start 





A priming dose (76 g in 0.9% saline) was administered followed by a 3-hour infusion of d2-
cortisone (105 g/hour, 0.9% saline). Venous blood was sampled at intervals from the 
contralateral arm over 3 hours. Spot morning urine and saliva samples (~8:30am) (one 
sample of each) were obtained before the infusion. 
 
Sample collection and processing 
 
Blood samples were collected, processed and stored as per section 4.3.3. Urine samples were 
collected in a plain universal container and saliva samples were obtained by asking the 
volunteer to chew on cotton wool sticks (Salivette, Sarstedt, Beaumont Leys, UK) for 1 
minute. Salivettes underwent centrifugation (3000 x g 10min, 4°C) and urine and saliva were 
stored at -20ºC. A sample of d2-cortisone infusate was collected at the end of the study and 




Endogenous and deuterated glucocorticoids were extracted from plasma as per section 2.6.3 
and analysed by LC-MS/MS (section 2.8.2). Urine and salivary glucocorticoids were 
extracted  as  per  sections  2.6.5  and  2.6.4  and  analysed  by  GC-MS  and  LC-MS/MS  







Effect of inhibition of 11 -dehydrogenase by liquorice on cortisone production rate 
 
To test the effect of inhibition of 11 -dehydrogenase with liquorice on cortisone production 
rate, subjects in the ‘measuring cortisone production rate in vivo by steady state infusion’ 
study attended a second time after eating 200g of black liquorice (Panda liquorice chews 
3.8% liquorice extract, Vaajakoski, Finland) per day for 2 days. The study protocol above 
was repeated.  
 
4.3.4 Calculations and data analysis  
 
Quantitation of steroids was performed as described in section 2.8.2. Tracer: tracee ratios 
(TTRs) of peak areas of d2-cortisol:cortisol and d2-cortisone:cortisone were corrected for the 
abundances of naturally occurring isotopomers at baseline. Concentrations of d2-cortisone 
and endogenous cortisol and cortisone in plasma were determined using calibration curves as 
described in section 2.6.3.  As a standard for d2-cortisol was not available initially, plasma 
d2-cortisol concentrations were calculated by multiplying total cortisol concentration by the 
TTR d2-cortisol:cortisol. As the d2-cortisone tracer contained ~10-15% cortisone impurity, 




Corrected plasma [cortisone] (nM) = 








Volume of distribution, half-life and clearance of d2-cortisone were calculated from data 
obtained following bolus injection using Kinetica software (Thermo Scientific, Philadelphia, 
PA), by fitting the data to a one compartmental model. 
 
To calculate the amount of d2-cortisone to administer as a bolus dose and achieve a plasma 




Bolus dose ( g) = Concentration required in plasma (Cp) • Volume of distribution (Vd) 
 
To confirm the amount of d2-cortisone to administer as a bolus dose and continuous infusion 




Infusion rate= Css (nM) • Clearance (L.min-1) 
 





Clearance = Vd • Kel 
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Clearance (L.min-1) = rate of infusion (nmol.min-1) / Steady state concentration (Css, (nM)) 
 
Net  rate  of  appearance (Ra) of  cortisone in the plasma was calculated from the mean TTR 
(d2-cortisone:cortisone) in steady state (Equation 6). Rate of d2-cortisone infusion was 












4.4.1 Mass spectrometric analysis 
 
Ionisation parameters, mass transitions and structural composition of ions monitored during 
LC-MS/MS are summarised in Table 4.1. The proposed fragmentation mechanism of d2-
cortisol and d2-cortisone within the mass spectrometer is displayed in Figure 4.2. The 
protonated molecular ions of the d2-cortisone and d2-cortisol differed from cortisone and 
 143 
cortisol by 2 mass units respectively, whereas d2-cortisol formed a product ion differing by 
only one mass unit from cortisol, due to loss of deuterium following fragmentation across the 
steroidal B ring, confirmed by FT-MS.  Fragmentation of d2-cortisol also resulted in a 
product ion with m/z ratio of 329 at low collision energies (13V) so the sum of the 
abundances of these two ions was used for quantitative analysis.  
 
Cortisone was ionized with greater efficiency than d2-cortisone and this was taken into 
account by correcting values obtained in experimental samples using the enrichment curve 
(Figure 4.3).  
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 Table 4.1: Chemical formulae, mass transitions and MS ionisation conditions for endogenous and deuterated steroids  
 













Cortisone 361 163 22 168 163.1114 -2.2546 C11H15O 
Cortisol 363 121 31 142 121.0647 -0.4000 C8H9O 
d2-Cortisone 363 165 21 118 165.1239 -2.397 C11H13 D2O 
d2-Cortisol 365 122 23 118 122.0710 -0.5659 C8H8D1O 
d2-Cortisol 365 329 13 118 329.2079 0.4572 C21H25D2O3 
 
V=Volts, ppm = delta parts per million from calculated accurate mass, *assessed by the LTQ Orbitrap FT-MS, amu= atomic mass units, d= deuterium, 






Figure 4.2: Proposed fragmentation mechanisms for (A) d2-cortisone and (B) d2-cortisol during mass spectrometric analysis.  
 
A) d2-Cortisone fragmentation across the steroidal C-ring resulting in a product ion with 2 deuteriums attached and m/z 165. B) d2-Cortisol 
fragmentation across the steroidal B-ring results in a protonated product ion with m/z 122 retaining 1 deuterium atom. D= deuterium, m/z = mass charge 












































Figure 4.3: Enrichment curve for tracer (d2-cortisone) and tracee (cortisone) 
 
Enrichment (Enrichment = tracer / tracer + tracee). To assess the equivalence of ionisation an enrichment curve with fixed proportions of tracer (d2-
cortisone) to tracee (cortisone) was prepared. From the curve, it is apparent that the ratio of tracer to tracee was not 1:1, eg a fixed enrichment of 20% 
reads as a value of 10% for d2-cortisone / cortisone. Thus the enrichment curve was used to correct data when calculating cortisone concentrations in 
vivo. 
y = 0.4761x + 0.0048 
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Using selective reaction monitoring (SRM), endogenous cortisone (mass+2, m/z 363) gave a 
signal equivalent to 1% of the cortisone peak area which would interfere with d2-cortisone. 
It was determined that this background isotopic interference did not contribute significantly 
to the d2-cortisone  signal as in plasma it did not exceed noise, and therefore did not need to 
be corrected for when assessing d2-cortisone concentrations, although this can be readily 
achieved mathematically. 
 
However, a ~15% interference of the d2-cortisone peak area was detected when infusing d2-
cortisone at an ion with a m/z of 361 (i.e. equivalent to cortisone). Possible explanations for 
this interference included inaccurate isotopic-labelling during manufacture of the tracer, 
contamination of d2-cortisone during sample preparation, or detection of a different naturally 
occurring contaminant with m/z 361 in the LC-MS.  
 
To identify the cause of the m/z 361 interference, fresh stock steroid solutions were prepared 
and analysed on a full scan protocol of a Finnigan Voyager GC-MS (ie a different analytical 
instrument).  A sample with reagents only was analysed as a control and the interference was 
not detected. Approximately 15% contamination remained when the derivatised d2-cortisone 
standard was analysed (m/z ion of methoxime-trimethylsilyl derivative of cortisone = m/z 
531 (Andrew et al, 2002)) suggesting that the isotopic enrichment of the d2-cortisone tracer 
was less than 98% deuterated as claimed by the manufacturer manufacture (Figure 4. 4). 
This was subsequently confirmed on analysis of a different batch of tracer. The manufacturer 
was unable to provide a purer powder. Thus the contribution of this contamination to the 
signal for endogenous cortisone was corrected for mathematically by subtracting the amount 
of endogenous cortisone measured in a sample of d2-cortisone powder (dissolved in 
methanol) from the concentration of cortisone in experimental samples.  
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To identify the cause of the m/z 361 interference, a solution of d2-cortisone was derivatised to its MO-TMS derivatives and 
analysed on a full scan protocol using a Finnigan Voyager GC-MS.  (a) Approximately 15% contamination remained (thick grey 
bar) when the derivatised d2-cortisone (MO-TMS m/z 533) standard was analysed (m/z ion of methoxime-trimethylsilyl 
derivative of cortisone = m/z 531). The compound with m/z 532 may represent an m-1 isotopomer of d2-cortisone. (b) Mass 
chromatogram of isomers of MO-TMS derivative of d2-cortisone.m/z = mass charge ratio; RT= retention time. 
a) b) 
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The presence of naturally occurring mass isotopomers was also assessed in solutions of both 
d2-cortisol and cortisol. Using SRM, cortisol (mass+2, m/z 365) gave a signal equivalent to 
3% of the cortisol peak area in d2-cortisol. In contrast to the d2-cortisone standard which 
contained a significant amount of cortisone, the d2-cortisol standard did not contain any 
measurable cortisol. The presence of mass isotopomers detected was not significantly greater 




All the responses of analytes exhibited a linear relationship with concentration, when 
quantified using an internal standard; regression lines of calibration curves had r2 >0.99. This 
relationship was linear over a wide range of amounts of physiological relevance (Figure 4.5) 
 
Despite injecting equal amounts of cortisone and d2-cortisone, the peak area ratios of d2-
cortisone were smaller than those of cortisone, yielding a calibration line with a less steep 
gradient, suggesting that the deuterated cortisone was not ionised with the same efficiency as 
the non-deuterated steroid in the LC-MS. Thus data pertaining to d2-cortisone was corrected 
using an enrichment curve. Similar inequalities were encountered with d2-cortisol since two 
transitions were monitored for d2-cortisol, but only one for cortisol.  
 
The limit of detection (LOD) for the d2-cortisone assay was determined as 1ng, with a signal 
to noise ratio >3. The limit of quantification (LOQ) was determined as 2.5ng at which intra-
assay  RSD and  RME were  7.0% and  -0.1% respectively.  Inter-assay  RSD and  RME were  
7.5% and 2.3% respectively. At the highest point on the standard curve (200ng) intra-assay 
RSD and RME were 5.7% and 2.3% and inter-assay RSD and RME 9.1% and -2.8% 






Figure 4.5: Cortisone and d2-cortisone calibration curves with epi-cortisol internal standard.  
Increasing amounts of cortisone (grey diamonds) and d2-cortisone (black squares) were analysed by LC-MS/MS to calibrate quantitation. Epi-cortisol 
(500ng) was used as an internal standard. The calibration curve was plotted by calculating the peak area ratio of analyte versus that of internal standard 
(epi-cortisol, y axis) against the amount of added analyte (x axis). 
y = 0.0008x + 0.0061 
r 2  = 0.995 
y = 0.0019x + 0.0101 



















Cortisone: epi- cortisol 
d2-Cortisone: epi-cortisol 
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4.4.2 In vitro metabolism of d2-cortisone  
 
d2-Cortisone is a substrate for human 11 HSD1-reductase 
 
d2-Cortisone was a substrate for human 11 HSD1 in that incubation of HEK293h11 HSD1 
cells with d2-cortisone or cortisone resulted in production of d2-cortisol or cortisol, 
respectively, at similar rates (0.38±0.20 vs 1.05±0.50 pmol/105 cells/min, p=0.19). d2-
Cortisone and cortisone concentrations declined at a similar rate (Figure 4.6A) and d2-
cortisol and cortisol concentration increased (Figure 4.6B). Similarly, d2-cortisone and 
cortisone had comparable abilities to compete with [3H]2-cortisone for metabolism: Vmax for 
formation of [3H]2-cortisol in the presence of d2-cortisone was 1.80±0.64 and in the presence 
of cortisone was 2.18±0.78 pmol/ 105 cells/min (p=0.56); apparent Km was 2.29±1.05 vs 
2.76±1.23µM (p=0.57), respectively (Figure 4.6 C and D). In control samples without cells 
or without [3H]2-steroid there was no evidence of [3H]2-cortisone reduction to [3H]2-cortisol.  
 
d2-Cortisone is a substrate for human 5 -reductase/3 -hydroxysteroid dehydrogenase  
 
In hepatic cytosol, -reduced cortisol metabolites are rapidly reduced by 3 HSDs in vitro, 
resulting in only the tetrahydro-steroids being measurable (Iyer et al, 1990). Human hepatic 
cytosols converted [3H]2-cortisone to [3H]2-3 ,5 THE. The identity of the product was 
confirmed using HPLC with UV detection (Figure 2.1) and a assay with cold substrate only 
and the product confirmed by GC-MS. Cortisone and d2-cortisone were metabolised at 
similar rates by 5 -reductase/3 HSD (0.050±0.004 vs 0.045±0.006 pmol/mg/h, p=0.71). A 
further, as yet unidentified, peak formed from ~15% of substrate levels was obtained 
(velocity: 0.069±0.002 vs 0.084±0.008 pmol/mg/h, p=0.15).  [3H]2-Products were not formed 
in control samples without cytosol or co-factor.  
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Figure 4.6: In vitro metabolism of d2-cortisone and cortisone by HEK 293 cells stably transfected with human 
11 HSD1 
 
A) d2-Cortisone (d2E) or cortisone (E) were extracted from media of HEK293/h11 HSD1) cells during incubation with d2E 
or E, respectively. B) d2-Cortisol (d2F) or cortisol (F) were extracted from media of HEK293/h11 HSD1 cells incubated 
with d2E or E, respectively. C) Michaelis-Menten and D) Lineweaver-Burke plots demonstrating the velocity of the reaction 
with HEK293/h11 HSD1 cells incubated with increasing concentrations of E or d2E and a fixed quantity of tritiated 
cortisone ([3H]2E). 1/S = reciprocal of substrate concentration, 1/V= reciprocal of velocity. All data are mean ± SEM for n=3 
in duplicate. Differences in kinetic data generated during d2E and E incubation were not statistically significant, compared by 
Student’s t test. 
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4.4.3 In vivo kinetics 
 
To assess the pharmacokinetic behaviour of d2-cortisone, a bolus dose of d2-cortisone was 
administered to 3 healthy male volunteers. The mean age of participants was 36 (range 29-
49) y, and mean BMI 23.0 (18.8-26.5) kg /m2. After bolus administration, elimination of d2-
cortisone from blood conformed to first order kinetics and the tracer could be detected for 
1.5h after injection (Figure 4.7A). The half life was 57.5 min, volume of distribution 47.0 L, 
and area under the curve 494nmol/L/min. This data was used to inform the administration 
protocol for the steady state infusion aiming to achieve steady state plasma concentrations of 
10nM. 
 
To assess cortisone production rates, the tracer was infused at a rate of 105.3 g/h into 
participants with characteristics detailed in Table 4.2. d2-Cortisone was not detected in 
plasma at baseline. During infusion of d2-cortisone for 3 hours, cortisone, cortisol, d2-
cortisone and d2-cortisol were readily measured in plasma. Steady state d2-cortisone 
concentrations of 9.3±2.1nmol/L were achieved after just 15 minutes (Figure 4.7B), with 
mean plasma cortisone levels at steady state of 64.9±2.6nmol/L (Table 4.2). The dilution of 
d2-cortisone by endogenous cortisone resulted in a calculated net rate of appearance of 
cortisone of 40.4 ± 10.0 nmol/min. 
 
To assess if the technique for measuring dilution of d2-cortisone was sensitive enough to 
detect changes in cortisone production rates, liquorice was administered to the same healthy 
volunteers. Following liquorice, endogenous cortisone levels were significantly lower 
(Figure 4.7C). There was a trend towards a rise in enrichment of plasma cortisone with d2-
cortisone (Figure 4.7D), which resulted in a ~50% reduction in the calculated net rate of 
appearance of cortisone (p=0.05) (Table 4.2). Plasma cortisol:cortisone ratios in a pre-
infusion sample increased (Table 4.2),  however, neither urinary ratios (cortisol:cortisone or 
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cortisol:cortisone metabolite ratios) nor salivary cortisone concentrations were significantly 
affected by liquorice (Table 4.2). Cortisol was below the limit of quantitation in saliva.  
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Healthy volunteers were studied before ( )  and  after  ( ) administration of liquorice. A) Plasma d2-cortisone (d2E) concentrations after an 
intravenous bolus of d2E. B) Plasma d2E concentrations following infusion of tracer with and without liquorice administration. C) Plasma 
cortisone (E) concentrations following infusion of tracer were lower after taking liquorice. D) Plasma enrichment of E with d2E following 
infusion of tracer. All data are mean ± SEM for n=3. * = p<0.05 comparing plasma steady state concentrations before and after liquorice using 
paired Student’s t-tests. 
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Table 4.2: Participant characteristics and kinetic parameters of cortisone and its 










35.3±6.8 - - 
BMI (kg/m2) 
 
22.8±2.1 23.6±2.3 0.29 
SBP (mmHg) 123±6 133±6 0.36 
DBP (mmHg) 86±5 84±2 0.51 
Before tracer infusion    
Plasma cortisol (nmol/L) 
~9am 
287.8±46.3 339.8±24.4 0.03 
Plasma cortisone (nmol/L) 80.7±10.5 52.5±1.9 0.14 
Plasma cortisol:cortisone 3.6±0.3 6.5±0.5 0.04 
Urine cortisol:cortisone 3.0±0.2 3.9±1.1 0.42 
Urine cortisol:cortisone 
metabolites 
((5 THF+5 THF)/THE) 
1.2±0.1 1.4±0.2 0.58 
 








During tracer infusion    















Rate of appearance of 


















All data are mean ± SEM for n=3. BMI= Body Mass Index, SBP= Systolic Blood Pressure, 
mmHg  =  millimetres  of  Mercury,  DBP=  Diastolic  Blood  Pressure,  Css= Concentration at 




Using the above in vitro and in vivo studies a new stable isotope tracer method has been 
developed and validated to quantify cortisone production by 11 -dehydrogenase activity in 
vivo in humans. Tracer measurement was optimised using LCMS/MS, and the data 
demonstrate that d2-cortisone is metabolised in a similar fashion to cortisone in vitro not 
only by human 11 HSD1, but also by other cortisone metabolising enzymes in liver, 
indicating that there is no significant primary isotope effect from the deuteriums and the 
metabolism  of  the  tracer  is  similar  to  the  tracee.  Moreover,  using  liquorice,  the  rate  of  
appearance of cortisone is more sensitive as an indicator of inhibition of 11 -dehydrogenase 
activity than the existing methods of urinary cortisol:cortisone ratio or salivary cortisone 
analysis.  
 
Mass spectrometric analysis was used to confirm mass transitions of d2-cortisone, its 
metabolite, d2-cortisol, and the structural composition of the ions monitored during LC/MS-
MS. The pattern of d2-cortisone fragmentation was similar to endogenous cortisone with the 
exception that the 2 ‘tracer’ deuteriums remained on the product fragment. d2-Cortisol 
fragmentation differed to cortisol as a deuterium atom remained on the product after tandem 
mass spectrometry, however specific mass transitions could be assigned to distinguish tracer 
and tracee. Naturally occurring isotopomers of cortisone did not contribute significantly to 
the d2-cortisone signal and the LC-MS/MS assay was validated demonstrating suitable limits 
of quantification and detection for assays. 
 
In order for a compound to be a suitable tracer for in vivo analysis the following assumptions 
must hold true. Firstly, the tracer must be a substrate for the enzyme and metabolised and 
cleared at the same rate as the endogenous compound. Utilising HEK293h11 HSD1 cells, it 
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was apparent that d2-cortisone was a substrate for 11 HSD1 and was metabolised to d2-
cortisol at a similar rate to that of endogenous cortisone to cortisol. Furthermore, by 
assessing the combined actions of 5 -reducatse and 3 -HSD, it was demonstrated that d2-
cortisone and cortisone are metabolised at a similar rate resulting in the production of 5 ,3 -
tetrahydrocortisone or its d2-isotopomer. However, other routes of glucocorticoid 
metabolism were not assessed such as the 20 - or 20 -hydroxysteroid dehydrogenases or 
cytochrome P450s, but these do not make a major contribution to total rates of clearance, at 
least in health, unlike A-ring reduction. 
 
A second assumption is that the tracer must not be converted into the tracee. In the case of 
d2-cortisone, stripping of the deuteriums from the tracer would result in the production of a 
molecule identical to that of endogenous cortisone (ie the tracee) and add to the tracee pool if 
infused into humans. As the deuteriums on d2-cortisone are not positioned on carbon 6 or 
11  (sites where loss might occur through metabolism), it was hypothesised that this should 
not occur. To test this hypothesis, the mass transitions of d2-cortisone and d2-cortisol were 
monitored from extracts of in vitro cell studies. During, LC-MS/MS analysis, no obvious 
loss of all deuteriums occurred. However, the issue of whether stripping of deuteriums 
occurs in vivo has not been fully proven as endogenous cortisone (ie the product of stripping 
deuteriums  from  d2-cortisone)  is  present  in  human  plasma  samples.  To  try  and  assess  if  
deuteriums are lost from the tracer in vivo, d2-cortisone could be administered to a rodent 
which has corticosterone and 11-dehydrocorticosterone as its endogenous glucocorticoids. 
Analysis of the rodent plasma should reveal endogenous glucocorticoids and d2-cortisone 
and d2-cortisol. If any unlabelled cortisone is detected it would indicate stripping of 
deuteriums in vivo.  
 
Thirdly, when developing a stable isotope tracer method, one must ensure that tracer 
recycling does not occur or is accounted for. Some glucose tracers such as 3-[13C]-glucose 
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do recycle in vivo and  this  enables  calculation  of  the  rate  of  glucose  cycling  (Wolfe  &  
Chinkes, 2005).   However, if the isotope is taken up by a tissue, metabolised, and re-appears 
in the system as the tracer again because of recycling, the calculated rate of appearance will 
be under-estimated by that amount (Wolfe & Chinkes, 2005). d2-Cortisone may initially be 
reduced to d2-cortisol and then dehydrogenated back to d2-cortisone by the 11 HSDs. 
Indeed, this recycling occurs in vivo with endogenous cortisone. To address this issue, in a 
further set of healthy volunteers (n=6, please see Chapter 5), d2-cortisone and d4-cortisol 
were co-infused as part of a separate study. The rate of d2-cortisone to d2-cortisol 
conversion was calculated from the Ra d3-cortisol assuming this to be the same as the rate of 
d2-cortisol conversion to d2-cortisone and that inter-conversion remains to be in linear 
proportions to the substrate concentration (please see p178). As d4-cortisol is not regenerated 
from d3-cortisol, recycling by 11 HSD1-reductase does not need to be accounted for with 
this tracer. The rate of recycling of d3-cortisone to d3-cortisol was estimated as ~8nmol/min, 
which would increase the rate of appearance of cortisone in this study by ~15-20%.  
 
Having established the suitability and possible limitations of using d2-cortisone to trace 
cortisone, as series of experiments were performed to assess endogenous cortisone 
production. To design an infusion protocol, pharmacokinetics of the tracer were established 
initially. The results from the bolus injection of d2-cortisone suggest that d2-cortisone has a 
longer half-life than has been previously reported for cortisone (57.5 vs. 28min) (Peterson et 
al, 1957). However, the earlier report from the 1950s relied on older assay technology 
assessing the counter-current distribution of [14C]-labelled steroids reacting with phenyl-
hydrazine and the report does not comment whether a primary isotope effect was assessed or 
indeed exists with [14C]-cortisone.  
 
Cortisone production rate was also somewhat higher than the rate previously calculated 
using non-steady state kinetics with a d4-cortisol tracer (40.4 vs. 24.1nmol/min, adjusted for 
 160 
substrate concentration and Vd (Andrew et al, 2002)), but this likely reflects the advantages 
of making steady state measurements based on dilution of tracer by tracee, when both tracer 
and tracee are at physiological concentrations, rather than extrapolation of initial rates of 
metabolism. Notably, the cortisone production rate calculated here is approximately 60-70% 
of the cortisol production rate calculated in similar healthy men using d4-cortisol infusion 
(Andrew et al, 2002), confirming that 11 -dehydrogenase is a major route of cortisol 
metabolism.  
 
After short-term liquorice administration plasma endogenous cortisone concentrations fell 
substantially, consistent with impaired 11 -dehydrogenase and accounting for the rise in 
plasma cortisol:cortisone ratio. Differences in ratios of urinary free cortisol:cortisone and 
cortisol:cortisone metabolites were not statistically significant, but were in the expected 
directions. Previous investigators demonstrating significant changes in urinary metabolites 
used longer periods of liquorice treatment (Stewart et al, 1987). Thus urinary indices may 
change significantly in the longer term, but the approach using d2-cortisone tracer is able to 
pick up changes in 11 -dehydrogenase activity in the shorter term.  
 
The primary source of cortisone production is likely to be the kidney (Hellman et al, 
1971;Whitworth et al, 1989) from dehydrogenation of cortisol, but further studies using d2-
cortisone tracer will be able to dissect this further eg by arteriovenous sampling across tissue 
beds. Alternative sites of cortisone production include the gut (Hirasawa et al, 1997) or 
blood vessels (Christy et al, 2003). This study and the majority of published work estimating 
cortisone production (Hellman et al, 1971;Andrew et al, 2002;Vierhapper et al, 2007) have 
used intra-venous infusions of isotopes which should reduce / exclude any contribution from 
the gut. Theoretically another potential source of cortisone in man could be the reversible 
oxidation of tetrahydrocortisone or even tetrahydrocortisol (via tetrathydrocortisone by 
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11 HSD2). This is highly unlikely as although hepatic 3 -HSDs can act reversibly to form 
dihydrocortisone, reversibility of 5 -reductase has not been demonstrated (Bush & Mahesh, 
1959). 
 
The major advantage of d2-cortisone steady state tracer infusion over existing techniques is 
that it is specific to the 11 -dehydrogenase activity: if 11 -reductase activity is altered this 
will affect tracer and tracee equally. Other tools based on the ratio of cortisol:cortisone or of 
their metabolites reflect only the net balance of dehydrogenase and reductase activities, and 
are influenced by changes in either. By achieving steady state within 15 minutes, d2-
cortisone infusion will be relatively quick and easy to incorporate into investigation 
protocols. In principle, d2-cortisone can also be combined with d4-cortisol infusion (Andrew 
et al, 2002) to measure 11 -dehydrogenase and 11 -reductase activities simultaneously. 
Disadvantages include the need for mass spectrometry, but this is required for urinary steroid 
ratios too, and the care that must be taken to take account of background isotopomer 
enrichments.  
 
Dissection of 11 HSD dehydrogenase from reductase becomes important in tissues where 
both may exist either due to both 11 HSD1 and 11 HSD2 being present or through 
reversibility of 11 HSD1. In states of NADPH deficiency eg when 11 HSD1 is liberated 
from the intracellular environment or when H6PDH is lost through gene targeting in mice 
(Lavery et al, 2006), 11 HSD1 displays dehydrogenase activity. Adipose tissue 11 HSD1 
also demonstrates some dehydrogenase activity in primary cell cultures and in intra-adipose 
microdialysis in vivo (Bujalska et al, 2002;Wake et al,  2006).  As  human  adipose  tissue  
11 HSD2 expression is negligible and 11 HSD1 expression is abundant (Bujalska et al, 
2002), any dehydrogenase activity in human adipose tissue can be attributed to 11 HSD1.  
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In conclusion, d2-cortisone tracer can now be used to measure cortisone generation in whole 
body and in specific tissues to further our understanding of the role of 11 HSDs in 
physiological control of tissue steroid levels, pathological amplification of cortisol 
concentrations in hypertension and obesity, and pharmacological targeting. In the next 
chapter of this thesis, Chapter 5, d2-cortisone is used to measure 11 -dehydrogenase activity 
in subcutaneous adipose tissue and forearm skeletal muscle in vivo to explore in more detail 













Inter-conversion of cortisol and cortisone 
in human subcutaneous adipose tissue and 




This chapter addresses aims 5 and 6 in Chapter 1 Introduction, applying the newly developed 
tracer method for d2-cortisone and measuring 11 -dehydrogenase activity in the whole body, 
across subcutaneous adipose tissue, forearm skeletal muscle and assessing the effect of 




Cortisol is generated locally in tissues through the conversion of inert cortisone to cortisol by 
the intracellular enzyme 11 -hydroxysteroid dehydrogenase type 1 (Seckl & Walker, 2001). 
Recent studies using a stable isotope tracer 9,11,12,12-[2H]4-cortisol show that in vivo 
adipose tissue 11 HSD1 predominantly functions as a reductase generating 15pmol of 
cortisol per min/100g tissue (Stimson et al, 2009). 11 HSD1-reductase activity is driven by 
NADPH co-factor derived from hexose-6-phosphate dehydrogenase (H6PDH), co-localised 
with 11 HSD1 in the endoplasmic reticulum lumen (White et al, 2007). Altered cortisol 
generation   in  tissues  such  as  adipose  tissue  and  the  liver  has  been  implicated  in  the  
metabolic complications of obesity (Rask et al, 2001), and 11 HSD1 inhibition has been 
investigated as a potentially useful therapeutic target to lower intracellular cortisol levels 
(Hughes et al, 2008). However, in states of NADPH deficiency eg when 11 HSD1 is 
liberated from the intracellular environment or when H6PDH is lost through gene targeting 
in mice (Lavery et al, 2006), 11 HSD1-dehydrogenase activity predominates. It has been 
demonstrated that adipose tissue 11 HSD1 has some dehydrogenase activity, inactivating 
cortisol to cortisone, in primary cell cultures and in intra-adipose microdialysis in vivo 
(Bujalska et al, 2002;Wake et al, 2006). As human adipose tissue 11 HSD2 expression is 
negligible and 11 HSD1 expression is abundant (Bujalska et al, 2002), any dehydrogenase 
activity in human adipose tissue can be attributed to 11 HSD1and this may be metabolically 
protective (Kershaw et al, 2005).  
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11 HSD1 is also expressed in skeletal muscle (Jang et al, 2006), an important site of insulin 
resistance in type 2 diabetes. In rodents skeletal muscle 11 HSD1 activity is low compared 
to adipose (Livingstone et al, 2000), whilst in humans the evidence for in vivo skeletal 
muscle 11 HSD1 activity is equivocal as no gradient in cortisol and cortisone concentrations 
was found in forearm muscle  (Katz et al, 1999) but a small amount of reductase activity was 
detected in the leg using the stable isotope tracer 9,11,12,12-[2H]4-cortisol (Basu et al, 
2004;Basu et al, 2005). Ex-vivo studies have demonstrated skeletal muscle 11 HSD1-
reductase activity and a small amount of 11 HSD1-dehydrogenase activity in tissue 
homogenates (Jang et al, 2007) . Since increased 11 HSD1 expression in skeletal muscle 
associates with diabetes (Jang et al, 2007; Morgan et al,  2009) it  is  important  to  clarify its  
function. 
 
To quantify 11 HSD1 dehydrogenase activity in adipose tissue and skeletal muscle in vivo, a 
novel stable isotope tracer 1,2-[2H]2-cortisone has been developed and validated (see Chapter 
4). Using  1,2-[2H]2-cortisone in combination with 9,11,12,12-[2H]4-cortisol (Andrew et al, 
2002) simultaneous 11 HSD1-reductase and dehydrogenase activity can be measured in 




To use the isotopes 1,2-[2H]2-cortisone (d2-cortisone) and 9,11,12,12-[2H]4-cortisol (d4-
cortisol) in conjunction with arteriovenous sampling techniques to selectively measure 
11 HSD1 activity in adipose tissue and skeletal muscle of healthy subjects. Secondly to test 
the effect of hyperinsulinaemia on whole body, subcutaneous adipose tissue and forearm 
skeletal muscle 11 HSD1 activity and directionality; hypothesising that increasing glucose 
uptake may increase substrate supply to H6PDH and drive a switch from dehydrogenase to 





5.3.1 Study Design 
 
The study was approved by the Local Research Ethics Committee (Milton Keynes Research 




Six healthy male individuals were studied. The volunteers were recruited from the Oxford 
Clinical Research Bio-bank during 2009. The inclusion criteria included healthy non-obese 
men aged 20-70, with no glucocorticoid use within the last 3 months, alcohol intake <28 
units/ week and normal screening blood tests (full blood count, urea and electrolytes, thyroid  
and hepatic function and glucose). Study participants were aged between 30-49 years (mean 
±SEM 42.3±3.6y), with a body mass index of 21.1-27.6kg/m2 (24.6±0.9) and fat mass of 





Height and clothed weight were measured using standard techniques as described in Chapter 
3, section 3.3. Dual energy X-ray absorptiometry (DXA) (Lunar, GE Healthcare, Chalfont St 
Giles, UK) scanning was undertaken to assess total fat and lean body mass. Prior to inclusion 
in the study ultrasound screening of the vessels to be cannulated was undertaken by clinical 
staff from the Clinical Research Unit, Oxford Centre for Diabetes, Endocrinology and 
Metabolism, University of Oxford, Oxford.  
 167 
Preparation of the study infusions 
 
d4-Cortisol (40% d4-cortisol and 60% hydrocortisone) 
  
The stock solution was made by dissolving 12mg of cortisol and 8mg d4-cortisol (total 
20mg) in 2.0ml ethanol in a sterile airflow hood in the Oxford Clinical Research Facility. For 
the bolus injection, 0.4ml (containing 4mg total cortisol) of stock solution was dissolved in 
sodium chloride 0.9% v/w (19.6ml) (total volume 20mls).   2.5ml of this solution was 
discarded and the remaining 17.5ml (containing 3.5mg of total cortisol) injected over 5 
minutes.  For the infusion, 1.2ml of stock solution (containing 12mg of total cortisol) was 
dissolved in sodium chloride 0.9% v/w (248.8ml) to make a total volume of 250mls 




To make the stock solution, 1.0mg of d2-cortisone was dissolved in 2.0ml ethanol 
(500 g/ml). For the loading dose, 0.2ml (containing 100 g of d2-cortisone) of stock solution 
was added to sodium chloride 0.9% (9.8ml, total volume 10mls).  2.4ml of the solution was 
discarded and the remaining 7.6ml (containing 76 g of d2-cortisone) infused over 5 minutes. 
For the continuous infusion, 1.4ml of stock solution (containing 700 g of d2-cortisone) was 
mixed with sodium chloride 0.9% (248.6ml) to achieve a total volume of 250ml (2.8 g d2-





Actrapid (0.2ml, 200 units) was added to sodium chloride 0.9% (57ml) and 2.3ml of the 
subjects blood, to give a final concentration of 350 milliunits/ ml, and infused according to 




To measure forearm skeletal muscle and subcutaneous adipose tissue 11 HSD1 reductase 
and dehydrogenase activity, volunteers attended the Clinical Research Facility between 
07.15-07.30am after an overnight fast to a quiet temperature controlled room. With the 
volunteer supine, under ultrasonic guidance, a Careflow catheter (150mm, 20-gauge, BD, 
Oxford, UK) was placed into a superficial vein on the anterior abdominal wall with the tip 
just superior to the inguinal ligament. Catheter placement allowed access to the venous 
drainage of the subcutaneous adipose depot, with only a minor contribution from the skin 
(Frayn et al, 1989). To ensure blood collected was from the adipose depot and not from 
abdominal muscle, the O2 saturation of the blood was confirmed >85%. One retrograde 
cannula (20-guage) was then placed under ultrasonic guidance into a deep branch of the 
median cubital vein in the left antecubital fossa to obtain access to venous drainage from the 
forearm skeletal muscle with only minor contributions from the skin and adipose tissue of 
the forearm (Butler & Home, 1987) and O2 saturation confirmed as <40%. A further 
retrograde cannula in a vein draining the right hand, was warmed to 60 C in  a  hot-box  to  
arterialise the blood sampled (Roddie et al,  1956)  and  O2 saturation   confirmed  >98%.  A  
fourth cannula (18-guage) was placed antegradely into the right antecubital fossa for the 
study infusions. The cannulae were kept patent by continuous slow infusion of 0.9% saline 
(w/v, 30ml/h).  
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At t=-10 minutes, an arterialised blood sample was collected for assessment of basal 
endogenous glucocorticoid levels and background isotopomers and an intravenous bolus of 
d2-cortisone (76.0 g, 0.9% saline, w/v) and d4-cortisol (40:60 d4-cortisol: cortisol, 3.5mg, 
0.9% saline, w/v) administered into the antegrade antecubital fossa cannula over 5 minutes 
(Figure 5.1). Continuous intravenous infusions of d2-cortisone (105.3 g /hour) and d4-
cortisol (1.74mg/hour) (both in 0.9% saline w/v) were commenced immediately thereafter. 
Arterialised samples were obtained at 60 minute intervals to track enrichment of the blood 
with the tracers. 
 
From t=+3h, 4 sets of blood samples were obtained simultaneously from the 3 sites, 
(abdominal, forearm and arterialised cannulae), at 10 minute intervals. Prior to taking 
samples from the deep forearm vein a wrist cuff was inflated to 200mmHg for 2 minutes to 
remove blood flow from the hand. Forearm blood flow was measured by intermittent 
occlusion of the upper arm with a cuff inflated to 40mmHg during the sampling period using 
a strain gauge and a forearm venous occlusion plethysmography unit (Hokanson, Bellevue, 
WA). Adipose tissue blood flow was measured continuously during the study using 
Mediscint gamma-counter probes after a subcutaneous injection of 1-2 MBq 133Xenon lateral 
to the umbilicus (Larsen et al, 1966). This tracer washout technique relies on measuring the 
initial slope of the 133Xenon washout curve which is proportional to adipose tissue blood 
flow. Flow can be calculated from the plot of disappearance of 133Xenon counts versus time 
using the following equation, where the partition co-efficient refers to the partition between 
the lipid and aqueous phase of adipose and has a ratio of 10:1 with xenon gas. 
 
Adipose tissue blood flow (ml/ min/100g tissue) = 





After the sampling period, a hyperinsulinaemic-euglycaemic clamp was commenced by 
administering a primed continuous infusion of soluble Actrapid insulin with a final infusion 
rate of 35mU/m2/min-1. To prevent adhesion of the insulin to plastics in the syringe, 2.3ml of 
the participant’s blood was added to the solution (DeFronzo et al, 1979). To maintain an 
arterialised blood glucose concentration of ~5mmol/L, 20% dextrose (w/v) was co-
administered at a variable rate and blood glucose measured at 5-minute intervals using a 
reflectometer  (Hemocue  B-glucose  analyser,  Sheffield,  UK).  Estimates  of  the  amount  of  
dextrose to infuse during the study for each participant were calculated from a figure in the 
original description of the hyperinsulinaemic clamp protocol (DeFronzo et al, 1979) and the 
dextrose infusion rate changed by 5-10ml every 5 minutes until plasma glucose levels were 
stable. After 2h of hyperinsulinaemia, 4 sets of blood samples were obtained simultaneously 
from the 3 sites at 10 minute intervals and adipose and forearm blood flow was measured.  
 
Sample collection and processing 
 
Prior to obtaining any blood samples, the pumps infusing saline to keep cannulae patent were 
switched off for ~30 seconds and then 2ml of dead space / waste (a mixture of saline and 
blood in the cannula) was withdrawn from the sampling cannula.  Prior to taking samples 
from the deep forearm vein a  wrist  cuff  was inflated to 200mmHg for  2 minutes  to  reduce 
venous contribution from the hand. Whole blood samples were obtained in lithium heparin 
S-Monovette tubes (Starstedt, Beaumont Leys, UK). Blood samples were placed on wet ice 













-5 60 120 180 280 360 
MINUTES 
i.v. Insulin 
1-2 MBq 133Xenon gas 
Tracers: i.v. d4-cortisol and d2-cortisone 
FBF FBF 
Figure 5.1 Arterio-venous sampling study protocol.  
 
The tracers, d4-cortisol and d2-cortisone, were infused for 360 minutes after placement of cannulae. Intravenous insulin and dextrose was commenced 
at t=+210 mins.  Arrows indicate blood sampling; FBF = forearm blood flow measured by venous occlusion plethysmography; * = sampling sites- 
grey arterialised, black superficial epigastric vein, • = deep forearm vein; MBq= mega-Becquerel; i.v = intravenous. 
* • * 
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Endogenous and deuterated glucocorticoids were extracted from plasma using the method 
detailed in section 2.6.3. Extracts were analysed using LC-MS/MS as per section 2.8.2. The 
LC-MS/MS assay was optimised to assess specificity of detection of d2-cortisone and d4-
cortisol and their metabolites and ensure that there were no interfering isotopomers when the 
tracers were co-infused.  The following interferences were quantified: d2-cortisone (mass +1, 
m/z 364), which would interfere with d3-cortisone analysis; d2-cortisol (mass +1, m/z 366) 
which would interfere with d3-cortisol analysis; and d2-cortisol (mass +2, m/z 367) would 
interfere with d4-cortisol analysis if both d4-cortisol and d2-cortisone were simultaneously 
infused.   
 
Plasma glucose was measured within 24h on fresh plasma to avoid the variable loss of 




Whole blood oxygen saturation was measured immediately using a calibrated GEM OPL 
instrument (Instrumentation laboratory, Bedford, MA)  and haematocrit determined on 
arterialised samples using a Haematospin 1300 instrument (5 min, 4 C, Hawksley, Lancing, 







5.3.3 Data Analysis 
 
Blood flow analysis 
 
During forearm plethysmography, 3 readings were taken at the beginning and end of each 
sampling period over a 10 minute period and the mean obtained. For adipose blood flow, 
Mediscint gamma-counter probes (Oakfield Instruments, Eynsham, UK) were used to record 
counts per second over 20 second intervals. The mean adipose flow was calculated over 30 




Whole body rate  of  appearance (Ra) of  cortisol,  Ra d3-cortisol  and net  Ra cortisone in the 
plasma were calculated by multiplying the rate of tracer infusion by the respective 
tracer:tracee ratio (Equations 1-3) (Stimson et al, 2009). Total body cortisone production 
was estimated using Equation 4. 
 
Equation 1: 
 Ra-cortisol (nmol/min)= 
(Rate of d4-cortisol infused / TTR(d4-cortisol: cortisol)) - Rate of cortisol infused 
 
Equation 2: 
 Ra d3-cortisol = Rate of d4-cortisol infused/ TTR (d4-cortisol:d3-cortisol) 
 
Equation 3: 
Net Ra cortisone (nmol/min) =   




Total Ra cortisone (nmol/min) = 
(Rad3F (nmol/min)/ concentration d3-cortisone (nmol/L) + net Ra-cortisone (nmol/min) 
Concentration d2-cortisone (nmol/L) 
 
Subcutaneous adipose tissue and skeletal muscle production of cortisol, cortisone and d3-
cortisol were calculated using arterialised (A) and venous (V) samples (superficial epigastric 
vein for adipose tissue, and deep forearm vein for forearm skeletal muscle) and blood flow 
over 2 steady state periods (period 1: 180- 210 min and period 2: 330-360 min) using the 

















Tissue cortisol release (pmol/100g tissue/min) =  
 
(Blood flow • [cortisol]artery) •     d4-cortisol:cortisol artery       - (Blood flow • [cortisol]artery) 
    d4-cortisol:cortisol vein   
 
Tissue d3-cortisol release (pmol/100g tissue/min) =  
 
(Blood flow • [d3-cortisol]artery) •d4-cortisol:d3-cortisol artery  - (Blood flow • [d3-cortisol]artery) 
     d4-cortisol:d3-cortisol vein   
 
Net cortisone release from tissue (pmol/100g tissue/min) =  
 
(Blood flow • [cortisone]artery) •   d2-cortisone:cortisone artery     - (Blood flow • [cortisone]artery) 








Data are presented as mean ± SEM and were compared using paired Student’s t-tests. 





5.4.1 LC-MS/MS assay optimisation 
 
d2-Cortisone (mass +1, m/z 364) gave a 3% signal which would interfere with d3-cortisone 
formed from the d4-cortisol tracer, if the two tracers were co-infused, d2-cortisol (mass +1, 
m/z 366) gave a 1.6% signal and d2-cortisol (mass +2, m/z 367) gave a 0.2% signal which 
would interfere with the d3-cortisol and d4-cortisol signals, respectively. It was determined 
that none of these background isotopic interferences contributed significantly as in plasma 
the signal did not exceed noise and did not need to be corrected for. 
. 
5.4.2 Whole body glucocorticoid metabolism 
 
d4-Cortisol concentrations and enrichment of plasma with d4-cortisol were in steady state by 
3 hours (Figure 5.2). d4-Cortisol enrichment did not change throughout the study (Table 
5.1). There was evidence of whole body cortisol and d3-cortisol production (Table 5.2). 
During the hyperinsulinaemic clamp plasma insulin levels increased (9.9±0.9mmol/L prior 
Total cortisone release (pmol/L/100g tissue/min) =  
 
((Tissue d3-cortisol release/ [d3-cortisol]) •   [d2-cortisone]) + net cortisone release 
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to insulin clamp vs 83.4±4.0mmol/L during the insulin clamp, p<0.0001) but glucose levels 
remained stable (5.0±0.1mmol/L prior to insulin clamp vs 5.1±0.1mmol/L during the insulin 
clamp, p=0.69). d4-Cortisol and cortisol concentrations fell, with a concomitant increase in 
plasma d3-cortisol concentration, rate of appearance of d3-cortisol, and fall in d4-cortisol:d3-
cortisol ratio, consistent with increased 11 -reductase activity (Table 5.1). Whole body 
production rates of cortisol did not change during hyperinsulinaemia (Table 5.2). 
  
Plasma d2-cortisone concentrations and enrichment were in steady state at 3 hours and did 
not change during hyperinsulinaemia (Table 5.1). Dilution of d2-cortisone with cortisone 
was evident before insulin indicating 11 -dehydrogenase activity (Table 5.2), but did not 
change during hyperinsulinaemia. Plasma concentrations of cortisone fell during 
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Figure 5.2: Concentrations of endogenous glucocorticoids and tracer:tracee ratios 
measured in arterialised, deep forearm and superficial epigastric veins. 
 
Data are mean ± SEM for n=6 volunteers. The mean data for basal measurements were 
between t=+180-210 minutes and for hyperinsulinaemia between t=+330-360 minutes. (A) 
Cortisol concentrations; (B) d4-cortisol: cortisol ratio; (C) d4-cortisol:d3-cortisol ratio; (D) 
Cortisone concentrations; (E) d2-cortisone:cortisone ratios. Filled diamonds = arterialised 
vein; filled triangles = superficial epigastric vein; open squares = deep forearm vein; nM= 
nanomolar; d= deuterium; *p<0.05 comparing arterial basal vs hyperinsulinaemia and 




































5.4.3 Adipose tissue glucocorticoid metabolism 
 
There were no arterio-venous differences in glucose, cortisol, d3-cortisol, d4-cortisol and 
cortisone concentrations (data not shown). In particular there was no arterio-venous 
differences in glucose during hyperinsulinaemia across the adipose tissue bed 
(5.1±0.1mmol/L arterialised vs 5.1±0.1mmol/L venous adipose, p=0.57), suggesting no 
additional uptake of glucose into adipose tissue during hyperinsulinaemia. However, a 
glucose tracer was not co-infused in this study which may have provided a more sensitive 
measure of tissue glucose uptake or release, as was used for tissue glucocorticoids.  
 
Mean adipose tissue blood flow was unchanged during the study (5.7±1.3 basal vs 5.7 ±1.2 
ml/min/100g hyperinsulinaemia p=0.96). Cortisol and d3-cortisol release, indicating 
reductase activity, were of a similar magnitude to previous studies (Stimson et al, 2009) but 
did not achieve statistical significance. Cortisone was released from subcutaneous adipose 
tissue (Table 5.2) consistent with adipose 11 -dehydrogenase activity. Cortisol and d3-
cortisol release did not change during hyperinsulinaemia. The fall in cortisone release during 
hyperinsulinaemia did not achieve statistical significance (n=5), as one subject extracted 
cortisone  across  the  adipose  bed  (Figure  5.3).  The  ratio  of  11 -reductase  activity,  as  
measured by Ra cortisol, to 11 -dehydrogenase activity was ~1:1.5. 
 
5.4.4 Skeletal muscle glucocorticoid metabolism 
 
Mean forearm blood flow was unchanged during the study (2.8±0.2 ml/min basally vs 
2.7±0.5ml/min, p=0.89). There was significant release of cortisone, d3-cortisol and cortisol 
prior to hyperinsulinaemia indicating dehydrogenase and reductase activities respectively. 
During hyperinsulinaemia an arterio-venous difference in plasma glucose (5.1±0.1mmol/L 
arterialised vs 4.3±0.3mmol/L venous forearm, p=0.035) was measured indicating uptake of 
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glucose by the muscle bed. The ratio of 11 -reductase activity to 11 -dehydrogenase activity 
was ~1:1. Cortisone (Figure 5.3), cortisol and d3-cortisol release did not change during 
hyperinsulinaemia (Table 5.2).  
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Table 5.1: Plasma steady state concentrations, ratios and blood flow during deuterated 
cortisol and cortisone infusions 
 
Arterialised samples  
Basal Hyper-insulinaemia 
Css Cortisol (nmol/L) 263.8±30.6 241.5±25.4* 
Css d3-cortisol (nmol/L) 60.2±6.0 70.0±7.5* 
Css d4-cortisol (nmol/L) 76.3±6.9 67.9±5.3* 
D4-cortisol: d3-cortisol 1.3±0.1 1.0±0.1** 
D4-cortisol enrichment (%)  
(d4-cortisol/(cortisol +d4-cortisol)) 
22.8±1.3 22.6±1.0 
Css Cortisone (nmol/L) 42.0±5.3 37.9±4.7* 
Css d2-cortisone (nmol/L) 4.1±0.5 3.8±0.5 
D2-cortisone enrichment (%)  
(d2-cortisone/(cortisone +d2-cortisone)) 
7.2±0.6 7.7±0.5 
Css Glucose (nmol/L) 5.0±0.1 5.1±0.1 
Adipose tissue blood flow (ml/min/100g 
tissue) 
5.7±1.3 5.7 ±1.2 
Forearm blood flow (ml/min) 2.8±0.2  2.7±0.5 
 
Data  are  mean  ±  SEM  for  n=6  volunteers.  The  mean  data  for  basal  measurements  were  
between 180-210 minutes and hyperinsulinaemia between 330-360 minutes of tracer 
infusion.   Css = concentration at steady state; d=deuterium; * p<0.05 comparing basal vs 
hyperinsulinaemia and ** p<0.001 comparing basal vs hyperinsulinaemia using Student’s 
paired t-tests. 
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Table 5.2: Calculated whole body 11 HSD1 and 11 HSD2 activity and cortisol and cortisone release across adipose tissue and skeletal muscle 
during deuterated cortisol and cortisone infusions. 
 
 
 Ra Cortisol Ra D3-cortisol Net Ra Cortisone Total Ra Cortisone  


















19.7±4.1† 16.5±7.7 5.9±1.8† 4.9±1.5 15.2±5.8† 7.5±5.3 17.20±5.94† 9.16±5.30 
Data  are  mean  ±  SEM  for  n=6  volunteers.  The  mean  data  for  basal  measurements  were  calculated  between  180-210 minutes and 
hyperinsulinaemia between 330-360 minutes of tracer infusion.  Ra= rate of appearance; d=deuterium; **= p<0.01 comparing arterial basal vs 
hyperinsulinaemic measurements using Student’s paired t-tests; † = p<0.05 vs 0 and ††=p<0.001 vs 0 using single sample t-tests. 
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Figure 5.3: Net rate of appearance of cortisone across subcutaneous adipose tissue and 




For subcutaneous adipose tissue: n=5 participants, for muscle: n=6 participants. One subject 
extracted cortisone across both adipose tissue and skeletal muscle. 


























































This chapter describes a study which used the stable isotope tracer d2-cortisone to quantify 
11 HSD1-dehydrogenase activity in vivo. Substantial activity was present in both adipose 
tissue and forearm skeletal muscle of healthy men. Using d4-cortisol, significant forearm 
skeletal muscle 11 HSD1-reductase activity was also demonstrated. The subcutaneous 
adipose tissue 11 HSD1-reductase results are consistent with the previous report quantifying 
subcutaneous adipose 11 HSD1-reductase activity (Stimson et al, 2009). The study data also 
confirm the finding that hyperinsulinaemia increases whole body 11 HSD1-reductase 
activity (Wake et al, 2006) in vivo. Furthermore, the ratio of dehydrogenase to reductase 
activity is ~1 in the whole body and skeletal muscle and ~1.5 in subcutaneous adipose tissue 
suggesting net inactivation of cortisol in adipose tissue. 
 
Intracellular glucocorticoid cycling may be the mechanism by which cells control the local 
intracellular environment to enhance or dampen the effects of glucocorticoids in specific 
tissues rather than simply reflecting circadian or ultradian changes in circulating 
glucocorticoid levels. Some primary cell cultures, eg adipose stromal vascular cells and 
Leydig cells, display both 11 HSD1 reductase and dehydrogenase activity (Bujalska et al, 
2002;Gao et al, 1997) permitting glucocorticoid cycling in these tissues. It has been 
postulated that these activities regulate the balance between cellular proliferation and 
differentiation and protect normal physiological hormone secretory patterns (Bujalska et al, 
2002;Gao et al, 1997). The finding of both reductase and dehydrogenase activities in whole 
subcutaneous adipose tissue demonstrates that both these activities occur in vivo too, and 
may have a similar function in whole tissue and cells, although this study was not designed 
to explore the function of these activities. 
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In some cells and tissues, eg hepatocytes / liver, 11 -reductase activity prevails in vitro 
(Jamieson et al, 1995) and in vivo (Rask et al, 2001). Whether substantial glucocorticoid 
cycling occurs in the liver is not yet known. Using stable isotope tracers our group have been 
unable to measure cortisone production in the hepatic vein, but this probably reflects low 
plasma cortisone concentrations and inadequate instrument sensitivity to detect these levels 
rather than complete absence of dehydrogenase activity. 
 
Both net and total cortisone production have been presented as the d2-cortisone tracer may 
be recycled in vivo by 11 -dehydrogenase. By co-infusing d2-cortisone with d4-cortisol this 
recycling can be estimated through measuring d3-cortisone and d3-cortisol interconversion. 
This assumes a linear relationship of recycling rate with cortisol and cortisone concentrations 
and steady state with dehydrogenase and reductase activities for recycling.  As d4-cortisol is 
not regenerated from d3-cortisol, recycling by 11 HSD1-reductase does not need to be 
accounted for with d4-cortisol. Whole body net cortisone production rate was increased by 
8-10nmol/min and tissue production between 2-6pmol/min with this calculation. 
 
Confirming previous ex-vivo reports (Bujalska et al, 2002) the source of dehydrogenase 
activity in adipose tissue is likely to be 11 HSD1, as adipose tissue 11 HSD2 expression has 
been reported as negligible (Bujalska et al, 2002) or much lower than that of 11 HSD1 in 
subcutaneous adipocytes of obese women (Engeli et al, 2004), and the stromal fraction of 
human omental adipose tissue (Lee et al, 2008). Also techniques which may cause 
dissociation of 11 HSD1 from the co-localized H6PDH, eg micro-dialysis (Wake et al, 
2006) were not used in this study. In mice, increased adipose tissue dehydrogenase activity 
reduces the adverse metabolic effects of high fat feeding when 11 HSD2 is over-expressed 
in adipocytes (Kershaw et al, 2005). Thus, adipose tissue 11 HSD1-dehydrogenase activity 
may be metabolically beneficial in man. The origin of dehydrogenase activity in forearm 
samples  is  less  clear  cut  as  11 HSD2  is  expressed  in  skeletal  muscle  vascular  cells,  
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interstitial cells and perhaps in the myocyte (Jang et al, 2007). Although other investigators 
have not replicated these findings in needle biopsy muscle samples (Whorwood et al, 
2001;Abdallah et al, 2005).  Other potential sources of dehydrogenase activity in the forearm 
samples include the vasculature (Christy et al, 2003), bone, skin and adipose. As 11 HSD2 
expression is low in non-fetal osteoblasts (Cooper et al, 2000), negligible in adipose tissue 
(Bujalska et al, 2002), not expressed in the epidermis (Hirasawa et al, 1997), and blood flow 
from the hand was excluded in the study, it is likely that forearm skeletal muscle does 
display significant 11 HSD1-dehydrogenase activity in vivo.  
 
Previous in vivo studies measuring arteriovenous gradients in cortisol and cortisone 
concentrations, using  standard forearm arteriovenous sampling or incremental intra-arterial 
cortisol infusions, failed to demonstrate forearm 11 HSD1-reductase activity (van Uum et 
al, 2002;Katz et al, 1999;Asmal et al, 1974) despite skeletal muscle 11 HSD1 expression 
(Jang et al, 2006). However, stable isotope tracers and mass spectrometry were not used in 
these studies, which may have reduced the precision of the measurements especially if, as 
our data suggests, there is cycling of cortisol and cortisone. Using d4-cortisol, 11 -reductase 
activity has been demonstrated in the leg of obese subjects (Basu et al, 2004;Basu et al, 
2005), but as in this study, other tissues such as skin, vasculature and bone may have 
contributed to this activity. Furthermore, indocyanine green was used to measure blood flow 
which may not be significantly extracted across the leg, and venous flow from the foot was 
not excluded (Basu et al, 2004;Basu et al, 2005). Using different blood flow methods and 
skeletal muscle depot this study shows that there is significant reductase activity in human 
skeletal muscle of healthy subjects. 
 
To calculate the ratio of 11 -dehydrogenase to reductase activity rate of appearance (Ra) 
cortisol:cortisone was employed. Although Ra d3-cortisol is more specific for 11 HSD1-
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reductase activity than Ra cortisol, the substrate, d3-cortisone, may not have been in steady 
state in the tissues, compared to endogenous cortisol at the time of sampling leading to an 
under-estimation of Ra. Ex-vivo (Bleau et al, 1974) and in vivo studies (please see data from 
Chapter 3) have demonstrated the slow uptake of  glucocorticoids into adipose tissue, and 
thus it is unlikely that changes in adrenal cortisol secretion will have been reflected in 
adipose in this study and will not have contributed to the Ra cortisol obtained from 
arteriovenous sampling of tissues.  
 
In non-fasted obese subjects receiving an intravenous infusion of dextrose, subcutaneous 
adipose tissue 11 -reductase activity has been quantified as 15 and 8.7 pmol/min/100g 
adipose for cortisol and d3-cortisol respectively (Stimson et al, 2009). Our results in lean 
fasted men are of a similar magnitude to this but did not achieve statistical significance as in 
one subject both cortisol and d3-cortisol were extracted across the adipose tissue bed.   
 
The data from this study suggest that local production and turnover of cortisol and cortisone 
are lower per volume of tissue in skeletal muscle than in subcutaneous adipose tissue. 
Physiologically this higher rate of local cortisol production in adipose tissue may be a 
mechanism to selectively increase adipose tissue lipolysis and release fuel for 
gluconeogenesis, whilst relatively sparing skeletal muscle from proteolysis during times of 
caloric restriction, such as fasting during this study, thereby preserving muscular integrity. In 
skeletal muscle, short courses of oral glucocorticoids have detrimental effects on muscle 
insulin sensitivity which reverse upon cessation of therapy (Short et al, 2009). Thus lower 
local cortisol production in skeletal muscle may also be a mechanism to preserve muscle 
insulin-glucose homeostasis (Morgan et al, 2009). 
 
The effects of the non-selective 11 HSD inhibitor carbenoxolone have been examined in 
rodent and human studies producing variable results. In Zucker rats, carbenoxolone had no 
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effect on fasting glucose levels or 11 HSD1 activity in skeletal muscle or adipose tissue, but 
did inhibit 11 HSD1 activity in the liver (Livingstone & Walker, 2003). When administered 
to healthy lean men carbenoxolone improved whole body insulin sensitivity, probably 
through suppression of hepatic glucose production, but had no effect on forearm insulin 
sensitivity (Walker et al, 1995). As skeletal muscle has both 11 HSD1 reductase and 
dehydrogenase activities and glucocorticoid production in forearm tissue appears relatively 
slow, the absence of an effect of carbenoxolone in this tissue may be due to both the non-
selective nature of carbenoxolone (blocking both activities) and the slow tissue production. 
Furthermore, carbenoxolone undergoes hepatic first pass metabolism and is highly 
concentrated in the liver, suggesting that low extra-hepatic concentrations of drug may 
poorly penetrate other tissues and may explain the variable response to carbenoxolone in the 
published literature. 
 
Altered endoplasmic reticulum NADPH:NADP+ ratio is believed to change 11 HSD1 
directionality because reduced local supply of NADPH in H6PDH null mice alters the 
direction of 11 HSD1 from reductase to dehydrogenase (Lavery et al, 2006). As glucose-6-
phosphate (G6P) is a substrate for H6PDH and intracellular G6P levels may be dependent on 
glucose, we hypothesised that hyperinsulinaemia may increase glucose flux through the 
pentose phosphate pathway, leading to an increase in NADPH within the ER, which may in 
turn push tissue 11 HSD1 activity towards reductase in vivo. Hyper-insulinaemia increased 
whole body d3-cortisol production as previously (Wake et al, 2006), but had no significant 
effect on tissue 11 -reductase activity or blood flow. However, arteriovenous differences in 
plasma glucose, suggesting flux of glucose into tissues, were only seen in plasma samples 
from the forearm and not in plasma draining adipose tissue. Thus hyperinsulinaemia may not 
have increased glucose flux into adipose tissue and this may be a potential reason for the 
lack of change in 11 HSD1 activity in adipose tissue. Furthermore, activity of the pentose 
phosphate pathway is low in muscle compared to tissues such as the liver and adrenal. This 
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may further explain why despite an arterio-venous difference in glucose in forearm plasma 
samples, a difference in tissue 11 HSD1 activity was not seen. 
 
Adipose tissue cortisone production tended to fall with hyperinsulinaemia, but again in one 
subject cortisone was extracted across the adipose bed and the study was not of sufficient 
power to detect whether this change was real or not. Therefore, although the results suggest 
that hyperinsulinaemia does not affect 11 HSD1 directionality in tissues, this will need to be 
tested in a larger number of subjects in further studies. 
 
Using DXA-derived body fat measurements to assess total body adipose tissue mass along 
with adipose glucocorticoid release figures, I have extrapolated that adipose 11 HSD1 
contributes 7.3 nmoles /min of cortisone, which is ~10% of whole body cortisone production 
rate calculated here. This figure is based on the assumption that the 11 HSD1 substrate (d2-
cortisone) was in steady state during the measurements, and 11 HSD1 expression and 
activity were uniform during the study. During the study mean blood flow in the 
subcutaneous adipose tissue depot was confirmed to be stable, but biopsies of adipose depots 
were not collected for assessment of 11 HSD1 expression, nor factors such as prolonged 
fasting assessed when measuring adipose blood flow (Frayn et al, 2003) and thus this figure 
needs to be interpreted within these limitations. The contribution of adipose cortisol 
production to whole body rates was marginally lower than previously reported  at 10.2% (vs 
12 %) (Stimson et al, 2009). These differences may relate to our subjects being leaner and 
having lower adipose tissue 11 HSD1 activity, as measurements in adipose biopsies suggest 
that activity is ~3-fold higher (per gram adipose tissue) in obesity (BMI 31.7kg/m2) 
compared to normal weight (BMI 22.9kg/m2) (Rask et al, 2001).   
 
In conclusion, both 11 HSD1 reductase and dehydrogenase activities occur in vivo in human 
forearm skeletal muscle and subcutaneous adipose tissue suggesting that cycling of cortisol 
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and cortisone at the tissue level may occur. Whole body 11 HSD1 reductase activity was 
increased by hyperinsulinaemia but activity and directionality do not appear to be influenced 


















Obesity is an increasing problem in society with almost a quarter of adults in the UK being 
classed as obese. Obesity is associated with an increased adipose tissue mass which has the 
ability to generate hormones and cytokines with local and systemic effects. Adipose tissue 
expresses the enzyme 11 HSD1 which has previously been thought to predominantly 
generate active glucocorticoid from inert cortisone in tissues.  Mice over-expressing 
11 HSD1 in adipose tissue develop a metabolic syndrome phenotype (Masuzaki et al, 2001). 
In human obesity subcutaneous adipose 11 HSD1 is also up-regulated (Rask et al, 2001). 
Since the increase in 11 HSD1 in adipose tissue in these mice is similar to the up-regulation 
observed in adipose tissue in human obesity, these findings suggest that increased intra-
adipose 11 HSD1 may be responsible for the metabolic complications of obesity and has led 
to this enzyme becoming a therapeutic target. However many important questions regarding 
adipose tissue 11 HSD1 remain and this thesis aimed to address some of them. 
 
After establishing a method to extract and measure adipose tissue glucocorticoids, the results 
described in Chapter 3 helped address the issue of absolute adipose tissue glucocorticoid 
levels, uptake of glucocorticoids into adipose tissue and the contribution of 11 HSD1 to the 
intra-adipose glucocorticoid pool. Adipose tissue glucocorticoid levels were higher than 
previously reported using a LC-MS/MS assay and this may have reflected the assay 
development strategy to remove the steroids from the tissue completely rather than analyse 
the crude tissue extract.   
 
In vivo data suggested that accumulation of glucocorticoids into adipose tissue is slow with 
only ~10% of the intra-adipose glucocorticoid pool replaced per hour. To my knowledge no 
previous in vivo studies have studied cortisol transport and turnover in adipose tissue, 
although one ex-vivo study reported adipose uptake of [3H]-cortisol was ~5 times slower than 
that of sex steroids and androgens (only 12.7% uptake at 3 hours) (Bleau et al, 1974). In the 
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rat brain, ultradian pulses of glucocorticoids are quickly reflected in hippocampal 
extracellular fluid in rodents (Droste et al, 2008) and in vitro induce the pulsatile 
transcription of RNA from GR-regulated genes (Stavreva et al, 2009) suggesting uptake in 
the rodent brain and in vitro is  quicker  than  adipose  tissue  and  that  there  may  be  a  rapid  
signalling system in place to effect these changes. The results in Chapter 3 suggest that this 
may not be the case in adipose tissue and the intra-adipose cortisol pool may have a role in 
integrating the longer-term variations in circulating glucocorticoid concentrations compared 
to the brain and liver. Moreover, unless there are multiple pools of glucocorticoid within 
adipose tissue, with a cytosolic ‘free’ pool that turns over more quickly than a triglyceride-
bound pool, then it appears unlikely that intra-adipose cortisol concentrations vary widely 
during acute changes in plasma cortisol, but this delayed rate needs to be confirmed under 
normal physiological circumstances where adipose blood flow, meal pattern and insulin 
levels normally occur, rather than during surgery. 
 
The rates of regeneration of cortisol by intra-adipose 11 HSD1 measured in previous studies 
(Stimson et al, 2009) were high compared with the rate of accumulation of plasma-derived 
cortisol within adipose, emphasising the importance of 11 HSD1 in  human  adipose  tissue  
glucocorticoid signalling. It will be important to establish the rates of exchange between 
plasma and other intra-cellular cortisol pools in other organs.  Indeed, further studies 
assessing time to steady state of d4-cortisol in adipose tissue of rodents and assessing 
adipose glucocorticoid transporters are underway. These may further elucidate the 
mechanisms of glucocorticoid transport into adipose tissue and may help identify why 
glucocorticoid uptake in adipose tissue appears slow. 
 
To address the question as to whether adipose tissue 11 HSD1 displays dehydrogenase 
activity in vivo, a new stable isotope tracer technique was developed to measure 11 -
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dehydrogenase activity in vivo as described in Chapter 4. After optimising tracer 
measurement using LC-MS/MS and establishing that it was a substrate for human 11 HSD1, 
a primary isotope effect was also excluded. Pharmacokinetics were derived in vivo and 
whole body net cortisone production rate measured before and after eating liquorice which 
contains inhibitors of 11 -dehydrogenase and a substantial fall in whole body cortisone 
production was observed. 
 
Using arterio-venous sampling techniques and the expertise of staff in the Clinical Research 
Facility, OCDEM, University of Oxford, Oxford, subcutaneous adipose tissue and skeletal 
muscle 11 HSD1 reductase and dehydrogenase activities were simultaneously measured. 
The findings reported in Chapter 5 demonstrate that 11 HSD1 is bidirectional in human 
subcutaneous adipose tissue and skeletal muscle in vivo, suggesting that glucocorticoids can 
cycle in these tissues.  Intracellular glucocorticoid cycling may be the mechanism by which 
cells control the local intracellular environment to enhance or dampen the effects of 
glucocorticoids in specific tissues rather than simply reflecting circadian or ultradian changes 
in circulating glucocorticoid levels. Some cells, eg adipose stromal vascular cells and Leydig 
cells, display both 11 HSD1 reductase and dehydrogenase activity (Bujalska et al, 2002;Gao 
et al, 1997) permitting glucocorticoid cycling in these tissues. Whether the impact of this 
glucocorticoid cycling is autocrine or paracrine is not known.  
 
The finding that 11 HSD1 is bidirectional in metabolically important tissues leads to the 
question as to what will happen to this activity when transcript levels are increased eg in 
subcutaneous adipose tissue in obesity.  To study this one could repeat the study described in 
Chapter 5 with obese individuals and also take subcutaneous adipose tissue biopsies to 
confirm the increased 11 HSD1 mRNA in the adipose of these subjects. If both 11 HSD1 
reductase and dehydrogenase activities increased in parallel, glucocorticoid balance in the 
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tissue will not be disrupted, but if this equilibrium was disturbed due to other as yet 
undiscovered factors affecting 11 HSD1 activity and directionality this may be 
metabolically detrimental. From a physiological perspective, an increase in both 
dehydrogenase and reductase activities appears futile, but may have a role to buffer any 
compensatory changes in cortisol concentrations. 
 
Increasing glucose flux into tissues and thus increasing NADPH co-factor supply does not 
appear to regulate the balance of activities of 11 HSD1 in adipose tissue or skeletal muscle. 
However, we were only able to demonstrate an increase in uptake of glucose into skeletal 
muscle only. The study assessing 11 HSD1 during hyperinsulinaemia was not powered to 
detect these changes and studying additional healthy individuals may help answer the 
question further. Nevertheless it can be concluded from this study that the dysregulation of 
11 HSD1 transcription in obesity in adipose tissue may affect cortisol inactivation as well as 
regeneration. 
 
To conclude, these studies confirm that 11 HSD1 has an important role in adipose tissue 
glucocorticoid homeostasis. Traditional teaching regarding glucocorticoid action in adipose 
tissue suggests that cortisone and cortisol enter the cell, that an additional source of 
intracellular cortisol is reduction of cortisone by 11 HSD1, and this cortisol can activate 
adipose glucocorticoid receptors, or be metabolised by 5 -reductase. However, the results 
from these studies suggest that in addition to the above model, although these findings need 
to be confirmed under physiological conditions, we can now add that transport of 
glucocorticoids into adipose tissue is slow and we speculate that there are 2 cortisol pools in 
adipose tissue – one free pool able to interact with glucocorticoid receptors rapidly and a 
further triglyceride-bound pool, which probably takes a longer period of time to ‘fill’ and 
equilibrate. Furthermore, the studies suggest that in adipose tissue an additional source of 
 195 
both cortisol and cortisone results from cycling of glucocorticoids. Whether this cycling is 
autocrine or occurs is nearby stromal vascular cells resulting in a paracrine effect is not 
known. 
 
Through developing new techniques to measure 11 HSD1 in tissues samples and in vivo we 
have furthered the understanding of normal adipose 11 HSD1 physiology. These techniques 
may in turn be applied to further studies in obesity where adipose 11 HSD1 is dysregulated. 
Furthermore, the work described in this thesis suggests that 11 HSD1-inhibitors do need to 
be selective for 11 HSD1-reductase to ensure they give the maximum metabolic benefits 
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